
<!DOCTYPE html>
<html lang="en" >
    <head >

        <meta charset="UTF-8" />
        <meta http-equiv="X-UA-Compatible" content="IE=edge" />
        <meta name="HandheldFriendly" content="True" />
        <meta name="MobileOptimized" content="320" />
        <meta name="viewport" content="width=device-width, initial-scale=1.0" />

        
        

        
        
  <link rel="stylesheet" href="/static/assets/style-8258669d.css" />
<script type="module" crossorigin="" src="/static/assets/base_style-f4a99799.js"></script>

  <link rel="stylesheet" href="/static/assets/style-ef962842.css" />
<link rel="stylesheet" href="/static/assets/style-3ade8b5c.css" />
<script type="module" crossorigin="" src="/static/assets/article_style-d757a0dd.js"></script>

  
  
    <style>
  
  
  @media screen and (min-width: 64em) {
    div.pmc-wm {
      background: repeat-y;
      background-image: url("data:image/svg+xml,%3Csvg xmlns='http://www.w3.org/2000/svg' width='20' height='350' xmlns:xlink='http://www.w3.org/1999/xlink'%3E%3Cdefs%3E%3Cfilter x='-.02' y='0' width='1.05' height='1' id='c'%3E%3CfeFlood flood-color='%23FFF'/%3E%3CfeComposite in='SourceGraphic'/%3E%3C/filter%3E%3Ctext id='b' font-family='Helvetica' font-size='11pt' style='opacity:1;fill:%23005ea2;stroke:none;text-anchor:middle' x='175' y='14'%3E%3C/text%3E%3Cpath id='a' style='fill:%23005ea2' d='M0 8h350v3H0z'/%3E%3C/defs%3E%3Cuse xlink:href='%23a' transform='rotate(90 10 10)'/%3E%3Cuse xlink:href='%23b' transform='rotate(90 10 10)' filter='url(%23c)'/%3E%3C/svg%3E");
      padding-left: 3rem;
    }
  }
</style>

  



        
            <link rel="apple-touch-icon"
                  sizes="180x180"
                  href="/static/img/favicons/apple-touch-icon.png" />
            <link rel="icon"
                  type="image/png"
                  sizes="48x48"
                  href="/static/img/favicons/favicon-48x48.png" />
            <link rel="icon"
                  type="image/png"
                  sizes="32x32"
                  href="/static/img/favicons/favicon-32x32.png" />
            <link rel="icon"
                  type="image/png"
                  sizes="16x16"
                  href="/static/img/favicons/favicon-16x16.png" />
            <link rel="manifest" href="/static/img/favicons/site.webmanifest" />
            <link rel="mask-icon"
                  href="/static/img/favicons/safari-pinned-tab.svg"
                  color="#0071bc" />
            <meta name="msapplication-config"
                  content="/static/img/favicons/browserconfig.xml" />
            <meta name="theme-color" content="#ffffff" />
        

        <title>
            Pyrotinib targeted EGFR/GRP78 mediated cell apoptosis in high EGFR gene copy number gastric cancer - PMC
        </title>

        
        
  
  <!-- Logging params: Pinger defaults -->
<meta name="ncbi_app" content="cloudpmc-viewer" />
<meta name="ncbi_db" content="pmc" />
<meta name="ncbi_phid" content="15254FEB8AF40E83054FEB002A09C768.m_1" />
<meta name="ncbi_pinger_stat_url" content="https://pmc.ncbi.nlm.nih.gov/stat" />
<!-- Logging params: Pinger custom -->
<meta name="ncbi_pdid" content="article" />
  
    <link rel="preconnect" href="https://www.google-analytics.com" />

    
        <link rel="preconnect" href="https://cdn.ncbi.nlm.nih.gov" />
    

    <!-- Include USWDS Init Script -->
    <script src="/static/assets/uswds-init.js"></script>


    <meta name="ncbi_domain" content="jeccr">
<meta name="ncbi_type" content="fulltext">
<meta name="ncbi_pcid" content="journal">
<meta name="ncbi_feature" content="associated_data">
<link rel="canonical" href="https://pmc.ncbi.nlm.nih.gov/articles/PMC12363034/">
<meta name="robots" content="INDEX,NOFOLLOW,NOARCHIVE">
<meta name="citation_journal_title" content="Journal of Experimental &amp; Clinical Cancer Research : CR">
<meta name="citation_title" content="Pyrotinib targeted EGFR/GRP78 mediated cell apoptosis in high EGFR gene copy number gastric cancer">
<meta name="citation_author" content="Lingbo Bao">
<meta name="citation_author_institution" content="Cancer Center of Daping Hospital, Army Medical University, Chongqing, 400037 China">
<meta name="citation_author_institution" content="Department of Oncology, General Hospital of Western Theater Command, Chengdu, 610083 China">
<meta name="citation_author" content="Xudong Wang">
<meta name="citation_author_institution" content="Cancer Center of Daping Hospital, Army Medical University, Chongqing, 400037 China">
<meta name="citation_author" content="Xiuyong Liao">
<meta name="citation_author_institution" content="Department of Oncology, Chongqing University Qianjiang Hospital, Qianjiang Central Hospital of Chongqing, No. 360, South Section of Zhengzhou Road, Qianjiang District, Chongqing, 409000 China">
<meta name="citation_author" content="Dong Li">
<meta name="citation_author_institution" content="Department of Oncology, General Hospital of Western Theater Command, Chengdu, 610083 China">
<meta name="citation_author" content="ChunXue Li">
<meta name="citation_author_institution" content="Department of General Surgery, Daping Hospital, Third Military Medical University (Army Medical University), Chongqing, 400042 China">
<meta name="citation_author" content="Nan Dai">
<meta name="citation_author_institution" content="Cancer Center of Daping Hospital, Army Medical University, Chongqing, 400037 China">
<meta name="citation_author" content="Xiaoyan Dai">
<meta name="citation_author_institution" content="Cancer Center of Daping Hospital, Army Medical University, Chongqing, 400037 China">
<meta name="citation_author" content="Jing Yang">
<meta name="citation_author_institution" content="Cancer Center of Daping Hospital, Army Medical University, Chongqing, 400037 China">
<meta name="citation_author" content="Nana Hu">
<meta name="citation_author_institution" content="Cancer Center of Daping Hospital, Army Medical University, Chongqing, 400037 China">
<meta name="citation_author" content="Xueling Tong">
<meta name="citation_author_institution" content="Cancer Center of Daping Hospital, Army Medical University, Chongqing, 400037 China">
<meta name="citation_author" content="Zhenjie He">
<meta name="citation_author_institution" content="Cancer Center of Daping Hospital, Army Medical University, Chongqing, 400037 China">
<meta name="citation_author" content="Yuancheng Zhao">
<meta name="citation_author_institution" content="Department of Ophthalmology, The General Hospital of Western Theater Command, Chengdu, 610083 China">
<meta name="citation_author" content="Zheng Liu">
<meta name="citation_author_institution" content="Cancer Center of Daping Hospital, Army Medical University, Chongqing, 400037 China">
<meta name="citation_author_institution" content="Department of Oncology, General Hospital of Western Theater Command, Chengdu, 610083 China">
<meta name="citation_author" content="Yue Hu">
<meta name="citation_author_institution" content="Cancer Center of Daping Hospital, Army Medical University, Chongqing, 400037 China">
<meta name="citation_author" content="Jinlu Shan">
<meta name="citation_author_institution" content="Cancer Center of Daping Hospital, Army Medical University, Chongqing, 400037 China">
<meta name="citation_author" content="Dong Wang">
<meta name="citation_author_institution" content="Department of Oncology, Chongqing University Qianjiang Hospital, Qianjiang Central Hospital of Chongqing, No. 360, South Section of Zhengzhou Road, Qianjiang District, Chongqing, 409000 China">
<meta name="citation_author" content="Mengxia Li">
<meta name="citation_author_institution" content="Cancer Center of Daping Hospital, Army Medical University, Chongqing, 400037 China">
<meta name="citation_author" content="Qian Chen">
<meta name="citation_author_institution" content="Cancer Center of Daping Hospital, Army Medical University, Chongqing, 400037 China">
<meta name="citation_publication_date" content="2025 Aug 19">
<meta name="citation_volume" content="44">
<meta name="citation_firstpage" content="245">
<meta name="citation_doi" content="10.1186/s13046-025-03485-6">
<meta name="citation_pmid" content="40830980">
<meta name="citation_abstract_html_url" content="https://pmc.ncbi.nlm.nih.gov/articles/PMC12363034/">
<meta name="citation_fulltext_html_url" content="https://pmc.ncbi.nlm.nih.gov/articles/PMC12363034/">
<meta name="citation_pdf_url" content="https://pmc.ncbi.nlm.nih.gov/articles/PMC12363034/pdf/13046_2025_Article_3485.pdf">
<meta name="description" content="Despite frequent Epidermal Growth Factor Receptor (EGFR) amplification and overexpression in gastric cancer, limited therapeutic responses were observed in existing EGFR-targeted agents. Pyrotinib, an irreversible dual EGFR/HER2 tyrosine kinase ...">
<meta name="og:title" content="Pyrotinib targeted EGFR/GRP78 mediated cell apoptosis in high EGFR gene copy number gastric cancer">
<meta name="og:type" content="article">
<meta name="og:site_name" content="PubMed Central (PMC)">
<meta name="og:description" content="Despite frequent Epidermal Growth Factor Receptor (EGFR) amplification and overexpression in gastric cancer, limited therapeutic responses were observed in existing EGFR-targeted agents. Pyrotinib, an irreversible dual EGFR/HER2 tyrosine kinase ...">
<meta name="og:url" content="https://pmc.ncbi.nlm.nih.gov/articles/PMC12363034/">
<meta name="og:image" content="https://cdn.ncbi.nlm.nih.gov/pmc/cms/images/pmc-card-share.jpg?_=0">
<meta name="twitter:card" content="summary_large_image">
<meta name="twitter:site" content="@ncbi">
    
    

    </head>
    <body >
        
    <a class="usa-skipnav " href="#main-content">
      Skip to main content
    </a>


        
            

<section class="usa-banner " aria-label="Official website of the United States government" >
    <div class="usa-accordion">
        <header class="usa-banner__header">
            <div class="usa-banner__inner">
                <div class="grid-col-auto">
                    <img aria-hidden="true"
                         class="usa-banner__header-flag"
                         src="/static/img/us_flag.svg"
                         alt="" />
                </div>

                <div class="grid-col-fill tablet:grid-col-auto" aria-hidden="true">
                    <p class="usa-banner__header-text">
                        An official website of the United States government
                    </p>
                    <span class="usa-banner__header-action">Here's how you know</span>
                </div>

                



















    
        <button
            type="button"
        
    
    class="usa-accordion__button usa-banner__button
           

           
               
               
               
               
            

           
           
           
           "
    aria-expanded="false"
    aria-controls="gov-banner-default"
    
    data-testid="storybook-django-banner"
    
    >
    
        

        
                    <span class="usa-banner__button-text">Here's how you know</span>
                

        
    
        
            </button>
        


            </div>
        </header>

        <div class="usa-banner__content usa-accordion__content"
             id="gov-banner-default"
             hidden>
            <div class="grid-row grid-gap-lg">
                <div class="usa-banner__guidance tablet:grid-col-6">
                    <img class="usa-banner__icon usa-media-block__img"
                         src="/static/img/icon-dot-gov.svg"
                         alt=""
                         aria-hidden="true" />
                    <div class="usa-media-block__body">
                        <p>
                            <strong>Official websites use .gov</strong>
                            <br />
                            A
                            <strong>.gov</strong> website belongs to an official
                            government organization in the United States.
                        </p>
                    </div>
                </div>

                <div class="usa-banner__guidance tablet:grid-col-6">
                    <img class="usa-banner__icon usa-media-block__img"
                         src="/static/img/icon-https.svg"
                         alt=""
                         aria-hidden="true" />

                    <div class="usa-media-block__body">
                        <p>
                            <strong>Secure .gov websites use HTTPS</strong>
                            <br />
                            A <strong>lock</strong> (
                            <span class="icon-lock">
                                <svg xmlns="http://www.w3.org/2000/svg"
                                     width="52"
                                     height="64"
                                     viewBox="0 0 52 64"
                                     class="usa-banner__lock-image"
                                     role="graphics-symbol"
                                     aria-labelledby="banner-lock-description"
                                     focusable="false">
                                    <title id="banner-lock-title">Lock</title>
                                    <desc id="banner-lock-description">
                                    Locked padlock icon
                                    </desc>
                                    <path fill="#000000"
                                          fill-rule="evenodd"
                                          d="M26 0c10.493 0 19 8.507 19 19v9h3a4 4 0 0 1 4 4v28a4 4 0 0 1-4 4H4a4 4 0 0 1-4-4V32a4 4 0 0 1 4-4h3v-9C7 8.507 15.507 0 26 0zm0 8c-5.979 0-10.843 4.77-10.996 10.712L15 19v9h22v-9c0-6.075-4.925-11-11-11z" />
                                </svg>
</span>) or <strong>https://</strong> means you've safely
                                connected to the .gov website. Share sensitive
                                information only on official, secure websites.
                            </p>
                        </div>
                    </div>
                </div>
            </div>
        </div>
    </section>

        

        
    
    
    

<div class="usa-overlay">
</div>



<header class="usa-header usa-header--extended usa-header--wide" data-header data-testid="header"    >
    <div class="ncbi-header">
        <div class="ncbi-header__container">
            <a class="ncbi-header__logo-container"
               href="https://www.ncbi.nlm.nih.gov/">
                <img alt="NCBI home page"
                     class="ncbi-header__logo-image"
                     src="/static/img/ncbi-logos/nih-nlm-ncbi--white.svg"
                     width="410"
                     height="100" />
            </a>

            <!-- Mobile menu hamburger button -->
            



















    
        <button
            type="button"
        
    
    class="usa-menu-btn ncbi-header__hamburger-button
           

           
               
               
               
               
            

           
           
           
           "
    
    
    aria-label="Show menu"
    data-testid="navMenuButton"
    
    >
    
        

        
                <svg aria-hidden="true"
                     class="ncbi-hamburger-icon"
                     fill="none"
                     focusable="false"
                     height="21"
                     viewBox="0 0 31 21"
                     width="31"
                     xmlns="http://www.w3.org/2000/svg">
                    <path clip-rule="evenodd"
                          d="M0.125 20.75H30.875V17.3333H0.125V20.75ZM0.125 12.2083H30.875V8.79167H0.125V12.2083ZM0.125 0.25V3.66667H30.875V0.25H0.125Z"
                          fill="#F1F1F1"
                          fill-rule="evenodd" />
                </svg>
            

        
    
        
            </button>
        



            
                <!-- Desktop buttons-->
                <div class="ncbi-header__desktop-buttons">
                    
                        <!-- Desktop search button -->
                        



















    
        <button
            type="button"
        
    
    class="usa-button
           

           
               
               
               
               
            

           
           
           usa-button--unstyled ncbi-header__desktop-button
           "
    aria-expanded="false"
    aria-controls="search-field-desktop-navigation"
    aria-label="Show search overlay"
    data-testid="toggleSearchPanelButton"
    data-toggle-search-panel-button
    >
    
        

        
                            



    <svg class="usa-icon " role="graphics-symbol" aria-hidden="true" >
        
        <use xlink:href="/static/img/sprite.svg#search" />
    </svg>


                            Search
                        

        
    
        
            </button>
        


                    

                    <!-- Desktop login dropdown -->
                    
                        <div class="ncbi-header__login-dropdown">
                            



















    
        <button
            type="button"
        
    
    class="usa-button
           

           
               
               
               
               
            

           
           
           usa-button--unstyled ncbi-header__desktop-button ncbi-header__login-dropdown-button
           "
    aria-expanded="false"
    aria-controls="login-dropdown-menu"
    aria-label="Show login menu"
    data-testid="toggleLoginMenuDropdown"
    data-desktop-login-button
    >
    
        

        
                                



    <svg class="usa-icon " role="graphics-symbol" aria-hidden="true" >
        
        <use xlink:href="/static/img/sprite.svg#person" />
    </svg>



                                <span data-login-dropdown-text>Log in</span>

                                <!-- Dropdown icon pointing up -->
                                



    <svg class="usa-icon ncbi-header__login-dropdown-icon ncbi-header__login-dropdown-icon--expand-less ncbi-header__login-dropdown-icon--hidden" role="graphics-symbol" aria-hidden="true" data-login-dropdown-up-arrow>
        
        <use xlink:href="/static/img/sprite.svg#expand_less" />
    </svg>



                                <!-- Dropdown icon pointing down -->
                                



    <svg class="usa-icon ncbi-header__login-dropdown-icon ncbi-header__login-dropdown-icon--expand-more ncbi-header__login-dropdown-icon--hidden" role="graphics-symbol" aria-hidden="true" data-login-dropdown-down-arrow>
        
        <use xlink:href="/static/img/sprite.svg#expand_more" />
    </svg>


                            

        
    
        
            </button>
        



                            <!-- Login dropdown menu -->
                            <ul class="usa-nav__submenu ncbi-header__login-dropdown-menu"
                                id="login-dropdown-menu"
                                data-desktop-login-menu-dropdown
                                hidden>
                                
                                    <li class="usa-nav__submenu-item">
                                        <!-- Uses custom style overrides to render external and document links. -->
                                        









    <a href="https://www.ncbi.nlm.nih.gov/myncbi/" class="usa-link  "  >
        

        
            Dashboard
        

        
    </a>


                                    </li>
                                
                                    <li class="usa-nav__submenu-item">
                                        <!-- Uses custom style overrides to render external and document links. -->
                                        









    <a href="https://www.ncbi.nlm.nih.gov/myncbi/collections/bibliography/" class="usa-link  "  >
        

        
            Publications
        

        
    </a>


                                    </li>
                                
                                    <li class="usa-nav__submenu-item">
                                        <!-- Uses custom style overrides to render external and document links. -->
                                        









    <a href="https://www.ncbi.nlm.nih.gov/account/settings/" class="usa-link  "  >
        

        
            Account settings
        

        
    </a>


                                    </li>
                                
                                <li class="usa-nav__submenu-item">
                                    



















    
        <button
            type="button"
        
    
    class="usa-button
           

           
               
               
               
               
            

           
           
           usa-button--outline ncbi-header__login-dropdown-logout-button
           "
    
    
    
    data-testid="desktopLogoutButton"
    data-desktop-logout-button
    >
    
        

        Log out

        
    
        
            </button>
        


                                </li>
                            </ul>
                        </div>
                    
                </div>
            
        </div>
    </div>

    <!-- Search panel -->
    
        <div class="ncbi-search-panel ncbi--show-only-at-desktop"
             data-header-search-panel
             hidden>
            <div class="ncbi-search-panel__container">
                <form action="https://www.ncbi.nlm.nih.gov/search/all/"
                      
                      autocomplete="off"
                      class="usa-search usa-search--big ncbi-search-panel__form"
                      data-testid="desktop-navigation-search-form"
                      method="GET"
                      role="search">
                    <label class="usa-sr-only" for="search-field-desktop-navigation">
                        Searchâ€¦
                    </label>
                    <input class="usa-input"
                           id="search-field-desktop-navigation"
                           name="term"
                           
                               placeholder="Search NCBI"
                           
                           type="search"
                           value="" />
                    



















    
        <button
            type="submit"
        
    
    class="usa-button
           

           
               
               
               
               
            

           
           
           
           "
    
    
    
    
    
    >
    
        

        
                        <span class="usa-search__submit-text">
                            Search NCBI
                        </span>
                    

        
    
        
            </button>
        


                </form>

                
            </div>
        </div>
    

    <nav aria-label="Primary navigation" class="usa-nav">
        <p class="usa-sr-only" id="primary-navigation-sr-only-title">
            Primary site navigation
        </p>

        <!-- Mobile menu close button -->
        



















    
        <button
            type="button"
        
    
    class="usa-nav__close ncbi-nav__close-button
           

           
               
               
               
               
            

           
           
           
           "
    
    
    aria-label="Close navigation menu"
    data-testid="navCloseButton"
    
    >
    
        

        
            <img src="/static/img/usa-icons/close.svg" alt="Close" />
        

        
    
        
            </button>
        



        
            <!-- Mobile search component -->
            <form class="usa-search usa-search--small ncbi--hide-at-desktop margin-top-6"
                  action="https://www.ncbi.nlm.nih.gov/search/all/"
                  
                  autocomplete="off"
                  data-testid="mobile-navigation-search-form"
                  method="GET"
                  role="search">
                <label class="usa-sr-only" for="search-field-mobile-navigation">
                    Search
                </label>

                <input class="usa-input"
                       id="search-field-mobile-navigation"
                       type="search"
                       
                           placeholder="Search NCBI"
                       
                       name="term" />

                



















    
        <button
            type="submit"
        
    
    class="usa-button
           

           
               
               
               
               
            

           
           
           
           "
    
    
    
    
    
    >
    
        

        
                    <!-- This SVG should be kept inline and not replaced with a link to the icon as otherwise it will render in the wrong color -->
                    <img src="data:image/svg+xml;base64,PHN2ZyB4bWxucz0iaHR0cDovL3d3dy53My5vcmcvMjAwMC9zdmciIGhlaWdodD0iMjQiIHZpZXdCb3g9IjAgMCAyNCAyNCIgd2lkdGg9IjI0Ij48cGF0aCBkPSJNMCAwaDI0djI0SDB6IiBmaWxsPSJub25lIi8+PHBhdGggZmlsbD0iI2ZmZiIgZD0iTTE1LjUgMTRoLS43OWwtLjI4LS4yN0E2LjQ3MSA2LjQ3MSAwIDAgMCAxNiA5LjUgNi41IDYuNSAwIDEgMCA5LjUgMTZjMS42MSAwIDMuMDktLjU5IDQuMjMtMS41N2wuMjcuMjh2Ljc5bDUgNC45OUwyMC40OSAxOWwtNC45OS01em0tNiAwQzcuMDEgMTQgNSAxMS45OSA1IDkuNVM3LjAxIDUgOS41IDUgMTQgNy4wMSAxNCA5LjUgMTEuOTkgMTQgOS41IDE0eiIvPjwvc3ZnPg=="
                         class="usa-search__submit-icon"
                         alt="Search" />
                

        
    
        
            </button>
        


            </form>

            
        

        <!-- Primary navigation menu items -->
        <!-- This usa-nav__inner wrapper is required to correctly style the navigation items on Desktop -->
        

        
            <div class="ncbi-nav__mobile-login-menu ncbi--hide-at-desktop"
                 data-mobile-login-menu
                 hidden>
                <p class="ncbi-nav__mobile-login-menu-status">
                    Logged in as:
                    <strong class="ncbi-nav__mobile-login-menu-email"
                            data-mobile-login-email-text></strong>
                </p>
                <ul class="usa-nav__primary usa-accordion">
                    
                        <li class="usa-nav__primary-item">
                            









    <a href="https://www.ncbi.nlm.nih.gov/myncbi/" class="usa-link  "  >
        

        
            Dashboard
        

        
    </a>


                        </li>
                    
                        <li class="usa-nav__primary-item">
                            









    <a href="https://www.ncbi.nlm.nih.gov/myncbi/collections/bibliography/" class="usa-link  "  >
        

        
            Publications
        

        
    </a>


                        </li>
                    
                        <li class="usa-nav__primary-item">
                            









    <a href="https://www.ncbi.nlm.nih.gov/account/settings/" class="usa-link  "  >
        

        
            Account settings
        

        
    </a>


                        </li>
                    
                </ul>
            </div>
        

        



















    
        <button
            type="button"
        
    
    class="usa-button
           

           
               
               
               
               
            

           
           
           ncbi-nav__mobile-login-button ncbi--hide-at-desktop
           "
    
    
    
    data-testid="mobileLoginButton"
    data-mobile-login-button
    >
    
        

        Log in

        
    
        
            </button>
        


    </nav>
</header>

    
    
        

<section class="pmc-header pmc-header--basic" aria-label="PMC Header with search box">
    <div class="pmc-nav-container">
        <div class="pmc-header__bar">
           <div class="pmc-header__logo">
               <a href="/" title="Home" aria-label="PMC Home"></a>
           </div>
            <button
                    type="button"
                    class="usa-button usa-button--unstyled pmc-header__search__button"
                    aria-label="Open search"
                    data-ga-category="search"
                    data-ga-action="PMC"
                    data-ga-label="pmc_search_panel_mobile"
            >
                <svg class="usa-icon width-4 height-4 pmc-icon__open" aria-hidden="true" focusable="false" role="img">
                    <use xlink:href="/static/img/sprite.svg#search"></use>
                </svg>
                <svg class="usa-icon width-4 height-4 pmc-icon__close" aria-hidden="true" focusable="false" role="img">
                    <use xlink:href="/static/img/sprite.svg#close"></use>
                </svg>
            </button>
        </div>
        <div class="pmc-header__search">
            


<form class="usa-search usa-search--extra usa-search--article-right-column  pmc-header__search__form" id="pmc-search-form" autocomplete="off" role="search">
<label class="usa-sr-only" for="pmc-search">Search PMC Full-Text Archive</label>
<span class="autoComplete_wrapper flex-1">
<input class="usa-input width-full maxw-none" required="required" placeholder="Search PMC Full-Text Archive" id="pmc-search"  type="search" name="term" data-autocomplete-url="https://pmc.ncbi.nlm.nih.gov/autocomp/search/autocomp/"/>
</span>
<button
class="usa-button"
type="submit"
formaction="https://www.ncbi.nlm.nih.gov/pmc/"
data-ga-category="search"
data-ga-action="PMC"
data-ga-label="PMC_search_button"
>
<span class="usa-search__submit-text">Search in PMC</span>
<img
src="/static/img/usa-icons-bg/search--white.svg"
class="usa-search__submit-icon"
alt="Search"
/>
</button>
</form>
            <div class="display-flex flex-column tablet:flex-row tablet:flex-justify flex-justify-center flex-align-center width-full desktop:maxw-44">
                <ul class="pmc-header__search__menu">
                    <li>
                        
                            <a class="usa-link" href="/journals/" data-ga-action="featured_link" data-ga-label="journal list">
                                Journal List
                            </a>
                        
                    </li>
                    <li>
                        
                            <a class="usa-link" href="/about/userguide/" data-ga-action="featured_link"
                            data-ga-label="user guide">
                                User Guide
                            </a>
                        
                    </li>
                </ul>
                
                    <button form="pmc-search-form" formaction="https://pmc.ncbi.nlm.nih.gov/search/" type="submit" class="usa-button usa-button--unstyled hover:text-no-underline text-no-underline width-auto margin-top-1 tablet:margin-top-0">
     <span class="bg-green-label padding-05 text-white">New</span><span class="text-underline text-primary">Try this search in PMC Beta Search</span>
</button>
                
            </div>
        </div>
    </div>
</section>

    


        
        

       
  <div class="usa-section padding-top-0 desktop:padding-top-6 pmc-article-section" data-article-db="pmc" data-article-id="12363034">

    

   



<div class="grid-container pmc-actions-bar" aria-label="Actions bar" role="complementary">
    <div class="grid-row">
        <div class="grid-col-fill display-flex">
             <div class="display-flex">
                <ul class="usa-list usa-list--unstyled usa-list--horizontal">
                    <li class="margin-right-2 mobile-lg:margin-right-4 display-flex mob">
                        <button
                                type="button"
                                class="usa-button pmc-sidenav__container__open usa-button--unstyled width-auto display-flex"
                                aria-label="Open resources"
                                data-extra-class="is-visible-resources"
                                data-ga-category="resources_accordion"
                                data-ga-action="click"
                                data-ga-label="mobile_icon"
                        >
                            <svg class="usa-icon width-4 height-4" aria-hidden="true" focusable="false" role="img">
                                <use xlink:href="/static/img/sprite.svg#more_vert"></use>
                            </svg>
                        </button>
                    </li>
                    
                    <li class="margin-right-2 mobile-lg:margin-right-4 display-flex mob">
                        <a
                                href="https://doi.org/10.1186/s13046-025-03485-6"
                                class="usa-link display-flex usa-tooltip"
                                role="button"
                                target="_blank"
                                rel="noreferrer noopener"
                                title="View on publisher site"
                                data-position="bottom"
                                aria-label="View on publisher site"
                                data-ga-category="actions"
                                data-ga-action="click"
                                data-ga-label="publisher_link_mobile"
                        >
                                <svg class="usa-icon width-4 height-4" aria-hidden="true" focusable="false" role="img">
                                    <use xlink:href="/static/img/sprite.svg#launch"></use>
                                </svg>
                        </a>
                    </li>
                    
                    
                        <li class="margin-right-2 mobile-lg:margin-right-4 display-flex">
                             <a
                                     href="pdf/13046_2025_Article_3485.pdf"
                                     class="usa-link display-flex usa-tooltip"
                                     role="button"
                                     title="Download PDF"
                                     data-position="bottom"
                                     aria-label="Download PDF"
                                     data-ga-category="actions"
                                     data-ga-action="click"
                                     data-ga-label="pdf_download_mobile"
                             >
                                <svg class="usa-icon width-4 height-4" aria-hidden="true" focusable="false" role="img">
                                    <use xlink:href="/static/img/sprite.svg#file_download"></use>
                                </svg>
                            </a>
                        </li>
                    
                    <li class="margin-right-2 mobile-lg:margin-right-4 display-flex">
                        <button
                            class="usa-button usa-button--unstyled  usa-tooltip collections-dialog-trigger collections-button display-flex collections-button-empty"
                            title="Add to Collections"
                            data-position="bottom"
                            aria-label="Save article in MyNCBI collections."
                            data-ga-category="actions"
                            data-ga-action="click"
                            data-ga-label="collections_button_mobile"
                            data-collections-open-dialog-enabled="false"
                            data-collections-open-dialog-url="https://account.ncbi.nlm.nih.gov/?back_url=https%3A%2F%2Fpmc.ncbi.nlm.nih.gov%2Farticles%2FPMC12363034%2F%3Freport%3Dclassic%23open-collections-dialog"
                            data-in-collections="false"
                        >
                            <svg class="usa-icon width-4 height-4 usa-icon--bookmark-full" aria-hidden="true" focusable="false" role="img" hidden>
                                <use xlink:href="/static/img/action-bookmark-full.svg#icon"></use>
                            </svg>
                            <svg class="usa-icon width-4 height-4 usa-icon--bookmark-empty" aria-hidden="true" focusable="false" role="img" hidden>
                                <use xlink:href="/static/img/action-bookmark-empty.svg#icon"></use>
                            </svg>
                        </button>
                    </li>
                    
                    <li class="margin-right-2 mobile-lg:margin-right-4 display-flex">
                        <button role="button" class="usa-button usa-button--unstyled usa-tooltip citation-dialog-trigger display-flex"
                            aria-label="Open dialog with citation text in different styles"
                            title="Cite"
                            data-position="bottom"
                            data-ga-category="actions"
                            data-ga-action="open"
                            data-ga-label="cite_mobile"
                            data-all-citations-url="/resources/citations/12363034/"
                            data-citation-style="nlm"
                            data-download-format-link="/resources/citations/12363034/export/"
                        >
                            <svg class="usa-icon width-4 height-4 usa-icon--bookmark-empty" aria-hidden="true" focusable="false" role="img" hidden>
                                <use xlink:href="/static/img/sprite.svg#format_quote"></use>
                            </svg>
                        </button>
                    </li>
                    
                    <li class="pmc-permalink display-flex" >
                         <button
                                 type="button"
                                 title="Permalink"
                                 data-position="bottom"
                                 class="usa-button usa-button--unstyled display-flex usa-tooltip"
                                 aria-label="Show article permalink"
                                 aria-expanded="false"
                                 aria-haspopup="true"
                                 data-ga-category="actions"
                                 data-ga-action="open"
                                 data-ga-label="permalink_mobile"
                         >
                            <svg class="usa-icon width-4 height-4" aria-hidden="true" focusable="false" role="img">
                                <use xlink:href="/static/img/sprite.svg#share"></use>
                            </svg>
                        </button>
                        

<div class="pmc-permalink__dropdown" hidden>
    <div class="pmc-permalink__dropdown__container">
          <h2 class="usa-modal__heading margin-top-0 margin-bottom-2 text-uppercase font-sans-xs">PERMALINK</h2>
          <div class="pmc-permalink__dropdown__content">
              <input type="text" class="usa-input" value="https://pmc.ncbi.nlm.nih.gov/articles/PMC12363034/" aria-label="Article permalink">
              <button class="usa-button display-inline-flex pmc-permalink__dropdown__copy__btn margin-right-0" title="Copy article permalink" data-ga-category="save_share" data-ga-action="link" data-ga-label="copy_link">
                  <svg class="usa-icon" aria-hidden="true" focusable="false" role="img">
                    <use xlink:href="/static/img/sprite.svg#content_copy"></use>
                  </svg>
                  <span class="margin-left-1">Copy</span>
              </button>
          </div>
    </div>
</div>
                    </li>
                </ul>
            </div>
            <button
                    type="button"
                    class="usa-button pmc-sidenav__container__open usa-button--unstyled width-auto display-flex"
                    aria-label="Open article navigation"
                    data-extra-class="is-visible-in-page"
                    data-ga-category="actions"
                    data-ga-action="open"
                    data-ga-label="article_nav_mobile"
            >
                <svg class="usa-icon width-4 height-4" aria-hidden="true" focusable="false" role="img">
                    <use xlink:href="/static/img/sprite.svg#list"></use>
                </svg>
            </button>
        </div>
    </div>
</div>
    <div class="grid-container desktop:padding-left-6">
      <div id="article-container" class="grid-row grid-gap">
        <div class="grid-col-12 desktop:grid-col-8 order-2 pmc-layout__content">
            <div class="grid-container padding-left-0 padding-right-0">
                <div class="grid-row desktop:margin-left-neg-6">
                    <div class="grid-col-12">
                        <div class="pmc-layout__disclaimer" role="complementary" aria-label="Disclaimer note">
    As a library, NLM provides access to scientific literature. Inclusion in an NLM database does not imply endorsement of, or agreement with,
    the contents by NLM or the National Institutes of Health.<br/>
    Learn more:
    <a class="usa-link" data-ga-category="Link click" data-ga-action="Disclaimer" data-ga-label="New disclaimer box" href="/about/disclaimer/">PMC Disclaimer</a>
    |
    <a class="usa-link" data-ga-category="Link click" data-ga-action="PMC Copyright Notice" data-ga-label="New disclaimer box" href="/about/copyright/">
        PMC Copyright Notice
    </a>
</div>
                    </div>
                </div>
                <div class="grid-row pmc-wm desktop:margin-left-neg-6">
                    <!-- Main content -->
                    <main
                      id="main-content"
                      class="usa-layout-docs__main usa-layout-docs grid-col-12 pmc-layout pmc-prose padding-0"
                    >

                      
                        <section class="pmc-journal-banner text-center line-height-none" aria-label="Journal banner"><img src="https://cdn.ncbi.nlm.nih.gov/pmc/banners/logo-jeccr.png" alt="Journal of Experimental &amp; Clinical Cancer Research : CR logo" usemap="#pmc-banner-imagemap" width="500" height="75"><map name="pmc-banner-imagemap"><area alt="Link to Journal of Experimental &amp; Clinical Cancer Research : CR" title="Link to Journal of Experimental &amp; Clinical Cancer Research : CR" shape="default" href="https://jeccr.biomedcentral.com/" target="_blank" rel="noopener noreferrer"></map></section><article lang="en"><section aria-label="Article citation and metadata"><section class="pmc-layout__citation font-secondary font-xs"><div>
<div class="display-inline-block"><button type="button" class="cursor-pointer text-no-underline bg-transparent border-0 padding-0 text-left margin-0 text-normal text-primary" aria-controls="journal_context_menu">J Exp Clin Cancer Res</button></div>. 2025 Aug 19;44:245. doi: <a href="https://doi.org/10.1186/s13046-025-03485-6" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">10.1186/s13046-025-03485-6</a>
</div>
<nav id="journal_context_menu" hidden="hidden"><ul class="menu-list font-family-ui" role="menu">
<li role="presentation"><a href="https://www.ncbi.nlm.nih.gov/pmc/?term=%22J%20Exp%20Clin%20Cancer%20Res%22%5Bjour%5D" class="usa-link" role="menuitem">Search in PMC</a></li>
<li role="presentation"><a href="https://pubmed.ncbi.nlm.nih.gov/?term=%22J%20Exp%20Clin%20Cancer%20Res%22%5Bjour%5D" lang="en" class="usa-link" role="menuitem">Search in PubMed</a></li>
<li role="presentation"><a href="https://www.ncbi.nlm.nih.gov/nlmcatalog?term=%22J%20Exp%20Clin%20Cancer%20Res%22%5BTitle%20Abbreviation%5D" class="usa-link" role="menuitem">View in NLM Catalog</a></li>
<li role="presentation"><a href="?term=%22J%20Exp%20Clin%20Cancer%20Res%22%5Bjour%5D" class="usa-link" role="menuitem" data-add-to-search="true">Add to search</a></li>
</ul></nav></section><section class="front-matter"><div class="ameta p font-secondary font-xs">
<hgroup><h1>Pyrotinib targeted EGFR/GRP78 mediated cell apoptosis in high EGFR gene copy number gastric cancer</h1></hgroup><div class="cg p">
<a href="https://pubmed.ncbi.nlm.nih.gov/?term=%22Bao%20L%22%5BAuthor%5D" class="usa-link" aria-describedby="id1"><span class="name western">Lingbo Bao</span></a><div hidden="hidden" id="id1">
<h3><span class="name western">Lingbo Bao</span></h3>
<div class="p">
<sup>1</sup>Cancer Center of Daping Hospital, Army Medical University, Chongqing, 400037 China </div>
<div class="p">
<sup>3</sup>Department of Oncology, General Hospital of Western Theater Command, Chengdu, 610083 China </div>
<div class="p">Find articles by <a href="https://pubmed.ncbi.nlm.nih.gov/?term=%22Bao%20L%22%5BAuthor%5D" class="usa-link"><span class="name western">Lingbo Bao</span></a>
</div>
</div>
<sup>1,</sup><sup>3,</sup><sup>#</sup>, <a href="https://pubmed.ncbi.nlm.nih.gov/?term=%22Wang%20X%22%5BAuthor%5D" class="usa-link" aria-describedby="id2"><span class="name western">Xudong Wang</span></a><div hidden="hidden" id="id2">
<h3><span class="name western">Xudong Wang</span></h3>
<div class="p">
<sup>1</sup>Cancer Center of Daping Hospital, Army Medical University, Chongqing, 400037 China </div>
<div class="p">Find articles by <a href="https://pubmed.ncbi.nlm.nih.gov/?term=%22Wang%20X%22%5BAuthor%5D" class="usa-link"><span class="name western">Xudong Wang</span></a>
</div>
</div>
<sup>1,</sup><sup>#</sup>, <a href="https://pubmed.ncbi.nlm.nih.gov/?term=%22Liao%20X%22%5BAuthor%5D" class="usa-link" aria-describedby="id3"><span class="name western">Xiuyong Liao</span></a><div hidden="hidden" id="id3">
<h3><span class="name western">Xiuyong Liao</span></h3>
<div class="p">
<sup>2</sup>Department of Oncology, Chongqing University Qianjiang Hospital, Qianjiang Central Hospital of Chongqing, No. 360, South Section of Zhengzhou Road, Qianjiang District, Chongqing, 409000 China </div>
<div class="p">Find articles by <a href="https://pubmed.ncbi.nlm.nih.gov/?term=%22Liao%20X%22%5BAuthor%5D" class="usa-link"><span class="name western">Xiuyong Liao</span></a>
</div>
</div>
<sup>2,</sup><sup>#</sup>, <a href="https://pubmed.ncbi.nlm.nih.gov/?term=%22Li%20D%22%5BAuthor%5D" class="usa-link" aria-describedby="id4"><span class="name western">Dong Li</span></a><div hidden="hidden" id="id4">
<h3><span class="name western">Dong Li</span></h3>
<div class="p">
<sup>3</sup>Department of Oncology, General Hospital of Western Theater Command, Chengdu, 610083 China </div>
<div class="p">Find articles by <a href="https://pubmed.ncbi.nlm.nih.gov/?term=%22Li%20D%22%5BAuthor%5D" class="usa-link"><span class="name western">Dong Li</span></a>
</div>
</div>
<sup>3,</sup><sup>#</sup>, <a href="https://pubmed.ncbi.nlm.nih.gov/?term=%22Li%20C%22%5BAuthor%5D" class="usa-link" aria-describedby="id5"><span class="name western">ChunXue Li</span></a><div hidden="hidden" id="id5">
<h3><span class="name western">ChunXue Li</span></h3>
<div class="p">
<sup>4</sup>Department of General Surgery, Daping Hospital, Third Military Medical University (Army Medical University), Chongqing, 400042 China </div>
<div class="p">Find articles by <a href="https://pubmed.ncbi.nlm.nih.gov/?term=%22Li%20C%22%5BAuthor%5D" class="usa-link"><span class="name western">ChunXue Li</span></a>
</div>
</div>
<sup>4,</sup><sup>#</sup>, <a href="https://pubmed.ncbi.nlm.nih.gov/?term=%22Dai%20N%22%5BAuthor%5D" class="usa-link" aria-describedby="id6"><span class="name western">Nan Dai</span></a><div hidden="hidden" id="id6">
<h3><span class="name western">Nan Dai</span></h3>
<div class="p">
<sup>1</sup>Cancer Center of Daping Hospital, Army Medical University, Chongqing, 400037 China </div>
<div class="p">Find articles by <a href="https://pubmed.ncbi.nlm.nih.gov/?term=%22Dai%20N%22%5BAuthor%5D" class="usa-link"><span class="name western">Nan Dai</span></a>
</div>
</div>
<sup>1</sup>, <a href="https://pubmed.ncbi.nlm.nih.gov/?term=%22Dai%20X%22%5BAuthor%5D" class="usa-link" aria-describedby="id7"><span class="name western">Xiaoyan Dai</span></a><div hidden="hidden" id="id7">
<h3><span class="name western">Xiaoyan Dai</span></h3>
<div class="p">
<sup>1</sup>Cancer Center of Daping Hospital, Army Medical University, Chongqing, 400037 China </div>
<div class="p">Find articles by <a href="https://pubmed.ncbi.nlm.nih.gov/?term=%22Dai%20X%22%5BAuthor%5D" class="usa-link"><span class="name western">Xiaoyan Dai</span></a>
</div>
</div>
<sup>1</sup>, <a href="https://pubmed.ncbi.nlm.nih.gov/?term=%22Yang%20J%22%5BAuthor%5D" class="usa-link" aria-describedby="id8"><span class="name western">Jing Yang</span></a><div hidden="hidden" id="id8">
<h3><span class="name western">Jing Yang</span></h3>
<div class="p">
<sup>1</sup>Cancer Center of Daping Hospital, Army Medical University, Chongqing, 400037 China </div>
<div class="p">Find articles by <a href="https://pubmed.ncbi.nlm.nih.gov/?term=%22Yang%20J%22%5BAuthor%5D" class="usa-link"><span class="name western">Jing Yang</span></a>
</div>
</div>
<sup>1</sup>, <a href="https://pubmed.ncbi.nlm.nih.gov/?term=%22Hu%20N%22%5BAuthor%5D" class="usa-link" aria-describedby="id9"><span class="name western">Nana Hu</span></a><div hidden="hidden" id="id9">
<h3><span class="name western">Nana Hu</span></h3>
<div class="p">
<sup>1</sup>Cancer Center of Daping Hospital, Army Medical University, Chongqing, 400037 China </div>
<div class="p">Find articles by <a href="https://pubmed.ncbi.nlm.nih.gov/?term=%22Hu%20N%22%5BAuthor%5D" class="usa-link"><span class="name western">Nana Hu</span></a>
</div>
</div>
<sup>1</sup>, <a href="https://pubmed.ncbi.nlm.nih.gov/?term=%22Tong%20X%22%5BAuthor%5D" class="usa-link" aria-describedby="id10"><span class="name western">Xueling Tong</span></a><div hidden="hidden" id="id10">
<h3><span class="name western">Xueling Tong</span></h3>
<div class="p">
<sup>1</sup>Cancer Center of Daping Hospital, Army Medical University, Chongqing, 400037 China </div>
<div class="p">Find articles by <a href="https://pubmed.ncbi.nlm.nih.gov/?term=%22Tong%20X%22%5BAuthor%5D" class="usa-link"><span class="name western">Xueling Tong</span></a>
</div>
</div>
<sup>1</sup>, <a href="https://pubmed.ncbi.nlm.nih.gov/?term=%22He%20Z%22%5BAuthor%5D" class="usa-link" aria-describedby="id11"><span class="name western">Zhenjie He</span></a><div hidden="hidden" id="id11">
<h3><span class="name western">Zhenjie He</span></h3>
<div class="p">
<sup>1</sup>Cancer Center of Daping Hospital, Army Medical University, Chongqing, 400037 China </div>
<div class="p">Find articles by <a href="https://pubmed.ncbi.nlm.nih.gov/?term=%22He%20Z%22%5BAuthor%5D" class="usa-link"><span class="name western">Zhenjie He</span></a>
</div>
</div>
<sup>1</sup>, <a href="https://pubmed.ncbi.nlm.nih.gov/?term=%22Zhao%20Y%22%5BAuthor%5D" class="usa-link" aria-describedby="id12"><span class="name western">Yuancheng Zhao</span></a><div hidden="hidden" id="id12">
<h3><span class="name western">Yuancheng Zhao</span></h3>
<div class="p">
<sup>5</sup>Department of Ophthalmology, The General Hospital of Western Theater Command, Chengdu, 610083 China </div>
<div class="p">Find articles by <a href="https://pubmed.ncbi.nlm.nih.gov/?term=%22Zhao%20Y%22%5BAuthor%5D" class="usa-link"><span class="name western">Yuancheng Zhao</span></a>
</div>
</div>
<sup>5</sup>, <a href="https://pubmed.ncbi.nlm.nih.gov/?term=%22Liu%20Z%22%5BAuthor%5D" class="usa-link" aria-describedby="id13"><span class="name western">Zheng Liu</span></a><div hidden="hidden" id="id13">
<h3><span class="name western">Zheng Liu</span></h3>
<div class="p">
<sup>1</sup>Cancer Center of Daping Hospital, Army Medical University, Chongqing, 400037 China </div>
<div class="p">
<sup>3</sup>Department of Oncology, General Hospital of Western Theater Command, Chengdu, 610083 China </div>
<div class="p">Find articles by <a href="https://pubmed.ncbi.nlm.nih.gov/?term=%22Liu%20Z%22%5BAuthor%5D" class="usa-link"><span class="name western">Zheng Liu</span></a>
</div>
</div>
<sup>1,</sup><sup>3</sup>, <a href="https://pubmed.ncbi.nlm.nih.gov/?term=%22Hu%20Y%22%5BAuthor%5D" class="usa-link" aria-describedby="id14"><span class="name western">Yue Hu</span></a><div hidden="hidden" id="id14">
<h3><span class="name western">Yue Hu</span></h3>
<div class="p">
<sup>1</sup>Cancer Center of Daping Hospital, Army Medical University, Chongqing, 400037 China </div>
<div class="p">Find articles by <a href="https://pubmed.ncbi.nlm.nih.gov/?term=%22Hu%20Y%22%5BAuthor%5D" class="usa-link"><span class="name western">Yue Hu</span></a>
</div>
</div>
<sup>1</sup>, <a href="https://pubmed.ncbi.nlm.nih.gov/?term=%22Shan%20J%22%5BAuthor%5D" class="usa-link" aria-describedby="id15"><span class="name western">Jinlu Shan</span></a><div hidden="hidden" id="id15">
<h3><span class="name western">Jinlu Shan</span></h3>
<div class="p">
<sup>1</sup>Cancer Center of Daping Hospital, Army Medical University, Chongqing, 400037 China </div>
<div class="p">Find articles by <a href="https://pubmed.ncbi.nlm.nih.gov/?term=%22Shan%20J%22%5BAuthor%5D" class="usa-link"><span class="name western">Jinlu Shan</span></a>
</div>
</div>
<sup>1,</sup><sup>âœ‰</sup>, <a href="https://pubmed.ncbi.nlm.nih.gov/?term=%22Wang%20D%22%5BAuthor%5D" class="usa-link" aria-describedby="id16"><span class="name western">Dong Wang</span></a><div hidden="hidden" id="id16">
<h3><span class="name western">Dong Wang</span></h3>
<div class="p">
<sup>2</sup>Department of Oncology, Chongqing University Qianjiang Hospital, Qianjiang Central Hospital of Chongqing, No. 360, South Section of Zhengzhou Road, Qianjiang District, Chongqing, 409000 China </div>
<div class="p">Find articles by <a href="https://pubmed.ncbi.nlm.nih.gov/?term=%22Wang%20D%22%5BAuthor%5D" class="usa-link"><span class="name western">Dong Wang</span></a>
</div>
</div>
<sup>2,</sup><sup>âœ‰</sup>, <a href="https://pubmed.ncbi.nlm.nih.gov/?term=%22Li%20M%22%5BAuthor%5D" class="usa-link" aria-describedby="id17"><span class="name western">Mengxia Li</span></a><div hidden="hidden" id="id17">
<h3><span class="name western">Mengxia Li</span></h3>
<div class="p">
<sup>1</sup>Cancer Center of Daping Hospital, Army Medical University, Chongqing, 400037 China </div>
<div class="p">Find articles by <a href="https://pubmed.ncbi.nlm.nih.gov/?term=%22Li%20M%22%5BAuthor%5D" class="usa-link"><span class="name western">Mengxia Li</span></a>
</div>
</div>
<sup>1,</sup><sup>âœ‰</sup>, <a href="https://pubmed.ncbi.nlm.nih.gov/?term=%22Chen%20Q%22%5BAuthor%5D" class="usa-link" aria-describedby="id18"><span class="name western">Qian Chen</span></a><div hidden="hidden" id="id18">
<h3><span class="name western">Qian Chen</span></h3>
<div class="p">
<sup>1</sup>Cancer Center of Daping Hospital, Army Medical University, Chongqing, 400037 China </div>
<div class="p">Find articles by <a href="https://pubmed.ncbi.nlm.nih.gov/?term=%22Chen%20Q%22%5BAuthor%5D" class="usa-link"><span class="name western">Qian Chen</span></a>
</div>
</div>
<sup>1,</sup><sup>âœ‰</sup>
</div>
<ul class="d-buttons inline-list">
<li><button class="d-button" aria-controls="aip_a" aria-expanded="false">Author information</button></li>
<li><button class="d-button" aria-controls="anp_a" aria-expanded="false">Article notes</button></li>
<li><button class="d-button" aria-controls="clp_a" aria-expanded="false">Copyright and License information</button></li>
</ul>
<div class="d-panels font-secondary-light">
<div id="aip_a" class="d-panel p" style="display: none">
<div class="p" id="Aff1">
<sup>1</sup>Cancer Center of Daping Hospital, Army Medical University, Chongqing, 400037 China </div>
<div id="Aff2">
<sup>2</sup>Department of Oncology, Chongqing University Qianjiang Hospital, Qianjiang Central Hospital of Chongqing, No. 360, South Section of Zhengzhou Road, Qianjiang District, Chongqing, 409000 China </div>
<div id="Aff3">
<sup>3</sup>Department of Oncology, General Hospital of Western Theater Command, Chengdu, 610083 China </div>
<div id="Aff4">
<sup>4</sup>Department of General Surgery, Daping Hospital, Third Military Medical University (Army Medical University), Chongqing, 400042 China </div>
<div id="Aff5">
<sup>5</sup>Department of Ophthalmology, The General Hospital of Western Theater Command, Chengdu, 610083 China </div>
<div class="author-notes p">
<div class="fn" id="_fncrsp93pmc__">
<sup>âœ‰</sup><p class="display-inline">Corresponding author.</p>
</div>
<div class="fn" id="_eqcntrb93pmc__">
<sup>#</sup><p class="display-inline">Contributed equally.</p>
</div>
</div>
</div>
<div id="anp_a" class="d-panel p" style="display: none"><div class="notes p"><section id="historyarticle-meta1" class="history"><p>Received 2025 Mar 19; Accepted 2025 Jul 21; Collection date 2025.</p></section></div></div>
<div id="clp_a" class="d-panel p" style="display: none">
<div>Â© The Author(s) 2025</div>
<p><strong>Open Access</strong> This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the articleâ€™s Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the articleâ€™s Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit <a href="https://creativecommons.org/licenses/by/4.0/" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">http://creativecommons.org/licenses/by/4.0/</a>. The Creative Commons Public Domain Dedication waiver (<a href="https://creativecommons.org/publicdomain/zero/1.0/" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">http://creativecommons.org/publicdomain/zero/1.0/</a>) applies to the data made available in this article, unless otherwise stated in a credit line to the data.</p>
<div class="p"><a href="/about/copyright/" class="usa-link">PMC Copyright notice</a></div>
</div>
</div>
<div>PMCID: PMC12363034Â Â PMID: <a href="https://pubmed.ncbi.nlm.nih.gov/40830980/" class="usa-link">40830980</a>
</div>
</div></section></section><section aria-label="Article content"><section class="body main-article-body"><section class="abstract" id="Abs1"><h2>Abstract</h2>
<section id="sec1"><h3 class="pmc_sec_title">Background</h3>
<p id="Par1">Despite frequent Epidermal Growth Factor Receptor (<em>EGFR</em>) amplification and overexpression in gastric cancer, limited therapeutic responses were observed in existing EGFR-targeted agents. Pyrotinib, an irreversible dual EGFR/HER2 tyrosine kinase inhibitor, has shown clinical efficacy in HER2-driven malignancies, but its potential role in <em>EGFR</em>-high copy number gastric cancer remains to be investigated.</p></section><section id="sec2"><h3 class="pmc_sec_title">Methods</h3>
<p id="Par2">Using <em>EGFR</em>-high copy number gastric cancer cell lines, primary cells and subcutaneous tumor models in nude mice, we systematically evaluated pyrotinibâ€™s anti-tumor activity through viability assays, apoptosis analysis, and transcriptomic profiling. Mechanistic studies included co-immunoprecipitation, proximity ligation assays, ubiquitination assays, and RNA sequencing.</p></section><section id="sec3"><h3 class="pmc_sec_title">Results</h3>
<p id="Par3">Pyrotinib selectively suppressed proliferation, induced apoptosis, and chemosensitized in <em>EGFR</em>-high copy number gastric cancer models. Mechanistically, pyrotinib promoted EGFR-GRP78 (Glucose-regulated protein 78) complex formation in the endoplasmic reticulum, activating the protein kinase R-like endoplasmic reticulum kinase/ activating transcription factor 4/ C-EBP homologous protein (PERK/ATF4/CHOP) axis to drive ER stress-mediated apoptosis. Concurrently, pyrotinib inhibited GRP78 phosphorylation at Thr62, triggering K48-linked ubiquitination (ubiquitin chains formed via lysine 48 linkages) and proteasomal degradation, which impaired DNA double-strand break (DSB) repair and sensitized cells to oxaliplatin-induced Î³-H2A.X accumulation.</p></section><section id="sec4"><h3 class="pmc_sec_title">Conclusion</h3>
<p id="Par4">This translational study suggests that pyrotinib combined with oxaliplatin may serve as a promising strategy for patients with <em>EGFR</em>-high copy number gastric cancer and highlighted the discovery of this previously unknown EGFR/ GRP78 signaling axis, which provides the molecular basis and the rationale to target EGFR.</p></section><section id="sec5"><h3 class="pmc_sec_title">Supplementary Information</h3>
<p>The online version contains supplementary material available at 10.1186/s13046-025-03485-6.</p></section><section id="kwd-group1" lang="en" class="kwd-group"><p><strong>Keywords:</strong> Pyrotinib, EGFR, GRP78, Ubiquitination, TRIM21</p></section></section><section id="Sec1"><h2 class="pmc_sec_title">Introduction</h2>
<p id="Par5">Gastric cancer (GC) is a prevailing malignant tumor globally, ranking fifth in incidence and mortality rates among all cancer types as reported by GLOBOCAN 2022 [<a href="#CR1" class="usa-link" aria-describedby="CR1">1</a>]. While targeted therapies have revolutionized cancer management, durable responses in GC remain limited. Since the landmark ToGA trial established trastuzumab, the anti-HER2 antibody, as first-line therapy for <em>HER2</em>-positive advanced gastric cancer [<a href="#CR2" class="usa-link" aria-describedby="CR2">2</a>], research has expanded to other targets including human epidermal growth factor receptor (EGFR), vascular endothelial growth factor (VEGF) [<a href="#CR3" class="usa-link" aria-describedby="CR3">3</a>], and Claudin 18.2 [<a href="#CR4" class="usa-link" aria-describedby="CR4">4</a>]. Nevertheless, not all patients respond to targeted therapy, underscoring the urgent need for novel targeted agents for GC to improve the clinical outcomes.</p>
<p id="Par6">The HER (human epidermal growth factor receptor) family, comprising EGFR/HER1, HER2, ErbB3/HER3, and ErbB4/HER4, plays a pivotal role in GC through ligand-independent homodimerization and subsequent activation of oncogenic signaling pathways [<a href="#CR5" class="usa-link" aria-describedby="CR5">5</a>]. Clinically, <em>HER</em> amplification and protein overexpression correlate with aggressive tumor behavior, including poor prognosis and therapeutic resistance in GC. Among these receptors, EGFR and HER2 have emerged as prime therapeutic targets, with their tyrosine kinase domains constituting key molecular sites for pharmacological intervention [<a href="#CR6" class="usa-link" aria-describedby="CR6">6</a>]. Malignant phenotype and poor prognosis, which is associated with activation of EGFR downstream signaling, occurred in multiple malignancies, specifically NSCLC, GC, glioma, and colorectal cancer, etc [<a href="#CR7" class="usa-link" aria-describedby="CR7">7</a>]. GC subtype with EGFR amplification and overexpression benefit from anti-EGFR treatment [<a href="#CR8" class="usa-link" aria-describedby="CR8">8</a>]. Despite the importance of the HER family in the tumorigenesis of GC, anti-EGFR therapies (e.g., cetuximab, panitumumab, gefitinib) have shown limited success in GC clinical trials [<a href="#CR9" class="usa-link" aria-describedby="CR9">9</a>, <a href="#CR10" class="usa-link" aria-describedby="CR10">10</a>]. Emerging evidence suggests pan-HER inhibitors may offer superior anti-tumor activity in preclinical GC models [<a href="#CR11" class="usa-link" aria-describedby="CR11">11</a>, <a href="#CR12" class="usa-link" aria-describedby="CR12">12</a>], suggesting that pan-HER inhibitors may be a more efficacious therapeutic strategy in GC.</p>
<p id="Par7">Mechanistically, many anti-tumor agents impede cell proliferation and induce cell apoptosis by triggering endoplasmic reticulum (ER) stress [<a href="#CR13" class="usa-link" aria-describedby="CR13">13</a>]. ER stress signaling also facilitates the survival of cancer cells tolerant to EGFR tyrosine kinase inhibitors [<a href="#CR14" class="usa-link" aria-describedby="CR14">14</a>], and mediates radioresistance subsequent to EGFR inhibition by cetuximab [<a href="#CR15" class="usa-link" aria-describedby="CR15">15</a>]. GRP78, a key ER protein, coordinates protein import, folding and ER-associated protein degradation by evoking endoplasmic reticulum stress under stress conditions like sugar deprivation, treatment with inhibitor of protein glycosylation or intracellular calcium storage disturbances [<a href="#CR16" class="usa-link" aria-describedby="CR16">16</a>]. Post-translational modifications of GRP78 including phosphorylation [<a href="#CR17" class="usa-link" aria-describedby="CR17">17</a>] and ubiquitination [<a href="#CR18" class="usa-link" aria-describedby="CR18">18</a>] regulate its basic function. GRP78 has a KDEL (Lys-Asp-Glu-Leu) sequence at its C-terminus, which signals its retention in the ER. GRP78 is post-translationally modified by phosphorylation on serine residues in the ER [<a href="#CR19" class="usa-link" aria-describedby="CR19">19</a>]. The phosphorylation of GRP78 may be converted into functional forms by dephosphorylation under starvation [<a href="#CR20" class="usa-link" aria-describedby="CR20">20</a>]. GRP78 phosphorylation also affects its ubiquitination [<a href="#CR21" class="usa-link" aria-describedby="CR21">21</a>], which is important in the progression of cancer [<a href="#CR22" class="usa-link" aria-describedby="CR22">22</a>].</p>
<p id="Par8">In our research, we screened a panel of HER inhibitors and identified pyrotinib as a potent HER inhibitor that selectively suppresses the growth of GC with high EGFR gene copy number (CN) in vitro and in vivo. The combination of pyrotinib with oxaliplatin demonstrated synergistic therapeutic potential in GC patients with <em>EGFR</em>-high CN. Mechanistic investigations revealed pyrotinib promoted EGFR-GRP78 complex formation in the ER lumen, subsequently activating the PERK/ATF4/CHOP signaling pathway, and finally resulted in tumor apoptosis. Additionally, pyrotinib sensitized GC cells to oxaliplatin by through the inhibition of GRP78 phosphorylation at Thr62, resulting in GRP78 ubiquitination. These findings establish the EGFR/GRP78 axis as a critical mediator of pyrotinib-induced apoptosis, and position this agent as a promising therapeutic for <em>EGFR</em>-hyperactive GC.</p></section><section id="Sec2"><h2 class="pmc_sec_title">Materials and methods</h2>
<section id="Sec3"><h3 class="pmc_sec_title">Human cell lines and primary cell culture</h3>
<p id="Par9">SGC7901, MGC803, MKN45, SNU5, SNU601, NUGC4, SNU719, AGS, NCI-N87, HEK293T were purchased from Pricella (Wuhan, China). AGS cells were cultured in F12 medium containing 10% FBS, and other cell lines were cultured in RPMI 1640 supplemented with 10% FBS.</p>
<p id="Par10">For primary culture of GC, fresh cancerous tissue was obtained from informed patients who had undergone surgical resection of primary GC and cut into pieces. The single cell suspension was digested with a mixture of collagenase I and IV. The primary cultures were established in RPMI 1640 medium containing 10% FBS. The successfully established primary GC cells was designated GC-1 and GC-2. All gastric cells were maintained at 37 â„ƒ with 5% CO<sub>2</sub> incubator.</p></section><section id="Sec4"><h3 class="pmc_sec_title">Reagents and antibodies</h3>
<p id="Par11">Antibodies against rabbit PERK (#3192), rabbit GRP78 (for western blot, #3177), rabbit eIF2Î± (#5324), rabbit p-eIF2Î± (#3398), rabbit HER family antibody sampler kit (#8339), mouse Cleaved Caspase-9 (Asp353; #9509), rabbit HA-Tag (#3724), rabbit DYKDDDDK Tag (#14793), rabbit HIS (#2365), rabbit AKT (#9272), rabbit p-AKT (#4060) and rabbit GAPDH (#2118) were purchased from Cell Signaling Technology. Antibodies against rabbit ATF4 (ab270980), rabbit p-EGFR (phospho Y1068; ab40815), rabbit Î³-H2A.X (ab81299) and rabbit p-(Ser/Thr)Phe (ab300625) were obtained from Abcam. Antibodies against rabbit CHOP (15204-1-AP), mouse GRP78 (for immunofluorecence, 66574-1-Ig) were purchased from Proteintech. Anti-FLAG M2 Magnetic Beads (M8823) were got from Sigma-Aldrich. Dacomotinib (HY-13272), afatinib (HY-10261), pyrotinib (HY-104065), oxaliplatin (HY-17371), MG132 (HY-13259), SAL003 (HY15869) were purchased from MedChemExpress (New Jersey, USA) respectively. Cycloheximide (CHX) was purchased from Selleck (S7418). Leupeptin was purchased from Beyotime (SG2012).</p></section><section id="Sec5"><h3 class="pmc_sec_title">Cell viability assay and synergy assay</h3>
<p id="Par12">Cells were seeded into 96-well plates and exposed to different concentrations of pan-HER TKIs (Pyrotinib, Afatinib, Dacomotinib) and Oxaliplatin for indicated times. Next, 100 ÂµL of CCK-8 (C0037, Beyotime) reagent were incubated at 37Â Â°C for 2Â h, and measured the absorbance at 450Â nm. For dose-response curves, cells were plated at 20â€“40% confluence and treated for 48Â h with the drugs dissolved in DMSO.</p>
<p id="Par13">Drug synergy was assessed with Combenefit software [<a href="#CR23" class="usa-link" aria-describedby="CR23">23</a>]. Cells were treated with drug combinations in a 5-by-5 drug concentration matrix and then the cell viability was evaluated. Bliss synergy scores were calculated for each drug combination using Combenefit software (v2.021).</p></section><section id="Sec6"><h3 class="pmc_sec_title">
<em>In vivo</em> study</h3>
<p id="Par14">Animal experiments were approved by the Ethics Committee of Third Military Medical University. Female nude mice (4â€“6 weeks old) were housed in the laboratory of animal center, Daping hospital, Third Military Medical University. SNU719 (2â€‰Ã—â€‰10<sup>6</sup>), NUGC4 (2â€‰Ã—â€‰10<sup>6</sup>), SGC7901 (1â€‰Ã—â€‰10<sup>6</sup>) cells were suspended in mixture of 0.1 mL Matrigel (Corning) and 0.1 mL of PBS, and were injected subcutaneously into the groin of the mice to establish a tumor xenograft model. When the tumor volume reached 100 mm<sup>3</sup>, mice were randomly divided into several groups. Pyrotinib (acquired from Hengrui Pharmaceuticals Co.) was administered orally at a dose of 10Â mg/kg daily, and/or oxaliplatin was given intraperitoneally twice a week at 5Â mg/kg, and the control group was treated with phosphate-buffered saline (PBS). Body weight and tumor size were measured every 2 days. Tumor volume was calculated using the formula: tumor volume = (width<sup>2</sup> Ã— length)/2. After 12 days, the mice were killed and examined by immunohistochemistry (IHC). Sample size of animal experiments were testified by power analysis.</p>
<p id="Par15">For testing the tumorigenicity of SNU719 pyrotinib-resistant (SNU719-Pyr<sup>R</sup>) cells, 2â€‰Ã—â€‰10<sup>6</sup> cells were suspended in mixture of PBS/Matrigel (1:1 v/v), and injected subcutaneously into the groin of the mice. At day 7, mice were randomly divided into four groups. Pyrotinib was given 10Â mg/kg orally once a day, and/or SAL003 were intratumorally injected 1.5Â mg/kg/day. The xenograft tumors were detected and quantified by bioluminescence imaging using In Vivo Image System (IVIS spectrum in vivo imaging system) at 21 days. And then, the mice were killed and examined by immunohistochemistry (IHC).</p></section><section id="Sec7"><h3 class="pmc_sec_title">Next-generation DNA sequencing and transcriptomic sequencing</h3>
<p id="Par16">Next-generation DNA sequencing and transcriptomic sequencing were performed and analyzed by ZhenHe Bioinformatics Institute Co. (Wuxi, China) as previous study [<a href="#CR24" class="usa-link" aria-describedby="CR24">24</a>]. And for DNA sequencing, we provide a quantitative threshold for defining â€œhighâ€ EGFR CN as CNâ€‰â‰¥â€‰5 [<a href="#CR25" class="usa-link" aria-describedby="CR25">25</a>].</p>
<p id="Par17">For transcriptomic profiling, differential gene expression analysis of RNA-seq raw counts was performed using the DESeq2 package (v1.38.3). Significant differentially expressed genes (DEGs) were identified with thresholds of|log2FoldChange| &gt;1 and adjusted <em>p</em>-value (<em>p</em>.adj)â€‰&lt;â€‰0.05. Gene Ontology (GO) enrichment analysis was conducted via the clusterProfiler package (v4.6.2), with gene ID conversion using â€œorg.Hs.eg.dbâ€ (v3.17.0). Top 20 enriched terms ranked by Rich factor (gene count normalized to background) were visualized.</p>
<p id="Par18">Gene Set Enrichment Analysis (GSEA) was performed using the clusterProfiler package (v4.6.2). Gene sets were retrieved from the MSigDB C5 ontology (v2024.1, GO biological processes) and mapped to gene symbols. Enrichment scores were calculated using the GSEA algorithm, with significance evaluated via 1000 permutations. Leading-edge gene sets (adjusted <em>p</em>-valueâ€‰&lt;â€‰0.05) were prioritized. Visualization of enriched pathways (e.g., â€œ<em>PERK</em>-mediated unfolded protein responseâ€) and key annotated genes (e.g., <em>ATF4</em>) was implemented via the â€œenrichplotâ€ package, employing running score plots and label-based gene highlighting. Analytical parameters and workflows are detailed in Supplementary Materials.</p></section><section id="Sec8"><h3 class="pmc_sec_title">Plasmid constructs, virus production and cell infection</h3>
<p id="Par19">Plasmid constructs for the ectopic expression of full-length EGFR (pCMV3-EGFR-FL-HA), extracellular domain deletion variant (pCMV3-EGFR-Î”ECD-HA), tyrosine kinase domain deletion variant (pCMV3-EGFR-Î”TKD-HA), C-terminal deletion variant (pCMV3-EGFR-Î”C-HA), full-length GRP78 (pCMV3-GRP78-FL-Flag), and other GRP78 mutants, pCMV3-PERK, pCMV3-control-Flag, pCMV3-Ub-his, pCMV3-Ub-K48O-His, and pCMV3-Ub-K63O-His were all obtained from Sino Biological (Beijing). NUGC4, SNU719 and HEK293T were transfected with plasmid using Lipofectamine 3000 (Thermo Fisher Scientific) according to the manufacturerâ€™s instructions.</p>
<p id="Par20">To generate stable EGFR and ATF4 knockdown GC cells, SNU719 and NUGC4 (1â€‰Ã—â€‰10<sup>6</sup> /well) were transfected with lentiviral vector (Genechem, Shanghai, China) carrying self-complementary hairpin DNA fragments that could generate EGFR or ATF4-specific shRNA, or non-targeting scrambled RNA (shNC). Cells were infected with lentivirus supplemented with 8Â mg/ml polybrene (Sigma-Aldrich) and then selected with 5Â Âµg/mL puromycin (MedChemExpress) for 7 days. The shRNA sequences are listed in Supplementary Table <a href="#MOESM1" class="usa-link">1</a>.</p></section><section id="Sec9"><h3 class="pmc_sec_title">RNA interference</h3>
<p id="Par21">NUGC4 or SNU719 GC cells were seeded in six-well plates (1â€‰Ã—â€‰10<sup>5</sup>) and transfected with si<em>RNA</em> using Lipofectamine 3000 in Opti-MEM medium for 6Â h. Then, the medium was replaced with fresh RPMI 1640 medium containing 10% FBS. After another 96Â h culture, indicated cells were harvested and analyzed protein expression by western blotting. The siRNA for EGFR (sc-29301), HER2 (sc-29405) and HER4 (sc-35329) were acquired from Santa Cruz. The <em>GRP78</em> si<em>RNA</em> was acquired from Genepharma and the sequences are listed in Supplementary Table <a href="#MOESM1" class="usa-link">2</a>.</p></section><section id="Sec10"><h3 class="pmc_sec_title">Cell cycle analysis</h3>
<p id="Par22">For cell cycle arrest assay, NUGC4 and SNU719 cells were subjected to treatment with pyrotinib (1 ÂµM), oxaliplatin (1Â Âµg/mL), and their combinations for 48Â h. Subsequently, the treated cells were harvested and washed twice with PBS, and then fixed at -20â„ƒ with 70% precooled ethanol for 1Â h. Finally, the cells were stained with propidium iodide (PI) at 4Â Â°C for another 30Â min and measured by flow cytometer (CytoFLEX, Beckman Coulter).</p></section><section id="Sec11"><h3 class="pmc_sec_title">Apoptosis analysis</h3>
<p id="Par23">SGC7901, NUGC4 and SNU719 cells (5â€‰Ã—â€‰10<sup>5</sup> cells/well) were seeded in 6-well plates for the apoptosis assay and exposed to DMSO or Pyr (1 ÂµM) for 48Â h. Subsequently, the cells were washed with PBS and processed with the Annexin V-FITC/PI apoptosis detection kit (C1052, Beyotime) in accordance with the protocol. Finally, the cells were detected by the flow cytometer (CytoFLEX, Beckman Coulter), and the analysis was performed using Flowjo software.</p></section><section id="Sec12"><h3 class="pmc_sec_title">EdU cell proliferation assay</h3>
<p id="Par24">The EdU cell proliferation assay was conducted in accordance with the manufacturerâ€™s protocol. 10 ÂµM EdU reagent (C0071S, Beyotime) was added to the cells treated with different drugs and incubated for 2Â h. After three washes with PBS, the cells were fixed with 4% paraformaldehyde solution for 15Â min, permeabilized with 0.3% Triton X-100 (P0096, Beyotime) for another 15Â min, and then incubated with the click-reaction reagent for 30Â min at room temperature in the dark. Finally, 1Ã— Hoechst 33,342 reagent was used to counterstain the nucleus.</p></section><section id="Sec13"><h3 class="pmc_sec_title">Measurement of ROS</h3>
<p id="Par25">Cells were seeded in six-well plates and treated with DMSO or different concentrations of pyrotinib (0.5, 1, and 2 ÂµM). Subsequently, cells were incubated with DCFH-DA (diluted 1:1000 in serum-free RPMI 1640, BB-47049, Bestbio) at 37Â Â°C for 30Â min and washed three times with the medium. The level of ROS was determined by flow cytometer.</p></section><section id="Sec14"><h3 class="pmc_sec_title">Measurement of intracellular calcium ion</h3>
<p id="Par26">The intracellular calcium ion levels were determined using the diluted Fluo-4 AM fluorescent probe (S1060, Beyotime). SNU719 cells were exposed to DMSO or different concentrations of pyrotinib (0.5, 1, and 2 ÂµM), washed three times with PBS, and subsequently incubated with the Fluo-4 AM working solution (2 ÂµM, 1:1000 diluted in PBS) at 37Â Â°C for 30Â min. After being washed three times with PBS, cells were further incubated for another 30Â min. Eventually, the calcium ion concentration was detected by flow cytometer using FITC channel.</p></section><section id="Sec15"><h3 class="pmc_sec_title">Western blotting and immunoprecipitation</h3>
<p id="Par27">Cells harvested from cultured dishes subjected to different treatments were lysed using RIPA lysis buffer supplemented with 1 mM Phenylmethanesulfonyl fluoride (PMSF, ST506, Beyotime) and 1% phosphatase inhibitor cocktail I (HY-K0021, MCE) and II (HY-k0023, MCE). The protein concentration was ascertained with the BCA protein Assay Kit (P0009, Beyotime). Total protein (30Â Âµg) was separated by 4â€“20% FuturePAGE (ET15420LGel, ACE), and transferred with 0.22 ÂµM polyvinylidene fluoride (PVDF) membrane (Millipore), blocked with 5% (w/v) skim milk/TBST at room temperature for 1Â h, and incubated with primary antibodies overnight. Subsequently, secondary antibodies were incubated at 37Â Â°C for 1Â h. Finally, the membranes were washed with TBST and the densitometric values were determined by gel image analysis system (Bio-Rad).</p>
<p id="Par28">Co-IP was performed as previously study [<a href="#CR26" class="usa-link" aria-describedby="CR26">26</a>]. Briefly, cells in 6Â cm cell culture dishes were transfected with the appropriate plasmids, which were extracted using Pierce IP lysis buffer (87787, Thermo Fisher) along with protease inhibitors. The IP lysates were captured with the appropriate anti-Flag M2 magnetic beads (M8823, Sigma-Aldrich) overnight at 4Â Â°C. After being washed three times with PBS, the beads were boiled with SDS-PAGE loading buffer for 10Â min and then further subjected to immunoblotting.</p></section><section id="Sec16"><h3 class="pmc_sec_title">Immunohistochemistry</h3>
<p id="Par29">Subcutaneous tumors were collected and fixed with 4% paraformaldehyde fixative. Subsequently, the tissues were paraffin-embedded and sectioned at 3Â Î¼m. The deparaffinized and rehydrated sections underwent antigen retrieval using sodium citrate buffer. After being incubated with 5% goat serum for 1Â h, the sections were incubated with the primary antibody overnight at 4Â Â°C. Then, the sections were washed and incubated with MaxVision HRP-Polymer anti-Mouse/Rabbit IHC Kit (KIT-5030, Maxim) for 30Â min at 37Â Â°C. The color was developed using 3,3â€²-diaminobenzidine (DAB) (P0202, Beyotime).</p></section><section id="Sec17"><h3 class="pmc_sec_title">Proximity ligation assay</h3>
<p id="Par30">For the proximity ligation assay, cells were seeded onto glass coverslips and fixed with 4% paraformaldehyde. The cells were washed with PBS and permeabilized with 0.1% Triton X-100 in PBS for 20Â min. After blocking, the cells were incubated overnight at 4Â Â°C with anti-EGFR (#4267, Cell Signal Technology) and anti-GRP78 antibodies (66574-1-Ig, Proteintech), which were diluted in Duolink Antibody diluent (DUO82008, Sigma Aldrich). Subsequently, the prediluted PLUS (DUO92002, Sigma Aldrich) and MINUS probes (DUO92004, Sigma Aldrich) were incubated at 37Â Â°C for 1Â h. Then, cells were incubated with 1Ã— ligase at 37Â Â°C for 30Â min and continued with 1Ã— polymerase at 37Â Â°C for 100Â min for amplification. Finally, the slides were mounted with Duolink in situ mounting medium with DAPI (DUO82040, Sigma Aldrich).</p></section><section id="Sec18"><h3 class="pmc_sec_title">TUNEL assay</h3>
<p id="Par31">TUNEL assay was conducted as described previously using the TUNEL apoptosis detection kit (BA2020, Enogene) (39389211). Briefly, the dewaxed sections were subjected to treatment with proteinase K and blocked by 3% H2O2 in methanol. Subsequently, they were reacted with TdT enzyme reaction buffer at 37Â Â°C in the dark for 60Â min, followed by incubation with Streptavidin-HRP for 30Â min. Finally, the sections were mounted using a mounting medium containing DAPI.</p></section><section id="Sec19"><h3 class="pmc_sec_title">Immunofluorescence</h3>
<p id="Par32">Immunofluorescence was conducted on slices. Initially, the cells were treated by 1 ÂµM ER-tracker red (Beyotime, C1041S) with or without Dio (Beyotime, C1038) at 37Â Â°C for 20Â min, followed by fixation with 4% paraformaldehyde for 5Â min and permeabilization with 0.1% Triton X-100 for 10Â min. After blocking with 5% goat serum for 30Â min, the cells were incubated with rabbit anti-EGFR (#4267, Cell Signal Technology) and mouse anti-GRP78 (66574-1-Ig, Proteintech) antibodies at 4â„ƒ overnight. Then incubated with Alexa Fluor 647-labeled goat anti-rabbit IgG (Hâ€‰+â€‰L) (A04268, Beyotime) and Alexa Fluor 488-labeled goat anti-mouse IgG (Hâ€‰+â€‰L) (A0428, Beyotime) at room temperature for 2Â h, and finally incubated with DAPI for 10Â min. The slides were observed under a confocal scanning microscope.</p></section><section id="Sec20"><h3 class="pmc_sec_title">Fluorescence in-situ hybridization</h3>
<p id="Par33">Fluorescence in-situ hybridization (FISH) was performed in accordance with the manufacturerâ€™s protocol. For pretreatment, the tumor slides were dewaxed and dehydrated. Firstly, 10 ÂµL EGFR/CEN7 FISH probe (FG0242, Abnova) was applied and then denatured at 75â„ƒ for 5Â min. Subsequently, hybridization incubation was conducted at 37â„ƒ in humidified hybridization chamber for 24Â h. Next, the washing procedure was carried out by sliding the section into 2x SSC, and successively incubated for 5Â min at room temperature (RT), 2Â min at 73â„ƒ, and 1Â min at RT. Finally, the sections were mounted with the mounting medium containing DAPI. The average <em>EGFR</em> CN per cell was calculated by the <em>EGFR/CEN7</em> ratio. The <em>EGFR/CEN7</em> ratio for each evaluable tissue core was calculated by dividing the total number of <em>EGFR</em> gene signals by the total number of chromosome 7 centromere (<em>CEN7</em>) signals counted across all evaluable tumor cells within that core. <em>EGFR</em>-high CN was defined as an <em>EGFR/CEN7</em> ratioâ€‰â‰¥â€‰1.5, and the other tumors were classified as <em>EGFR</em>-low. Cancer tissue cores that had no more than 1 signal for either EGFR or CEN7 per cell were excluded from further analyses [<a href="#CR27" class="usa-link" aria-describedby="CR27">27</a>].</p></section><section id="Sec21"><h3 class="pmc_sec_title">Statistical analysis</h3>
<p id="Par34">All experimental data were analyzed using GraphPad Prism 9.0 and R 4.3.1. Normality was assessed via Shapiro-Wilk test; parametric tests (Studentâ€™s <em>t</em>-test or ANOVA with Tukeyâ€™s post-hoc) or non-parametric equivalents (Mann-Whitney U or Kruskal-Wallis) were applied accordingly. Data are presented as meanâ€‰Â±â€‰SEM (<em>n</em>â€‰â‰¥â€‰3 biological replicates), with <em>p</em>â€‰&lt;â€‰0.05 considered significant. Multiple comparisons were adjusted via Benjamini-Hochberg false discovery rate (FDR). Paired Studentâ€™s <em>t</em>-tests were applied to evaluate differences between paired measurements (e.g., different transfection plasmids) under the same experimental conditions.</p></section><section id="Sec22"><h3 class="pmc_sec_title">Database on line and bioinformatics analysis</h3>
<p id="Par35">The correlation between <em>EGFR</em> copy number and pyrotinib sensitivity in GC cell lines was analyzed using the DepMap database (release 2024Q2). Cell lines were filtered to include only <em>HER2 (-)</em> subtypes based on genomic annotations. <em>EGFR</em> CN data were extracted logarithmically, and pyrotinib sensitivity was quantified log fold change (LFC) to control. Pearson correlation analysis was performed to assess associations. Results were visualized using scatter plots with regression lines, highlighting <em>EGFR</em> CN trends relative to drug response. Publicly accessible data and tools from DepMap (<a href="https://depmap.org" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">https://depmap.org</a>) were utilized for this study.</p></section><section id="Sec23"><h3 class="pmc_sec_title">Molecular docking procedures</h3>
<p id="Par36">Protein structures of EGFR (<a href="https://www.ncbi.nlm.nih.gov/protein/P00533" class="usa-link" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">P00533</a>) and GRP78 (<a href="https://www.ncbi.nlm.nih.gov/protein/P11021" class="usa-link" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">P11021</a>) were retrieved from the UniProt database [<a href="#CR28" class="usa-link" aria-describedby="CR28">28</a>]. The 3D structure of Pyrotinib (51039030) was obtained from PubChem. Primary docking between EGFR and Pyrotinib was performed using CB-DOCK2 [<a href="#CR29" class="usa-link" aria-describedby="CR29">29</a>]. Subsequently, the pre-docked EGFR-Pyrotinib complex was rigidly docked to GRP78 using the GRAMM web server (<a href="https://gramm.compbio.ku.edu/" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">https://gramm.compbio.ku.edu/</a>) [<a href="#CR30" class="usa-link" aria-describedby="CR30">30</a>].</p></section></section><section id="Sec24"><h2 class="pmc_sec_title">Results</h2>
<section id="Sec25"><h3 class="pmc_sec_title">High <em>EGFR</em> gene copy number predicts the therapeutic efficacy of pyrotinib in gastric cancer</h3>
<p id="Par37">To investigate the growth-inhibitory effects of pan-<em>HER</em> inhibitors on GC cells, two primary GC cell lines (GC-1 and GC-2) were established, and gene CN alterations were analyzed by next-generation sequencing (NGS). Notably, treatment with pan-HER inhibitors (pyrotinib, dacomitinib, afatinib) significantly suppressed cell proliferation in GC-1 but showed no inhibitory effect on GC-2 (Fig.Â <a href="#Fig1" class="usa-link">1</a>A). Comprehensive genomic profiling by NGS revealed both cell lines were <em>HER2/HER3/HER4</em>-negative metastatic GC models, while EGFR CN analysis identified GC-1 with high <em>EGFR</em> CN and GC-2 with low CN (Fig. <a href="#MOESM2" class="usa-link">S1</a>A), suggesting a correlation between <em>EGFR</em> status and pan-HER inhibitor sensitivity. Among the tested inhibitors, pyrotinib demonstrated superior anti-proliferative activity across multiple concentrations compared to dacomitinib and afatinib (Fig. <a href="#MOESM2" class="usa-link">S1</a>B). Consistent with this, DepMap database analysis revealed a positive correlation between pyrotinib sensitivity and <em>EGFR</em> CN in 17 <em>HER2/HER3/HER4</em>-negative GC cell lines (Fig.Â <a href="#Fig1" class="usa-link">1</a>B).</p>
<figure class="fig xbox font-sm" id="Fig1"><h4 class="obj_head">Fig. 1.</h4>
<p class="img-box line-height-none margin-x-neg-2 tablet:margin-x-0 text-center"><a class="tileshop" target="_blank" href="https://www.ncbi.nlm.nih.gov/core/lw/2.0/html/tileshop_pmc/tileshop_pmc_inline.html?title=Click%20on%20image%20to%20zoom&amp;p=PMC3&amp;id=12363034_13046_2025_3485_Fig1_HTML.jpg"><img class="graphic zoom-in" src="https://cdn.ncbi.nlm.nih.gov/pmc/blobs/c4cf/12363034/7edae8f1ab22/13046_2025_3485_Fig1_HTML.jpg" loading="lazy" id="d33e796" height="806" width="743" alt="Fig. 1"></a></p>
<div class="p text-right font-secondary"><a href="figure/Fig1/" class="usa-link" target="_blank" rel="noopener noreferrer">Open in a new tab</a></div>
<figcaption><p>Pyrotinib suppresses <em>EGFR</em>-high copy number gastric cancer through inhibition of EGFR signaling. <strong>A</strong>. Primary gastric cancer (GC-1 and GC-2) cells treated with pyrotinib, dacomitinib, afatinib, or DMSO (control) at 1 ÂµM concentration over 3 days, growth curves represent three independent experiments. <strong>B</strong>. Correlation analysis between pyrotinib sensitivity (log fold change, LFC) and <em>EGFR</em> gene copy number in a set of 17 HER2 negative GC cell lines from DepMap database. <em>p</em>â€‰=â€‰0.026, R<sup>2</sup>â€‰=â€‰0.288. <strong>C</strong>. Cell growth of 6 GC cell lines was measured after exposure to indicated concentrations of pyrotinib (0, 10, 100, 1000, 10000 nM) for 72Â h using CCK-8 assay. <strong>D</strong>. <em>EGFR</em> copy number in four gastric carcinoma induced xenograft was detected by fluorescence in situ hybridization. <strong>E</strong>. GC cells were harvested and stained with Annexin V-FITC and PI for apoptotic analysis with increasing concentrations of pyrotinib treatment for 48Â h. <strong>F</strong>. Western blotting analysis showed the cleaved caspase-9 level in GC cells treated with different dose of pyrotinib. <strong>G-I</strong>. GC cells were subcutaneously implanted into nude mice. After 10 days, PBS or pyrotinib was orally administered into the mice respectively (<em>n</em>â€‰=â€‰5). Tumor specimens were collected from sacrificed mice on day 11 after administration. (<strong>G</strong>) Tumor volume of indicated xenograft models treated with PBS or Pyr were displayed by growth curves. (<strong>H</strong>) Representative immunohistochemical staining of Ki-67 and phosphorylated EGFR (p-EGFR) in xenograft tumor tissues excised from indicated mice. Bars, 100Â Î¼m. (<strong>I</strong>) Representative TUNEL immunostaining (green) of apoptosis in xenograft tumor tissues excised from indicated mice. Bars, 100Â Î¼m. <strong>J</strong>. Western blot analysis of EGFR, HER2, HER4, and downstream signaling (AKT and p-AKT) in 7 GC cell lines treated with pyrotinib or DMSO. HER2 high CN: NCI-N87; HER2 low CN and <em>EGFR</em> high CN: NUGC4 and SNU719; HER-2 low CN and EGFR low CN: AGS, SNU601, MGC803, SGC7901. <strong>K</strong>. GC cells transfected with siRNAs targeting <em>EGFR</em>, HER2, or HER4 were treated with 1 ÂµM pyrotinib for 48Â h. Cells were harvested and stained with Annexin V-FITC/PI for apoptosis analysis. <strong>L</strong>. Sensitivity of NUGC4 and SNU719 (transfected with sh<em>NC</em>, sh<em>EGFR-2</em> or sh<em>EGFR-3</em>) to pyrotinib (1 ÂµM, 24Â h) were detected by CCK-8 assay. Significance was determined by Paired t-test (A, E, G) and One-way ANOVA (K, L). *<em>p</em>â€‰&lt;â€‰0.05; **<em>p</em>â€‰&lt;â€‰0.01; ***<em>p</em>â€‰&lt;â€‰0.001</p></figcaption></figure><p id="Par39">To validate these findings, pyrotinib efficacy was assessed in six <em>HER2</em>-negative GC cell lines, with NUGC4 and SNU719 showing the highest sensitivity (Fig.Â <a href="#Fig1" class="usa-link">1</a>C and <a href="#MOESM2" class="usa-link">S1</a>C, D). FISH confirmed <em>EGFR</em>-high CN in NUGC4 and SNU719, whereas SGC7901 and MGC803 displayed <em>EGFR</em>-low CN (Fig.Â <a href="#Fig1" class="usa-link">1</a>D and <a href="#MOESM2" class="usa-link">S1</a>E). To further evaluate pyrotinibâ€™s effects on apoptosis and tumor growth in GC models with different EGFR CN status, Annexin V/PI staining, western blot and subcutaneous xenogarft experiments were performed. Flow cytometry analysis demonstrated that pyrotinib dose-dependently induced apoptosis in <em>EGFR</em>-high CN GC cells, whereas no significant effect was observed in <em>EGFR</em>-low CN counterparts (Fig.Â <a href="#Fig1" class="usa-link">1</a>E and <a href="#MOESM2" class="usa-link">S1</a>F). Western blot analysis revealed dose-dependent upregulation of cleaved caspase-9 in <em>EGFR</em>-high CN GC cells treated with pyrotinib (0â€“2 ÂµM), with no significant changes in <em>EGFR</em>-low CN cells (Fig.Â <a href="#Fig1" class="usa-link">1</a>F). In vivo, pyrotinib induced significant tumor regression in <em>EGFR</em>-high CN GC derived xenografts, whereas no inhibition was observed in <em>EGFR</em>â€low CN models (Fig.Â <a href="#Fig1" class="usa-link">1</a>G and <a href="#MOESM2" class="usa-link">S1</a>G). Immunohistochemical analysis corroborated these results, showing reduced Ki-67 proliferation indices and p-EGFR levels in responsive tumors (Fig.Â <a href="#Fig1" class="usa-link">1</a>H). Additionally, TUNEL assays confirmed enhanced apoptosis in pyrotinib-treated NUGC4 and SNU719 xenografts (Fig.Â <a href="#Fig1" class="usa-link">1</a>I and <a href="#MOESM2" class="usa-link">S1</a>H).</p>
<p id="Par40">To further elucidate pyrotinibâ€™s mechanism of activity and identified the potential targets of pyrotinib, we analyzed phosphorylation statuses of EGFR, HER2 and HER4 â€“ the established therapeutic targets of this pan-HER inhibitor across seven GC cell lines following pyrotinib treatment. As shown in Fig.Â <a href="#Fig1" class="usa-link">1</a>J, pyrotinib-sensitive cells (SNU719, NUGC4; <em>EGFR</em>-high CN and <em>HER2/HER4</em>-low CN) exhibited significant suppression of p-EGFR and its downstream p-AKT, whereas p-HER2/p-HER4 suppression was insignificant in AGS, SNU601, MGC803, SGC7901 (<em>EGFR/HER2/HER</em>4-low CN). This differential efficacy stems from intrinsically low basal phosphorylation of HER2/HER4 in low-CN cells, a key determinant of pyrotinibâ€™s cell type-dependent activity.</p>
<p id="Par41">Functional validation using si<em>RNA</em> knockdown revealed that EGFR silencing, but not <em>HER2</em> or <em>HER4</em> knockdown, rescued pyrotinib-induced apoptosis, as confirmed by Annexin V/PI staining assays (Fig.Â <a href="#Fig1" class="usa-link">1</a>K and <a href="#MOESM2" class="usa-link">S1</a>I, J). Similarly, sh<em>EGFR</em>-transfected GC cells displayed reduced pyrotinib sensitivity compared to sh<em>NC</em> cells (Fig.Â <a href="#Fig1" class="usa-link">1</a>L and <a href="#MOESM2" class="usa-link">S1</a>K).</p></section><section id="Sec27"><h3 class="pmc_sec_title">Pyrotinib synergizes with oxaliplatin to suppress <em>EGFR</em>-high CN gastric cancer growth</h3>
<p id="Par42">Given the clinical application of oxaliplatin-based chemotherapy in advanced GC, we systematically evaluated the therapeutic synergy between pyrotinib and oxaliplatin. Dose-response matrix analysis revealed synergistic interactions in <em>EGFR</em>-high CN GC cell lines (Fig.Â <a href="#Fig2" class="usa-link">2</a>A). EdU incorporation assays confirmed superior anti-proliferative activity of the drug combination, compared to oxaliplatin or pyrotinib treatment alone (Fig.Â <a href="#Fig2" class="usa-link">2</a>B and <a href="#MOESM2" class="usa-link">S2</a>A). Apoptosis assays demonstrated increased apoptotic populations in combination-treated SNU719 and NUGC4 cells compared to monotherapies (Fig.Â <a href="#Fig2" class="usa-link">2</a>C and <a href="#MOESM2" class="usa-link">S2</a>B). To investigate how the oxaliplatin-pyrotinib combination inhibits proliferation, we performed cell cycle analysis. The combination significantly increased G0/G1 phase accumulation compared to monotherapies, indicating cell cycle arrest-mediated growth inhibition (Fig.Â <a href="#Fig2" class="usa-link">2</a>D and <a href="#MOESM2" class="usa-link">S2</a>C). This arrest blocks DNA replication to inhibit proliferation and sensitizes cells to OXA-induced DNA damage, underpinning Pyr-OXA therapeutic synergy. Based on the observed in vitro synergy between pyrotinib and oxaliplatin, we established NUGC4 xenograft models to evaluate their individual and combined antitumor efficacy. The combination therapy demonstrated superior tumor growth suppression compared to either agent alone, with maximal efficacy observed at treatment endpoint (Fig.Â <a href="#Fig2" class="usa-link">2</a>E-H). Notably, no significant body weight loss was observed as a toxicity metric (Fig. <a href="#MOESM2" class="usa-link">S2</a>D).These results altogether demonstrated that the pyrotinib-oxaliplatin combination exerts enhanced anti-tumor effects in vitro and in vivo.</p>
<figure class="fig xbox font-sm" id="Fig2"><h4 class="obj_head">Fig. 2.</h4>
<p class="img-box line-height-none margin-x-neg-2 tablet:margin-x-0 text-center"><a class="tileshop" target="_blank" href="https://www.ncbi.nlm.nih.gov/core/lw/2.0/html/tileshop_pmc/tileshop_pmc_inline.html?title=Click%20on%20image%20to%20zoom&amp;p=PMC3&amp;id=12363034_13046_2025_3485_Fig2_HTML.jpg"><img class="graphic zoom-in" src="https://cdn.ncbi.nlm.nih.gov/pmc/blobs/c4cf/12363034/8e0560aa5a3b/13046_2025_3485_Fig2_HTML.jpg" loading="lazy" id="d33e1015" height="884" width="744" alt="Fig. 2"></a></p>
<div class="p text-right font-secondary"><a href="figure/Fig2/" class="usa-link" target="_blank" rel="noopener noreferrer">Open in a new tab</a></div>
<figcaption><p>Pyrotinib combined with oxaliplatin exerts synergistic effects in EGFR- high CN gastric cancer. <strong>A</strong>. Drug synergy maps of SNU719 and NUGC4 cells were plotted by Combenefit software (V2.021). Bliss synergy scores were calculated for oxaliplatin (OXA) and Pyr after 48Â h. One representative experiment out of 3 independent experiments is shown. <strong>B</strong>. Quantitative analysis of EdU positive in SNU719 and NUGC4 cells treated with Pyr (1 ÂµM) or/and OXA (1Â Âµg/ml) for 24Â h. <strong>C</strong>. Quantitative analysis of Annexin V-FITC/PI staining after the indicated treatment. <strong>D</strong>. Quantitative analysis of cell cycle distribution in SNU719 and NUGC4 cells after the indicated treatment. <strong>E</strong>. Schematic diagram of the protocol for the animal model experiments. <strong>F</strong>. Tumor volume curves were plotted every 2 days after indicated treatment (<em>n</em>â€‰=â€‰8). <strong>G</strong>-<strong>H</strong>. Tumor weight (<strong>G</strong>) and maximum diameter (<strong>H</strong>) were recorded after excision from xenograft models. Significance was determined by Paired t-test (<strong>F</strong>) and (<strong>B</strong>, <strong>C</strong>, <strong>G</strong>) One-way ANOVA. *<em>p</em>â€‰&lt;â€‰0.05; **<em>p</em>â€‰&lt;â€‰0.01; ***<em>p</em>â€‰&lt;â€‰0.001</p></figcaption></figure></section><section id="Sec29"><h3 class="pmc_sec_title">Pyrotinib induces ER stress-mediated apoptosis through the PERK/eIF2Î±/ATF4/CHOP axis in <em>EGFR</em>-high CN gastric cancer</h3>
<p id="Par44">EGFR, a critical receptor tyrosine kinase, that regulates multiple signaling pathway such as PI3K/AKT or /MAPK/ERK pathway [<a href="#CR31" class="usa-link" aria-describedby="CR31">31</a>]. However, pyrotinib promoted apoptosis in presence of MK2206 (AKT inhibitor) and ASN007 (ERK inhibitor) (Fig. <a href="#MOESM2" class="usa-link">S3</a>A), indicating it depends on a non-canonical EGFR kinase pathway.</p>
<p id="Par45">To explore the molecular mechanisms underlying pyrotinibâ€™s anti-tumor activity, we performed transcriptomic profiling of pyrotinib-treated xenograft tumors in vivo. Gene ontology (GO) analysis revealed significant enrichment of ER stress-related pathways in pyrotinib-treated versus PBS in SNU719 cells (Fig.Â <a href="#Fig3" class="usa-link">3</a>A). Additionally, gene set enrichment analysis (GSEA) in NUGC4-derived xenografts treated with pyrotinib or not demonstrated upregulation of PERK-mediated unfolded protein response (UPR) pathways (Fig.Â <a href="#Fig3" class="usa-link">3</a>B). Consistent with these findings, immunoblotting confirmed dose-dependent upregulation of ER stress-associated markers (p-eIF2Î±, ATF4, CHOP) in SNU719 and NUGC4 cells (Fig.Â <a href="#Fig3" class="usa-link">3</a>C). ER stress is mechanistically linked to calcium homeostasis dysregulation and reactive oxygen species (ROS) generation [<a href="#CR32" class="usa-link" aria-describedby="CR32">32</a>]. Consistent with this, pyrotinib treatment induced dose-dependent elevations in intracellular calcium levels of CaÂ²âº (Fig.Â <a href="#Fig3" class="usa-link">3</a>D) and ROS (Fig.Â <a href="#Fig3" class="usa-link">3</a>E).</p>
<figure class="fig xbox font-sm" id="Fig3"><h4 class="obj_head">Fig. 3.</h4>
<p class="img-box line-height-none margin-x-neg-2 tablet:margin-x-0 text-center"><a class="tileshop" target="_blank" href="https://www.ncbi.nlm.nih.gov/core/lw/2.0/html/tileshop_pmc/tileshop_pmc_inline.html?title=Click%20on%20image%20to%20zoom&amp;p=PMC3&amp;id=12363034_13046_2025_3485_Fig3_HTML.jpg"><img class="graphic zoom-in" src="https://cdn.ncbi.nlm.nih.gov/pmc/blobs/c4cf/12363034/bca15fe529a8/13046_2025_3485_Fig3_HTML.jpg" loading="lazy" id="d33e1140" height="843" width="744" alt="Fig. 3"></a></p>
<div class="p text-right font-secondary"><a href="figure/Fig3/" class="usa-link" target="_blank" rel="noopener noreferrer">Open in a new tab</a></div>
<figcaption><p>PERK/eIF2Î±/ATF4/CHOP mediated endoplasmic reticulum stress is involved in regulation of pyrotinib associated injuring in EGFR-high CN GC. <strong>A</strong>. Stress-related pathways gene ontology (GO) enrichment analysis highlighted the activation of ER stress and UPR in SNU719 cells treated with pyrotinib (1 ÂµM) compared to DMSO.<strong>B</strong>. GSEA plot identified significant enrichment of unfolded protein response (UPR) pathway with prominent ATF4 expression in NUGC4 derived xenograft treated with pyrotinib (1 ÂµM) compared to PBS. <strong>C</strong>. Lysates of SNU719 and NUGC4 cells treated with pyrotinib for 48Â h were blotted with the indicated antibodies. p-AKT<sup>S473</sup> and p-EGFRY<sup>1068</sup> was used to monitor the effect of pyrotinib. <strong>D</strong>. Ca<sup>2+</sup> of SNU719 cells were monitored using Fluo-4 AM by flow cytometry after treatment of increasing doses of pyrotinib for 48Â h. <strong>E</strong>. The cellular ROS levels were also analyzed by flow cytometry. <strong>F</strong>. Western blot analysis showed the expression levels of ATF4, CHOP, and cleaved caspase-9 in SNU719 cells transfected with sh<em>NC</em> or sh<em>ATF4</em>, and treated with or without pyrotinib (1 ÂµM). <strong>G</strong>-<strong>J</strong>. Nude mice were injected subcutaneously in the right groin with sh<em>NC</em> or sh<em>ATF4</em> SNU719 cells and treated with PBS or pyrotinib (10Â mg/kg) per day. After 11 days treatment, xenografts were harvested for experiments. (<strong>H</strong>) Tumor volume was recorded every 2 days. (<strong>I</strong>) tumor weight of excised xenografts was determined after sacrificed. (<strong>J</strong>) Representative IHC imaging (left panel) and quantitative analysis (right panel) of Ki-67 stained tumor from xenograft models. Bar, 100Â Î¼m. Significance was determined by (<strong>H</strong>) Paired t-test and (<strong>D</strong>, <strong>E</strong>, <strong>I</strong>, <strong>J</strong>) One-way ANOVA. *<em>p</em>â€‰&lt;â€‰0.05; <em>**p</em>â€‰&lt;â€‰0.01; ***<em>p</em>â€‰&lt;â€‰0.001</p></figcaption></figure><p id="Par47">Given the central role of ATF4 in PERK-mediated ER stress activation and distinct changes in RNA-seq (Fig. <a href="#MOESM2" class="usa-link">S3</a>B), we genetically knocked down <em>ATF4</em> using sh<em>RNA</em> to assess its functional contribution. At the same time, ATF4/CHOP axis was responsible for apoptosis and caspase activation in cancer [<a href="#CR33" class="usa-link" aria-describedby="CR33">33</a>]. <em>ATF4</em> knockdown significantly attenuated pyrotinib-induced C/EBP homologous protein (CHOP) upregulation and caspase activation (cleaved caspase-9) (Fig.Â <a href="#Fig3" class="usa-link">3</a>F). Furthermore, in SNU719 xenograft models, <em>ATF4</em> silencing partially reversed pyrotinibâ€™s therapeutic efficacy (Fig.Â <a href="#Fig3" class="usa-link">3</a>G), manifesting as attenuated tumor growth suppression (reduced volume and weight) (Fig.Â <a href="#Fig3" class="usa-link">3</a>H, I) and elevation of Ki-67 proliferation indices (Fig.Â <a href="#Fig3" class="usa-link">3</a>J).</p></section><section id="Sec31"><h3 class="pmc_sec_title">eIF2Î± phosphatase inhibition enhances pyrotinibâ€™s efficacy</h3>
<p id="Par48">To investigate the effect of PERK/eIF2Î±/ATF4/CHOP axis in pyrotinib-mediated cell injury, we established an acquired pyrotinib-resistant cell line (SNU719-Pyr<sup>R</sup>) from parental SNU719 cells, which exhibited a significantly higher IC50 compared to the parental line (Fig.Â <a href="#Fig4" class="usa-link">4</a>A and <a href="#MOESM2" class="usa-link">S4</a>A). This model replicates clinical acquired resistance to pyrotinib, thus establishing a platform to identify and overcome such resistance through mechanism-guided therapeutic strategies. Contrast to pyrotinib-sensitive SNU719 cells (SNU719-Pyr<sup>S</sup>), pyrotinib failed to suppress AKT phosphorylation or activate the PERK/eIF2Î±/ATF4/CHOP pathway in SNU719-Pyr<sup>R</sup> cells; however, co-treatment with pyrotinib and SAL003 (an eIF2Î± phosphatase inhibitor) restored these signaling effects in SNU719-Pyr<sup>R</sup> cells (Fig.Â <a href="#Fig4" class="usa-link">4</a>B). Consistent with these findings, the combination of SAL003 and pyrotinib demonstrated superior anti-proliferative activity to pyrotinib alone in SNU719-Pyr<sup>R</sup> cells, as evidenced by EdU assays (Fig.Â <a href="#Fig4" class="usa-link">4</a>C and <a href="#MOESM2" class="usa-link">S4</a>B). To validate these observations in vivo, we evaluated the effects of SAL003 and pyrotinib on SNU719-Pyr<sup>R</sup>-derived xenografts. Tumor weights (Fig.Â <a href="#Fig4" class="usa-link">4</a>D and <a href="#MOESM2" class="usa-link">S4</a>C) and bioluminescence intensity (Fig.Â <a href="#Fig4" class="usa-link">4</a>E, F) revealed that monotherapy with either SAL003 or pyrotinib induced partial tumor suppression, whereas combination therapy achieved significantly enhanced efficacy. Immunohistochemical analysis further confirmed reduced Ki-67 proliferation indices in tumors treated with the combination (Fig.Â <a href="#Fig4" class="usa-link">4</a>G). TUNEL assays also showed elevated apoptosis rate in tumors administered with the combination group (Fig.Â <a href="#Fig4" class="usa-link">4</a>H).</p>
<figure class="fig xbox font-sm" id="Fig4"><h4 class="obj_head">Fig. 4.</h4>
<p class="img-box line-height-none margin-x-neg-2 tablet:margin-x-0 text-center"><a class="tileshop" target="_blank" href="https://www.ncbi.nlm.nih.gov/core/lw/2.0/html/tileshop_pmc/tileshop_pmc_inline.html?title=Click%20on%20image%20to%20zoom&amp;p=PMC3&amp;id=12363034_13046_2025_3485_Fig4_HTML.jpg"><img class="graphic zoom-in" src="https://cdn.ncbi.nlm.nih.gov/pmc/blobs/c4cf/12363034/ac195402e74d/13046_2025_3485_Fig4_HTML.jpg" loading="lazy" id="d33e1314" height="1013" width="744" alt="Fig. 4"></a></p>
<div class="p text-right font-secondary"><a href="figure/Fig4/" class="usa-link" target="_blank" rel="noopener noreferrer">Open in a new tab</a></div>
<figcaption><p>Elevated p-eIF2Î± level can reverse acquired resistance to pyrotinib. <strong>A</strong>. IC50 values of Pyr in parental SNU719 (SNU719-Pyr<sup>S</sup>) and pyrotinib resistant (SNU719-Pyr<sup>R</sup>) cells. <strong>B</strong>. WB analysis of protein extracted from SNU719-Pyr<sup>R</sup> cells treated with pyrotinib (1 ÂµM), SAL003 (10 ÂµM), or their combination for 48Â h. <strong>C</strong>. EdU assays demonstrated the inhibitory effects of pyrotinib (1 ÂµM), SAL003 (10 ÂµM) or their combination on the proliferation of SNU719-Pyr<sup>R</sup> cells. <strong>D</strong>-<strong>F</strong>. A total of 20 nude mice were subcutaneously implanted with SNU719-Pyr<sup>R</sup> cells into the groin and randomly assigned to 4 treatment groups (<em>n</em>â€‰=â€‰5/group). After 7 days post-injection, mice were orally administered with pyrotinib (10Â mg/kg daily) or PBS, intratumorally injected with SAL003 (10 ÂµM), or combination. (<strong>D</strong>) Tumor weight and (<strong>E</strong>) bioluminescent intensity were quantified at the day 21. (<strong>F</strong>) Representative bioluminescent images of tumors. <strong>G</strong>-<strong>H</strong>. Immunohistochemical staining for Ki-67 (<strong>G</strong>) and TUNEL assay (<strong>h</strong>) illustrated representative microscopic images of tumor suppression effects induced by pyrotinib and SAL003 in SNU719-Pyr<sup>R</sup> induced xenograft models. Bars, 200Â Î¼m. (<strong>A</strong>, <strong>C</strong>, <strong>D</strong>, <strong>E</strong>, <strong>G</strong>, <strong>H</strong>) Significance was determined by One-way ANOVA. *<em>p</em>â€‰&lt;â€‰0.05; <em>**p</em>â€‰&lt;â€‰0.01; ***<em>p</em>â€‰&lt;â€‰0.001</p></figcaption></figure><p id="Par50">To elucidate the molecular basis of acquired resistance in SNU719-Pyr<sup>R</sup> cells, we performed RNA sequencing and differential gene expression analysis. <em>ATF4</em> downregulation was consistently observed (Fig. <a href="#MOESM2" class="usa-link">S4</a>D), aligning with the suppression of PERK/ATF4/CHOP axis in resistant cells. KEGG pathway enrichment further revealed compensatory upregulation of pro-survival pathways, including DNA replication, mismatch repair, cell cycle, metabolic reprogramming (specifically nitrogen metabolism), and PPAR signaling et al., which conferring evasion of pyrotinib-induced ER stress (Fig. <a href="#MOESM2" class="usa-link">S4</a>E).This model replicates clinical acquired resistance to pyrotinib, thus establishing a platform to identify and overcome such resistance through mechanism-guided therapeutic strategies.</p></section><section id="Sec33"><h3 class="pmc_sec_title">Pyrotinib drives EGFR translocated to ER and interacted with GRP78</h3>
<p id="Par51">The unfolded protein response (UPR), mediated by endoplasmic reticulum stress, is a critical mechanism for maintaining proteostasis. Under physiological conditions, GRP78/BIP â€“ a key ER stress sensor â€“ remains inactive in phosphorylation state through its association with the PERK. We hypothesized that pyrotinib-induced EGFR dephosphorylation might enhance EGFR-GRP78 interaction. Co-IP assays (Fig.Â <a href="#Fig5" class="usa-link">5</a>A) and proximity ligation assays (PLA) (Fig.Â <a href="#Fig5" class="usa-link">5</a>B, C) revealed enhanced EGFR-GRP78 complex formation following pyrotinib treatment. Multiplex fluorescence imaging showed pyrotinib treatment induced EGFR translocated from cell membrane to ER (Fig. <a href="#MOESM2" class="usa-link">S5</a>A), and co-localized with GRP78 (Fig.Â <a href="#Fig5" class="usa-link">5</a>D). Notably, pyrotinib suppressed GRP78-PERK binding while promoting GRP78-EGFR interaction (Fig.Â <a href="#Fig5" class="usa-link">5</a>E-G). To map the interaction domains, we generated EGFR truncation mutants lacking specific regions in 293T cells. EGFR deletion mutants lacking the tyrosine kinase domain, the target domain of pan-HER inhibitors, failed to interact with GRP78, suggesting this domain mediates pyrotinib-dependent complex formation (Fig.Â <a href="#Fig5" class="usa-link">5</a>H). Meanwhile, deletion of the C-terminal domain (Î”420â€“500 and Î”500â€“654) abolished GRP78-EGFR binding, whereas other truncations retained this interaction (Fig.Â <a href="#Fig5" class="usa-link">5</a>I). Three-dimensional models showed the pyrotinib-induced interaction of EGFR and GRP78 (Fig. <a href="#MOESM2" class="usa-link">S5</a>B). Based on these findings, we proposed that pyrotinib disrupts GRP78-PERK binding and promotes GRP78-EGFR interaction, thereby facilitating PERK/ATF4/CHOP axis activation.</p>
<figure class="fig xbox font-sm" id="Fig5"><h4 class="obj_head">Fig. 5.</h4>
<p class="img-box line-height-none margin-x-neg-2 tablet:margin-x-0 text-center"><a class="tileshop" target="_blank" href="https://www.ncbi.nlm.nih.gov/core/lw/2.0/html/tileshop_pmc/tileshop_pmc_inline.html?title=Click%20on%20image%20to%20zoom&amp;p=PMC3&amp;id=12363034_13046_2025_3485_Fig5_HTML.jpg"><img class="graphic zoom-in" src="https://cdn.ncbi.nlm.nih.gov/pmc/blobs/c4cf/12363034/e2ba4e472778/13046_2025_3485_Fig5_HTML.jpg" loading="lazy" id="d33e1417" height="1117" width="744" alt="Fig. 5"></a></p>
<div class="p text-right font-secondary"><a href="figure/Fig5/" class="usa-link" target="_blank" rel="noopener noreferrer">Open in a new tab</a></div>
<figcaption><p>Pyrotinib drives EGFR translocated to ER and interacted with GRP78. <strong>A</strong>. Lysates from SNU719 and NUGC4 cells treated with DMSO or Pyr (1 ÂµM) were precipitated with EGFR antibodies by immunoprecipitation. The precipitated proteins were assayed by western blot. <strong>B</strong>-<strong>C</strong>. Representative images (<strong>B</strong>) and quantification (<strong>C</strong>) of the proximity ligation assay (PLA) detecting EGFR-GRP78 interactions in SNU719 and NUGC4 cells treated with DMSO or Pyr (1ÂµM). Red dots indicate PLA signals. Scale bar, 40Â Î¼m. Significance between groups was determined by One-way ANOVA. *<em>p</em>â€‰&lt;â€‰0.05; <em>**p</em>â€‰&lt;â€‰0.01; ***<em>p</em>â€‰&lt;â€‰0.001. <strong>D</strong>. Immunofluorescence analysis of ER-tracker (red), GRP78 (green), and EGFR (cyan) in SNU719 cells treated with Pyr (1ÂµM). Scale bar, 50Â Î¼m. <strong>E</strong>. HEK293T cells were transfected with the indicated plasmid, treated with or without Pyr (1ÂµM), followed by immunoprecipitation with anti-flag antibody, and eventually assayed by WB analysis with the indicated antibodies. <strong>F</strong>-<strong>G</strong>. SNU719 (<strong>F</strong>) and NUGC4 (<strong>G</strong>) cells were transfected with flag-GRP78 and treated with or without Pyr (1 ÂµM) for 48Â h. Cell lysates were subjected to immunoprecipitation using an anti-Flag antibody, followed by western blot analysis with the indicated antibodies. <strong>H</strong>. HEK293T cells were co-transfected with GRP78-flag and EGFR-HA (FL: full length, or its truncation mutants) plasmids for 48Â h, followed by co-immunoprecipitation (CO-IP) assay. <strong>I</strong>. HEK293T cells were co-transfected with EGFR-HA and GRP78-FLAG (FL or its truncation mutants) plasmids for 48Â h and treated with Pyr (1 ÂµM) for 48Â h, followed by CO-IP assay</p></figcaption></figure></section><section id="Sec35"><h3 class="pmc_sec_title">Pyrotinib accelerated the ubiquitination of GRP78 via blocking Thr62 phosphorylation</h3>
<p id="Par53">Given the observed EGFR-GRP78 interaction and pyrotinib-mediated EGFR phosphorylation inhibition, we next investigated whether pyrotinib similarly modulates GRP78 phosphorylation status. Co-IP assay revealed decreased phosphorylated GRP78 levels in pyrotinib-treated SNU719 cells, whereas EGFR-overexpressing cells exhibited phosphorylation enhancement (Fig.Â <a href="#Fig6" class="usa-link">6</a>A, B). Through PhosphoSite Plus database screening of potential phosphorylation sites (Thr62, Thr69, Thr534), Thr62 of GRP78 was identified as the primary residue activated by EGFR (Fig.Â <a href="#Fig6" class="usa-link">6</a>C).</p>
<figure class="fig xbox font-sm" id="Fig6"><h4 class="obj_head">Fig. 6.</h4>
<p class="img-box line-height-none margin-x-neg-2 tablet:margin-x-0 text-center"><a class="tileshop" target="_blank" href="https://www.ncbi.nlm.nih.gov/core/lw/2.0/html/tileshop_pmc/tileshop_pmc_inline.html?title=Click%20on%20image%20to%20zoom&amp;p=PMC3&amp;id=12363034_13046_2025_3485_Fig6_HTML.jpg"><img class="graphic zoom-in" src="https://cdn.ncbi.nlm.nih.gov/pmc/blobs/c4cf/12363034/e77cb7c33ab4/13046_2025_3485_Fig6_HTML.jpg" loading="lazy" id="d33e1498" height="1117" width="744" alt="Fig. 6"></a></p>
<div class="p text-right font-secondary"><a href="figure/Fig6/" class="usa-link" target="_blank" rel="noopener noreferrer">Open in a new tab</a></div>
<figcaption><p>Pyrotinib accelerated the ubiquitination of GRP78 via blocking Thr62 phosphorylation. <strong>A</strong>. CO-IP assays were performed to assess GRP78 phosphorylation in SNU719 cells treated with EGF stimulation (100 ng/mL) for 5Â min, followed with or without treatment of Pyr for 24Â h. The lysates were incubated with indicated antibodies. <strong>B</strong>. CO-IP assays were performed to detect the phosphorylation of GRP78 in EGFR-overexpressing or/and GRP78-overexpressing SNU719 cells and HEK-293T cells after stimulating with EGF (100 ng/mL) for 5Â min. <strong>C</strong>. Mutational analysis of GRP78 residues (T62A, T69A, T534A) identified critical phosphorylation sites mediating Pyr-induced GRP78 dephosphorylation. <strong>D</strong>. Western blot analysis revealed dose-dependent reductions in GRP78 protein levels after 24Â h treatment with increasing Pyr concentrations in SNU719 cells. <strong>E</strong>. Cycloheximide (CHX, 100Â Âµg/mL) chase experiments demonstrated accelerated GRP78 degradation in Pyr (1 ÂµM, 24Â h) treated versus untreated SNU719 cells. <strong>F</strong>. SNU719 cells co-transfected with Ub-HA and GRP78-Flag plasmids were treated with Pyr (1 ÂµM) and MG132 (10 ÂµM). Immunoblotting confirmed enhanced GRP78 ubiquitination under proteasomal inhibition. <strong>G</strong>. HEK293T cells were co-transfected with the indicated plasmids for 48Â h and then treated with MG132 (10 ÂµM). The polyubiquitination levels of GRP78 protein were analyzed. <strong>H</strong>. HEK293T cells expressing GRP78-Flag with WT ubiquitin or mutant (Ub-K48O, Ub-K63O) plasmids were treated with Pyr (1 ÂµM, 24Â h). Ubiquitination patterns confirmed K48-linked polyubiquitination as the dominant degradation signal. <strong>I</strong>. Immunoprecipitation was performed in SNU719 lysates transfected with flag-GRP78 using Flag antibodies, and the precipitants were measured by western blotting with the indicated antibodies. <strong>J</strong>. Immunoprecipitation was performed in SNU719 lysates transfected with HA-TRIM21 using HA antibodies, and the precipitants were measured by western blotting with the indicated antibodies. <strong>K</strong>. SNU719 cells co-transfected with indicated plasmids and/or si<em>TRIM21</em>, then treated with or without Pyr (1 ÂµM). WB analysis showed reduced polyubiquitination of the si<em>TRIM21</em> group compared to control. <strong>L</strong>. HEK293T cells co-transfected with indicated plasmids and treated with MG132 (10 ÂµM) showed reduced polyubiquitination of the T62D mutant compared to WT GRP78 upon Pyr (1 ÂµM, 24Â h) stimulation. Significance between groups was determined by (<strong>E</strong>, <strong>I</strong>) Paired t-test. *<em>p</em>â€‰&lt;â€‰0.05; <em>**p</em>â€‰&lt;â€‰0.01; ***<em>p</em>â€‰&lt;â€‰0.001</p></figcaption></figure><p id="Par55">Notably, pyrotinib selectively downregulated GRP78 protein (Fig.Â <a href="#Fig6" class="usa-link">6</a>D and <a href="#MOESM2" class="usa-link">S6</a>A) but not mRNA levels (Fig. <a href="#MOESM2" class="usa-link">S6</a>B) in <em>EGFR</em>-high CN cells, indicating post-translational regulation. Cycloheximide (CHX) chase assays revealed that EGFR inhibition shortened GRP78 half-life (Fig.Â <a href="#Fig6" class="usa-link">6</a>E), suggesting that inactivation of the EGFR pathway appears to destabilize GRP78 protein. As ubiquitination and lysosomal degradation are key proteolytic pathways [<a href="#CR26" class="usa-link" aria-describedby="CR26">26</a>, <a href="#CR34" class="usa-link" aria-describedby="CR34">34</a>], we assessed their contributions. Proteasome inhibition by MG132 fully restored GRP78 levels in pyrotinib-treated cells, whereas lysosomal blockade (leupeptin) had no effect (Fig. <a href="#MOESM2" class="usa-link">S6</a>C). Consistently, pyrotinib increased poly-ubiquitinated GRP78 (Fig.Â <a href="#Fig6" class="usa-link">6</a>F). As expected, GRP78 ubiquitination was upregulated in EGFR-overexpression cells than that of mock cells (Fig.Â <a href="#Fig6" class="usa-link">6</a>G), indicating that the EGFR signaling pathway is involved in the proteasomal degradation of GRP78. To define ubiquitin chain specificity, we utilized lysine-restricted ubiquitin mutants (K48O: retains Lys48 only; K63O: retains Lys63 only). K48O, but not K63O, increased GRP78 ubiquitination (Fig.Â <a href="#Fig6" class="usa-link">6</a>H), demonstrating K48-linked ubiquitination drives pyrotinib-induced degradation.</p>
<p id="Par56">To identify the E3 ligase responsible for K48-linked GRP78 ubiquitination, we focused on TRIM21, implicated in GRP78 degradation in non-small cell lung cancer [<a href="#CR18" class="usa-link" aria-describedby="CR18">18</a>]. Co-IP assays in gastric cancer cells confirmed the GRP78-TRIM21 complex (Fig.Â <a href="#Fig6" class="usa-link">6</a>I, J). CHX chase assays revealed that ectopic TRIM21 overexpression markedly accelerated GRP78 degradation in SNU719 cells versus vector controls (Fig. <a href="#MOESM2" class="usa-link">S6</a>D), indicating TRIM21 promotes GRP78 degradation. Finally, si<em>RNA</em>-mediated <em>TRIM21</em> knockdown in HEK293T cells attenuated pyrotinib-induced K48-linked polyubiquitination of GRP78 with or without pyrotinib (Fig.Â <a href="#Fig6" class="usa-link">6</a>K), confirming TRIM21â€™s essential role in this specific modification.</p>
<p id="Par57">As phosphorylation often regulates ubiquitin ligase recognition and previous studies showed phosphorylation of GRP78 inhibit its own ubiquitination, we generated a phospho-deficient GRP78 mutant (T62A) and found T62A mutant accelerated the degradation of GRP78 (Fig. <a href="#MOESM2" class="usa-link">S6</a>E). Next, we also generated T62D phosphorylation-mimic mutant and found it was resistant to pyrotinib-induced ubiquitination (Fig.Â <a href="#Fig6" class="usa-link">6</a>L).</p>
<p id="Par58">Collectively, these findings demonstrate that pyrotinib promotes GRP78 degradation by suppressing EGFR-mediated phosphorylation at Thr62. This dephosphorylation specifically facilitates TRIM21 recruitment, thereby triggering K48-linked polyubiquitination and ultimately proteasomal degradation of GRP78. Critically, Thr62 phosphorylation status governs TRIM21-dependent degradation of GRP78.</p></section><section id="Sec37"><h3 class="pmc_sec_title">Pyrotinib enhances oxaliplatin chemosensitivity through GRP78 inhibition</h3>
<p id="Par59">Previous studies have demonstrated that EGFR-targeted inhibitors (cetuximab) could impair DNA double-strand break (DSB) repair mechanisms to increase radio-sensitivity [<a href="#CR15" class="usa-link" aria-describedby="CR15">15</a>]. Building on this evidence, we hypothesized that pyrotinib-induced GRP78 silencing would suppress oxaliplatin-triggered DNA damage response through DSB repair pathway modulation. Western blot analysis revealed that pyrotinib significantly attenuated oxaliplatin-induced expression of Î³-H2A.X, a key DSB repair biomarker, in GC cells (Fig.Â <a href="#Fig7" class="usa-link">7</a>A). Pyrotinib further increased the expression of oxaliplatin-induced ER stress-associated proteins in vitro (Fig. <a href="#MOESM2" class="usa-link">S7</a>A). To determine whether ER stress is essential for the synergistic pro-apoptotic effect of pyrotinib and oxaliplatin, we performed rescue experiments using the ER stress inhibitor 4-PBA (10Â Âµg/mL). Notably, flow cytometry analysis revealed that co-treatment with pyrotinib and oxaliplatin significantly increased apoptosis in SNU719 cells with or without ER stress inhibition (Fig. <a href="#MOESM2" class="usa-link">S7</a>B, C). Consistent with this, WB analysis confirmed sustained cleavage caspase-9 in the combination group despite 4-PBA co-administration (Fig. <a href="#MOESM2" class="usa-link">S7</a>D). These results demonstrate that the synergistic pro-apoptotic effect is not exclusively dependent on ER stress pathways, but is primarily driven by GRP78 ubiquitination-mediated DNA repair impairment.</p>
<figure class="fig xbox font-sm" id="Fig7"><h4 class="obj_head">Fig. 7.</h4>
<p class="img-box line-height-none margin-x-neg-2 tablet:margin-x-0 text-center"><a class="tileshop" target="_blank" href="https://www.ncbi.nlm.nih.gov/core/lw/2.0/html/tileshop_pmc/tileshop_pmc_inline.html?title=Click%20on%20image%20to%20zoom&amp;p=PMC3&amp;id=12363034_13046_2025_3485_Fig7_HTML.jpg"><img class="graphic zoom-in" src="https://cdn.ncbi.nlm.nih.gov/pmc/blobs/c4cf/12363034/dd6e930b1e2f/13046_2025_3485_Fig7_HTML.jpg" loading="lazy" id="d33e1658" height="1014" width="744" alt="Fig. 7"></a></p>
<div class="p text-right font-secondary"><a href="figure/Fig7/" class="usa-link" target="_blank" rel="noopener noreferrer">Open in a new tab</a></div>
<figcaption><p>Pyrotinib enhances oxaliplatin chemosensitivity through GRP78 inhibition. <strong>A</strong>. Western blot analysis revealed differential expression of DNA double-strand break repair proteins (Î³-H2A.X) and GRP78 in NUGC4 and SNU719 cells treated with DMSO, Pyr (1 ÂµM), or/and OXA (2.5 ÂµM) for 24Â h. <strong>B</strong>. The expression of GRP78 protein in SNU719 and NUGC4 cells transfected with si<em>NC</em> or si<em>GRP78</em>. <strong>C</strong>. CCK-8 cytotoxicity assays demonstrated enhanced OXA sensitivity in GRP78 silenced SNU719 and NUGC4 cells. <strong>D</strong>. The expression of GRP78 protein in SNU719 and NUGC4 cells transfected with MOCK or OE<em>GRP78</em> plasmid. <strong>E</strong>. GRP78 overexpressing GC cells exhibited OXA resistance in CCK-8 assays, showing higher viability than control cells. <strong>F</strong>-<strong>G</strong>. Immunofluorescence staining (<strong>F</strong>) and analysis (<strong>g</strong>) showed that after stimulation by OXA (2.5 ÂµM) for 24Â h, the Î³-H2A.X foci in SNU719 and NUGC4 cell nucleus distinguished in MOCK and OE<em>GRP78</em> groups. Blue background indicates DAPI, red dots indicate Î³-H2A.X foci. Bars, 40Â Î¼m. <strong>H</strong>. Schematic diagram display that Pyr promotes EGFR-GRP78 complex formation in the ER lumen, subsequently activating the PERK/eIF2Î±/ATF4/CHOP signaling pathway, and finally resulted in the tumor apoptosis in EGFR-high CN GC. Besides, Pyr could sensitize GC cells to OXA by inhibiting GRP78 phosphorylation at T62 which results in GRP78 ubiquitination. Significance between groups was determined by (<strong>C</strong>, <strong>E</strong>) Paired t-test and (<strong>G</strong>) One-way ANOVA. *<em>p</em>â€‰&lt;â€‰0.05; <em>**p</em>â€‰&lt;â€‰0.01; ***<em>p</em>â€‰&lt;â€‰0.001</p></figcaption></figure><p id="Par61">Functional validation demonstrated that GRP78 knockdown substantially enhanced cellular sensitivity to oxaliplatin (Fig.Â <a href="#Fig7" class="usa-link">7</a>B, C), whereas GRP78 overexpression conferred chemoresistance (Fig.Â <a href="#Fig7" class="usa-link">7</a>D, E). Notably, Î³-H2A.X foci formation showed significant elevation in oxaliplatin-treated control groups but remained unchanged in GRP78-overexpressing cells (Fig.Â <a href="#Fig7" class="usa-link">7</a>F, G). Taken together, these findings demonstrated that pyrotinib could enhance oxaliplatin chemosensitivity through GRP78 downregulation mediated impairment of DNA repair mechanisms (Fig.Â <a href="#Fig7" class="usa-link">7</a>H).</p></section></section><section id="Sec38"><h2 class="pmc_sec_title">Discussion</h2>
<p id="Par62">The HER family represents one of the most extensively targeted receptor families in oncology due to its frequent dysregulation across malignancies. Previous studies have established that afatinib sensitivity correlates with <em>EGFR/ERBB2</em> co-amplification in gastric cancer [<a href="#CR35" class="usa-link" aria-describedby="CR35">35</a>], highlighting the prospective therapeutic potential of pan-HER inhibitors in clinical practice. Pyrotinib, an oral pan-HER inhibitor, is widely used in patients with <em>HER2</em>-mutated non-small-cell lung cancer and <em>HER2</em>-amplicated breast cancer [<a href="#CR36" class="usa-link" aria-describedby="CR36">36</a>, <a href="#CR37" class="usa-link" aria-describedby="CR37">37</a>] and displays clinical activity in <em>HER2</em>-positive or <em>HER3</em>-mutated gastric cancer [<a href="#CR38" class="usa-link" aria-describedby="CR38">38</a>, <a href="#CR39" class="usa-link" aria-describedby="CR39">39</a>].</p>
<p id="Par63">In this study, we systematically screened and identified pyrotinib as a potent inhibitor selectively suppressing <em>EGFR</em>-high CN GC cells both in vitro and in vivo. Previous studies demonstrated anti-tumor effect of pyrotinib in HER2(+) GC [<a href="#CR40" class="usa-link" aria-describedby="CR40">40</a>]. Our findings reveal a strong correlation between pyrotinib response and <em>EGFR</em> high CN, independent of <em>HER2</em> or <em>HER4</em> status. This aligns with prior observations that cetuximab, an anti-EGFR monoclonal antibody, benefits a subset of GC patients with <em>EGFR</em> amplification [<a href="#CR8" class="usa-link" aria-describedby="CR8">8</a>]. Notably, pyrotinib has been reported to induce apoptosis in colon cancer and oral squamous cell carcinoma by targeting EGFR [<a href="#CR41" class="usa-link" aria-describedby="CR41">41</a>, <a href="#CR42" class="usa-link" aria-describedby="CR42">42</a>], underscoring its broader therapeutic relevance. While lapatinib, another pan-HER inhibitor, failed to improve overall survival in HER2-amplified gastroesophageal adenocarcinoma when combined with CapeOx, subgroup analyses suggested prolonged survival in Asian and younger populations [<a href="#CR43" class="usa-link" aria-describedby="CR43">43</a>]. Similarly, another pan-HER inhibitor afatinib has shown a good response in EGFR-mutated GC in clinical practice [<a href="#CR44" class="usa-link" aria-describedby="CR44">44</a>]. However, EPHA2, which is participates in crosstalk with other membrane receptors and impinged on downstream RAS/PI3K/AKT and RAS/MAPK signaling pathways, might be involved in the mechanism of acquired resistance to EGFR inhbitors in treating GC [<a href="#CR12" class="usa-link" aria-describedby="CR12">12</a>]. Together with our study, we highlight pan-HER inhibitors may be a viable strategy for GC subsets characterized by EGFR hyperactivity. Our data demonstrate that pyrotinib synergizes with oxaliplatin to induce ER-stress and activate the PERK-ATF4-CHOP apoptotic cascade, a key pathway that transcriptionally represses Bcl-2 while upregulating pro-apoptotic BIM and cleaved caspase-3 [<a href="#CR45" class="usa-link" aria-describedby="CR45">45</a>]. This CHOP-mediated process eliminates stress-damaged gastric cancer cells through intrinsic apoptosis, thereby synergizing with OXA-driven DNA damage to achieve tumor suppression [<a href="#CR46" class="usa-link" aria-describedby="CR46">46</a>].</p>
<p id="Par64"><em>EGFR</em> high CN is associated with chromosomal instability and poor prognosis in advanced GC [<a href="#CR47" class="usa-link" aria-describedby="CR47">47</a>]. Current therapeutic paradigms increasingly favor combining anti-EGFR agents with chemotherapy to overcome resistance while minimizing toxicity. Prior studies have demonstrated that underglycosylated EGFR forms stable complexes with GRP78 [<a href="#CR48" class="usa-link" aria-describedby="CR48">48</a>]. Notably, pyrotinib has been shown to enhance radiosensitivity and chemosensitivity in <em>HER2</em>-positive GC [<a href="#CR49" class="usa-link" aria-describedby="CR49">49</a>]. Here, we demonstrate that pyrotinib synergizes with oxaliplatin to augment apoptosis in <em>EGFR</em>-high CN GC. Mechanistically, this synergy arises from dual effects: EGFR inhibition induces ER stress-mediated apoptosis via the PERK/ATF4/CHOP axis, while GRP78 downregulation impairs DNA damage repair by suppressing BRCA1-mediated homologous recombination repair [<a href="#CR50" class="usa-link" aria-describedby="CR50">50</a>], thereby potentiating oxaliplatin-induced DSBs [<a href="#CR51" class="usa-link" aria-describedby="CR51">51</a>]. Prior studies indicate that ER stress compromises DSB repair, increasing chemosensitivity [<a href="#CR52" class="usa-link" aria-describedby="CR52">52</a>], while EGFR blockade induces ER stress in cancer cells [<a href="#CR13" class="usa-link" aria-describedby="CR13">13</a>, <a href="#CR53" class="usa-link" aria-describedby="CR53">53</a>]. Our work bridges these concepts by establishing pyrotinib as a dual modulator of ER stress and DNA repair pathways in <em>EGFR</em>-driven GC.</p>
<p id="Par65">GRP78, a central ER chaperone, undergoes phosphorylation-dependent regulation that influences cancer progression [<a href="#CR21" class="usa-link" aria-describedby="CR21">21</a>]. Structurally, GRP78 harbors ATPase and autophosphorylation activities critical for its function in the endoplasmic reticulum [<a href="#CR54" class="usa-link" aria-describedby="CR54">54</a>]. GRP78 phosphorylation, a process linked to spatial reorganization during sperm epididymal maturation, is markedly elevated in cancer cells compared to normal cells [<a href="#CR17" class="usa-link" aria-describedby="CR17">17</a>], underscoring its critical role in cancer progression. Our study reveals that pyrotinib suppresses GRP78 phosphorylation at Thr62, which may explain a novel mechanism for killing cancer cells. Furthermore, crosstalk between ubiquitination and phosphorylation has emerged as a key regulatory axis in cancer [<a href="#CR55" class="usa-link" aria-describedby="CR55">55</a>]. For instance, SCNN1B and GSC1 modulate GC progression by regulating GRP78 ubiquitination [<a href="#CR56" class="usa-link" aria-describedby="CR56">56</a>, <a href="#CR57" class="usa-link" aria-describedby="CR57">57</a>]. Besides, X-linked inhibitor of apoptosis-associated factor-1 interacts with and destabilizes ER stress sensor GRP78 and increased cell sensitivity to ER stress [<a href="#CR58" class="usa-link" aria-describedby="CR58">58</a>]. Actually, our findings showed that inhibition of EGFR activity by pyrotinib blocks GRP78 phosphorylation, subsequently improves GRP78 ubiquitination and proteasomal degradation, and finally enhance apoptosis induced by oxaliplatin stress in <em>EGFR</em>-high CN GC cells.</p>
<p id="Par66">In summary, our study not only reveals for the first time the significant therapeutic potential of pyrotinib combined with oxaliplatin in targeting <em>EGFR</em>-high CN GC, but also reveals the functional role of the EGFR/GRP78/ATF4/CHOP axis in anti-EGFR therapeutic strategies. These findings collectively propose a novel treatment regimen â€“ pyrotinib plus oxaliplatin â€“ as a promising option for posterior-line therapy in GC with <em>EGFR</em>-high CN.</p></section><section id="Sec39"><h2 class="pmc_sec_title">Conclusions</h2>
<p id="Par67">Our findings demonstrate that pyrotinib selectively targets GC with <em>EGFR</em>-high CN by mediating dual mechanisms: (1) facilitating EGFR-GRP78 complex formation in the endoplasmic reticulum to activate the PERK/ATF4/CHOP axis, thereby triggering ER stress-mediated apoptosis, and (2) suppressing GRP78 phosphorylation at Thr62, which promotes K48-linked ubiquitination and proteasomal degradation, impairing DNA repair and synergizing with oxaliplatin to amplify chemosensitivity. This study uncovers the pivotal role of the EGFR/GRP78 signaling axis and establishes pyrotinib-oxaliplatin combination therapy as a novel strategy for GC with <em>EGFR</em>-high CN.</p></section><section id="Sec40"><h2 class="pmc_sec_title">Electronic supplementary material</h2>
<p>Below is the link to the electronic supplementary material.</p>
<section class="sm xbox font-sm" id="MOESM1"><div class="media p"><div class="caption">
<a href="/articles/instance/12363034/bin/13046_2025_3485_MOESM1_ESM.docx" data-ga-action="click_feat_suppl" class="usa-link">Supplementary Material 1</a><sup> (12.4KB, docx) </sup>
</div></div></section><section class="sm xbox font-sm" id="MOESM2"><div class="media p"><div class="caption">
<a href="/articles/instance/12363034/bin/13046_2025_3485_MOESM2_ESM.docx" data-ga-action="click_feat_suppl" class="usa-link">Supplementary Material 2</a><sup> (1.5MB, docx) </sup>
</div></div></section></section><section id="ack1" class="ack"><h2 class="pmc_sec_title">Acknowledgements</h2>
<p>Thanks to Hengrui accompany for providing the original drug pyrotinib.</p></section><section id="glossary1" class="glossary"><h2 class="pmc_sec_title">Abbreviations</h2>
<dl class="def-list">
<dt>GC</dt>
<dd><p id="Par71">Gastric cancer</p></dd>
<dt>EGFR</dt>
<dd><p id="Par72">Epidermal growth factor receptor</p></dd>
<dt>ER</dt>
<dd><p id="Par73">Endoplasmic reticulum</p></dd>
<dt>GRP78</dt>
<dd><p id="Par74">Glucose-regulated protein 78</p></dd>
<dt>PERK</dt>
<dd><p id="Par75">Pancreatic ER kinase (PKR)-like ER kinase</p></dd>
<dt>CHOP</dt>
<dd><p id="Par76">The C/EBP homologous protein</p></dd>
<dt>CN</dt>
<dd><p id="Par77">Copy number</p></dd>
<dt>DSB</dt>
<dd><p id="Par78">Double-strand break</p></dd>
<dt>FISH</dt>
<dd><p id="Par79">Fluorescence in situ hybridization</p></dd>
</dl></section><section id="notes1"><h2 class="pmc_sec_title">Author contribution</h2>
<p>BLB: Conceptualization, Experimental work, Data curation, Formal analysis, WXD: Methodology, Writing original draft, Data curation. LXY: Writing review and editing. DN: review and editing. Li CX: review and editing, DXY: Experimental work. TXL: Experimental work. HZJ: Experimental work, HNN: Methodology. HY: Experimental work. ZYC: Experimental work. SJL and: Writing review and Editing, LMX: Conceptualization, Writing review and Editing. WD: Funding and Methodology. CQ: Writing review, Editing, Funding and Conceptualization. All authors reviewed the manuscript</p></section><section id="notes2"><h2 class="pmc_sec_title">Funding</h2>
<p>This work was supported by the Qianjiang Central Hospital Cancer National Clinical Key Specialized Project (QJCH2004-01) to Wang Dong and Chongqing Medical Youth Outstanding Talent project (YXQN202466) to Qian Chen and Science and Technology Innovation Capability Improvement Project of the Amry Military Medical University to Xu Dong Wang (2023XLC14).</p></section><section id="notes3"><h2 class="pmc_sec_title">Data availability</h2>
<p>No datasets were generated or analysed during the current study.</p></section><section id="notes4"><h2 class="pmc_sec_title">Declarations</h2>
<section id="FPar1"><h3 class="pmc_sec_title">Ethics approval and consent to participate</h3>
<p id="Par68">All procedures involving animal were in accordance with the ethical standards of the ethics committee of Army Medical university (approval number: AMUWEC20257010).</p></section><section id="FPar2"><h3 class="pmc_sec_title">Consent for publication</h3>
<p id="Par69">All authors agreed on the manuscript.</p></section><section id="FPar3"><h3 class="pmc_sec_title">Competing interests</h3>
<p id="Par70">The authors declare no competing interests.</p></section></section><section id="fn-group1" class="fn-group"><h2 class="pmc_sec_title">Footnotes</h2>
<div class="fn-group p font-secondary-light font-sm">
<div class="fn p" id="fn1">
<p><strong>Publisherâ€™s note</strong></p>
<p>Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.</p>
</div>
<div class="fn p" id="fn2"><p>Lingbo Bao, Xudong Wang, Xiuyong Liao, Dong Li and ChunXue Li contributed equally to this work.</p></div>
</div></section><section id="_ci93_" lang="en" class="contrib-info"><h2 class="pmc_sec_title">Contributor Information</h2>
<p>Jinlu Shan, Email: lulu7476@tmmu.edu.com.</p>
<p>Dong Wang, Email: Wangdong64@hotmail.com.</p>
<p>Mengxia Li, Email: limengxia@tmmu.edu.cn.</p>
<p>Qian Chen, Email: 13chenqian@tmmu.edu.cn.</p></section><section id="Bib1" class="ref-list"><h2 class="pmc_sec_title">References</h2>
<section id="Bib1_sec2"><ul class="ref-list font-sm" style="list-style-type:none">
<li id="CR1">
<span class="label">1.</span><cite>Bray F, Laversanne M, Sung H, Ferlay J, Siegel RL, Soerjomataram I, et al. Global cancer statistics 2022: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2024;74(3):229â€“63.
</cite> [<a href="https://doi.org/10.3322/caac.21834" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/38572751/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?Bray%20F,%20Laversanne%20M,%20Sung%20H,%20Ferlay%20J,%20Siegel%20RL,%20Soerjomataram%20I,%20et%20al.%20Global%20cancer%20statistics%202022:%20GLOBOCAN%20estimates%20of%20incidence%20and%20mortality%20worldwide%20for%2036%20cancers%20in%20185%20countries.%20CA%20Cancer%20J%20Clin.%202024;74(3):229%E2%80%9363." class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="CR2">
<span class="label">2.</span><cite>Bang YJ, Van Cutsem E, Feyereislova A, Chung HC, Shen L, Sawaki A, et al. Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trial. Lancet. 2010;376(9742):687â€“97.
</cite> [<a href="https://doi.org/10.1016/S0140-6736(10)61121-X" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/20728210/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?Bang%20YJ,%20Van%20Cutsem%20E,%20Feyereislova%20A,%20Chung%20HC,%20Shen%20L,%20Sawaki%20A,%20et%20al.%20Trastuzumab%20in%20combination%20with%20chemotherapy%20versus%20chemotherapy%20alone%20for%20treatment%20of%20HER2-positive%20advanced%20gastric%20or%20gastro-oesophageal%20junction%20cancer%20(ToGA):%20a%20phase%203,%20open-label,%20randomised%20controlled%20trial.%20Lancet.%202010;376(9742):687%E2%80%9397." class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="CR3">
<span class="label">3.</span><cite>Nie C, He Y, Lv H, Gao M, Gao X, Chen B, et al. Clinical study of anlotinib as third-line or above therapy in patients with advanced or metastatic gastric cancer: a multicenter retrospective study. Front Oncol. 2022;12:885350.
</cite> [<a href="https://doi.org/10.3389/fonc.2022.885350" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="/articles/PMC9289113/" class="usa-link">PMC free article</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/35860585/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?Nie%20C,%20He%20Y,%20Lv%20H,%20Gao%20M,%20Gao%20X,%20Chen%20B,%20et%20al.%20Clinical%20study%20of%20anlotinib%20as%20third-line%20or%20above%20therapy%20in%20patients%20with%20advanced%20or%20metastatic%20gastric%20cancer:%20a%20multicenter%20retrospective%20study.%20Front%20Oncol.%202022;12:885350." class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="CR4">
<span class="label">4.</span><cite>Qi C, Gong J, Li J, Liu D, Qin Y, Ge S, et al. Claudin18.2-specific CAR t cells in gastrointestinal cancers: phase 1 trial interim results. Nat Med. 2022;28(6):1189â€“98.
</cite> [<a href="https://doi.org/10.1038/s41591-022-01800-8" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="/articles/PMC9205778/" class="usa-link">PMC free article</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/35534566/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?Qi%20C,%20Gong%20J,%20Li%20J,%20Liu%20D,%20Qin%20Y,%20Ge%20S,%20et%20al.%20Claudin18.2-specific%20CAR%20t%20cells%20in%20gastrointestinal%20cancers:%20phase%201%20trial%20interim%20results.%20Nat%20Med.%202022;28(6):1189%E2%80%9398." class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="CR5">
<span class="label">5.</span><cite>Roskoski RJ. The erbb/her family of protein-tyrosine kinases and cancer. Pharmacol Res. 2014;79:34â€“74.
</cite> [<a href="https://doi.org/10.1016/j.phrs.2013.11.002" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/24269963/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?Roskoski%20RJ.%20The%20erbb/her%20family%20of%20protein-tyrosine%20kinases%20and%20cancer.%20Pharmacol%20Res.%202014;79:34%E2%80%9374." class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="CR6">
<span class="label">6.</span><cite>Wang Z. ErbB receptors and cancer. Methods Mol Biol. 2017;1652:3â€“35.
</cite> [<a href="https://doi.org/10.1007/978-1-4939-7219-7_1" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/28791631/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?Wang%20Z.%20ErbB%20receptors%20and%20cancer.%20Methods%20Mol%20Biol.%202017;1652:3%E2%80%9335." class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="CR7">
<span class="label">7.</span><cite>Lei ZN, Teng QX, Tian Q, Chen W, Xie Y, Wu K, et al. Signaling pathways and therapeutic interventions in gastric cancer. Signal Transduct Target Ther. 2022;7(1):358.
</cite> [<a href="https://doi.org/10.1038/s41392-022-01190-w" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="/articles/PMC9547882/" class="usa-link">PMC free article</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/36209270/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?Lei%20ZN,%20Teng%20QX,%20Tian%20Q,%20Chen%20W,%20Xie%20Y,%20Wu%20K,%20et%20al.%20Signaling%20pathways%20and%20therapeutic%20interventions%20in%20gastric%20cancer.%20Signal%20Transduct%20Target%20Ther.%202022;7(1):358." class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="CR8">
<span class="label">8.</span><cite>Zhang L, Yang J, Cai J, Song X, Deng J, Huang X, et al. A subset of gastric cancers with EGFR amplification and overexpression respond to cetuximab therapy. Sci Rep. 2013;3:2992.
</cite> [<a href="https://doi.org/10.1038/srep02992" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="/articles/PMC3801116/" class="usa-link">PMC free article</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/24141978/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?Zhang%20L,%20Yang%20J,%20Cai%20J,%20Song%20X,%20Deng%20J,%20Huang%20X,%20et%20al.%20A%20subset%20of%20gastric%20cancers%20with%20EGFR%20amplification%20and%20overexpression%20respond%20to%20cetuximab%20therapy.%20Sci%20Rep.%202013;3:2992." class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="CR9">
<span class="label">9.</span><cite>Lordick F, Kang YK, Chung HC, Salman P, Oh SC, Bodoky G, et al. Capecitabine and cisplatin with or without cetuximab for patients with previously untreated advanced gastric cancer (EXPAND): a randomised, open-label phase 3 trial. Lancet Oncol. 2013;14(6):490â€“9.
</cite> [<a href="https://doi.org/10.1016/S1470-2045(13)70102-5" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/23594786/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?Lordick%20F,%20Kang%20YK,%20Chung%20HC,%20Salman%20P,%20Oh%20SC,%20Bodoky%20G,%20et%20al.%20Capecitabine%20and%20cisplatin%20with%20or%20without%20cetuximab%20for%20patients%20with%20previously%20untreated%20advanced%20gastric%20cancer%20(EXPAND):%20a%20randomised,%20open-label%20phase%203%20trial.%20Lancet%20Oncol.%202013;14(6):490%E2%80%939." class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="CR10">
<span class="label">10.</span><cite>Waddell T, Chau I, Cunningham D, Gonzalez D, Okines AF, Okines C, et al. Epirubicin, oxaliplatin, and capecitabine with or without panitumumab for patients with previously untreated advanced oesophagogastric cancer (REAL3): a randomised, open-label phase 3 trial. Lancet Oncol. 2013;14(6):481â€“9.
</cite> [<a href="https://doi.org/10.1016/S1470-2045(13)70096-2" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="/articles/PMC3669518/" class="usa-link">PMC free article</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/23594787/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?Waddell%20T,%20Chau%20I,%20Cunningham%20D,%20Gonzalez%20D,%20Okines%20AF,%20Okines%20C,%20et%20al.%20Epirubicin,%20oxaliplatin,%20and%20capecitabine%20with%20or%20without%20panitumumab%20for%20patients%20with%20previously%20untreated%20advanced%20oesophagogastric%20cancer%20(REAL3):%20a%20randomised,%20open-label%20phase%203%20trial.%20Lancet%20Oncol.%202013;14(6):481%E2%80%939." class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="CR11">
<span class="label">11.</span><cite>Al-Janaby T, Nahi N, Seddon A, Bagwan I, Khelwatty S, Modjtahedi H. The combination of afatinib with dasatinib or miransertib results in synergistic growth inhibition of stomach cancer cells. World J Oncol. 2024;15(2):192â€“208.
</cite> [<a href="https://doi.org/10.14740/wjon1769" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="/articles/PMC10965263/" class="usa-link">PMC free article</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/38545471/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?Al-Janaby%20T,%20Nahi%20N,%20Seddon%20A,%20Bagwan%20I,%20Khelwatty%20S,%20Modjtahedi%20H.%20The%20combination%20of%20afatinib%20with%20dasatinib%20or%20miransertib%20results%20in%20synergistic%20growth%20inhibition%20of%20stomach%20cancer%20cells.%20World%20J%20Oncol.%202024;15(2):192%E2%80%93208." class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="CR12">
<span class="label">12.</span><cite>Chen Z, Liu Z, Zhang M, Huang W, Li Z, Wang S, et al. EPHA2 blockade reverses acquired resistance to afatinib induced by EPHA2-mediated MAPK pathway activation in gastric cancer cells and avatar mice. Int J Cancer. 2019;145(9):2440â€“9.
</cite> [<a href="https://doi.org/10.1002/ijc.32313" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/30957241/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?Chen%20Z,%20Liu%20Z,%20Zhang%20M,%20Huang%20W,%20Li%20Z,%20Wang%20S,%20et%20al.%20EPHA2%20blockade%20reverses%20acquired%20resistance%20to%20afatinib%20induced%20by%20EPHA2-mediated%20MAPK%20pathway%20activation%20in%20gastric%20cancer%20cells%20and%20avatar%20mice.%20Int%20J%20Cancer.%202019;145(9):2440%E2%80%939." class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="CR13">
<span class="label">13.</span><cite>Hong S, Gu Y, Gao Z, Guo L, Guo W, Wu X, et al. EGFR inhibitor-driven endoplasmic reticulum stress-mediated injury on intestinal epithelial cells. Life Sci. 2014;119(1â€“2):28â€“33.
</cite> [<a href="https://doi.org/10.1016/j.lfs.2014.10.008" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/25445223/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?Hong%20S,%20Gu%20Y,%20Gao%20Z,%20Guo%20L,%20Guo%20W,%20Wu%20X,%20et%20al.%20EGFR%20inhibitor-driven%20endoplasmic%20reticulum%20stress-mediated%20injury%20on%20intestinal%20epithelial%20cells.%20Life%20Sci.%202014;119(1%E2%80%932):28%E2%80%9333." class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="CR14">
<span class="label">14.</span><cite>Terai H, Kitajima S, Potter DS, Matsui Y, Quiceno LG, Chen T, et al. ER stress signaling promotes the survival of cancer persister cells tolerant to EGFR tyrosine kinase inhibitors. Cancer Res. 2018;78(4):1044â€“57.
</cite> [<a href="https://doi.org/10.1158/0008-5472.CAN-17-1904" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="/articles/PMC5815936/" class="usa-link">PMC free article</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/29259014/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?Terai%20H,%20Kitajima%20S,%20Potter%20DS,%20Matsui%20Y,%20Quiceno%20LG,%20Chen%20T,%20et%20al.%20ER%20stress%20signaling%20promotes%20the%20survival%20of%20cancer%20persister%20cells%20tolerant%20to%20EGFR%20tyrosine%20kinase%20inhibitors.%20Cancer%20Res.%202018;78(4):1044%E2%80%9357." class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="CR15">
<span class="label">15.</span><cite>Sun C, Han C, Jiang Y, Han N, Zhang M, Li G, et al. Inhibition of GRP78 abrogates radioresistance in oropharyngeal carcinoma cells after EGFR inhibition by cetuximab. PLoS ONE. 2017;12(12):e0188932.
</cite> [<a href="https://doi.org/10.1371/journal.pone.0188932" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="/articles/PMC5726659/" class="usa-link">PMC free article</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/29232380/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?Sun%20C,%20Han%20C,%20Jiang%20Y,%20Han%20N,%20Zhang%20M,%20Li%20G,%20et%20al.%20Inhibition%20of%20GRP78%20abrogates%20radioresistance%20in%20oropharyngeal%20carcinoma%20cells%20after%20EGFR%20inhibition%20by%20cetuximab.%20PLoS%20ONE.%202017;12(12):e0188932." class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="CR16">
<span class="label">16.</span><cite>Cai MN, Chen DM, Xiao LX, Li SS, Liao CH, Li J, et al. COLEC10 induces endoplasmic reticulum stress by occupying GRP78 and inhibits hepatocellular carcinoma. Lab Invest. 2023;103(7):100130.
</cite> [<a href="https://doi.org/10.1016/j.labinv.2023.100130" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/36925047/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?Cai%20MN,%20Chen%20DM,%20Xiao%20LX,%20Li%20SS,%20Liao%20CH,%20Li%20J,%20et%20al.%20COLEC10%20induces%20endoplasmic%20reticulum%20stress%20by%20occupying%20GRP78%20and%20inhibits%20hepatocellular%20carcinoma.%20Lab%20Invest.%202023;103(7):100130." class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="CR17">
<span class="label">17.</span><cite>Lobo V, Rao P, Gajbhiye R, Kulkarni V, Parte P. Glucose regulated protein 78 phosphorylation in sperm undergoes dynamic changes during maturation. PLoS ONE. 2015;10(11):e0141858.
</cite> [<a href="https://doi.org/10.1371/journal.pone.0141858" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="/articles/PMC4664250/" class="usa-link">PMC free article</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/26618558/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?Lobo%20V,%20Rao%20P,%20Gajbhiye%20R,%20Kulkarni%20V,%20Parte%20P.%20Glucose%20regulated%20protein%2078%20phosphorylation%20in%20sperm%20undergoes%20dynamic%20changes%20during%20maturation.%20PLoS%20ONE.%202015;10(11):e0141858." class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="CR18">
<span class="label">18.</span><cite>Wang L, Li D, Su X, Zhao Y, Huang A, Li H, et al. AGO4 suppresses tumor growth by modulating autophagy and apoptosis via enhancing TRIM21-mediated ubiquitination of GRP78 in a p53-independent manner. Oncogene. 2023;42(1):62â€“77.
</cite> [<a href="https://doi.org/10.1038/s41388-022-02526-0" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/36371565/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?Wang%20L,%20Li%20D,%20Su%20X,%20Zhao%20Y,%20Huang%20A,%20Li%20H,%20et%20al.%20AGO4%20suppresses%20tumor%20growth%20by%20modulating%20autophagy%20and%20apoptosis%20via%20enhancing%20TRIM21-mediated%20ubiquitination%20of%20GRP78%20in%20a%20p53-independent%20manner.%20Oncogene.%202023;42(1):62%E2%80%9377." class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="CR19">
<span class="label">19.</span><cite>Hendershot LM, Ting J, Lee AS. Identity of the immunoglobulin heavy-chain-binding protein with the 78,000-dalton glucose-regulated protein and the role of posttranslational modifications in its binding function. Mol Cell Biol. 1988;8(10):4250â€“6.
</cite> [<a href="https://doi.org/10.1128/mcb.8.10.4250" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="/articles/PMC365497/" class="usa-link">PMC free article</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/3141786/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?Hendershot%20LM,%20Ting%20J,%20Lee%20AS.%20Identity%20of%20the%20immunoglobulin%20heavy-chain-binding%20protein%20with%20the%2078,000-dalton%20glucose-regulated%20protein%20and%20the%20role%20of%20posttranslational%20modifications%20in%20its%20binding%20function.%20Mol%20Cell%20Biol.%201988;8(10):4250%E2%80%936." class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="CR20">
<span class="label">20.</span><cite>Satoh M, Nakai A, Sokawa Y, Hirayoshi K, Nagata K. Modulation of the phosphorylation of glucose-regulated protein, GRP78, by transformation and inhibition of glycosylation. Exp Cell Res. 1993;205(1):76â€“83.
</cite> [<a href="https://doi.org/10.1006/excr.1993.1060" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/8454000/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?Satoh%20M,%20Nakai%20A,%20Sokawa%20Y,%20Hirayoshi%20K,%20Nagata%20K.%20Modulation%20of%20the%20phosphorylation%20of%20glucose-regulated%20protein,%20GRP78,%20by%20transformation%20and%20inhibition%20of%20glycosylation.%20Exp%20Cell%20Res.%201993;205(1):76%E2%80%9383." class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="CR21">
<span class="label">21.</span><cite>Zhang T, Li J, Yang M, Ma X, Wang Z, Ma X, et al. CDK7/GRP78 signaling axis contributes to tumor growth and metastasis in osteosarcoma. Oncogene. 2022;41(40):4524â€“36.
</cite> [<a href="https://doi.org/10.1038/s41388-022-02446-z" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/36042349/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?Zhang%20T,%20Li%20J,%20Yang%20M,%20Ma%20X,%20Wang%20Z,%20Ma%20X,%20et%20al.%20CDK7/GRP78%20signaling%20axis%20contributes%20to%20tumor%20growth%20and%20metastasis%20in%20osteosarcoma.%20Oncogene.%202022;41(40):4524%E2%80%9336." class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="CR22">
<span class="label">22.</span><cite>Wang X, Wu X, Wang Q, Zhang Y, Wang C, Chen J. NLRP6 suppresses gastric cancer growth via GRP78 ubiquitination. Exp Cell Res. 2020;395(1):112177.
</cite> [<a href="https://doi.org/10.1016/j.yexcr.2020.112177" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/32682010/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?Wang%20X,%20Wu%20X,%20Wang%20Q,%20Zhang%20Y,%20Wang%20C,%20Chen%20J.%20NLRP6%20suppresses%20gastric%20cancer%20growth%20via%20GRP78%20ubiquitination.%20Exp%20Cell%20Res.%202020;395(1):112177." class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="CR23">
<span class="label">23.</span><cite>Di Veroli GY, Fornari C, Wang D, Mollard S, Bramhall JL, Richards FM, et al. Combenefit: an interactive platform for the analysis and visualization of drug combinations. Bioinformatics. 2016;32(18):2866â€“8.
</cite> [<a href="https://doi.org/10.1093/bioinformatics/btw230" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="/articles/PMC5018366/" class="usa-link">PMC free article</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/27153664/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?Di%20Veroli%20GY,%20Fornari%20C,%20Wang%20D,%20Mollard%20S,%20Bramhall%20JL,%20Richards%20FM,%20et%20al.%20Combenefit:%20an%20interactive%20platform%20for%20the%20analysis%20and%20visualization%20of%20drug%20combinations.%20Bioinformatics.%202016;32(18):2866%E2%80%938." class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="CR24">
<span class="label">24.</span><cite>Jian D, Lu X, Wang D, Li M, Yang Y, Chen Q, et al. Next generation sequencing targeted detection of somatic mutations in patients with mucinous adenocarcinoma of the appendix. Ann Diagn Pathol. 2022;61:152024.
</cite> [<a href="https://doi.org/10.1016/j.anndiagpath.2022.152024" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/36122512/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?Jian%20D,%20Lu%20X,%20Wang%20D,%20Li%20M,%20Yang%20Y,%20Chen%20Q,%20et%20al.%20Next%20generation%20sequencing%20targeted%20detection%20of%20somatic%20mutations%20in%20patients%20with%20mucinous%20adenocarcinoma%20of%20the%20appendix.%20Ann%20Diagn%20Pathol.%202022;61:152024." class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="CR25">
<span class="label">25.</span><cite>French PJ, Eoli M, Sepulveda JM, de Heer I, Kros JM, Walenkamp A, et al. Defining EGFR amplification status for clinical trial inclusion. Neuro Oncol. 2019;21(10):1263â€“72.
</cite> [<a href="https://doi.org/10.1093/neuonc/noz096" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="/articles/PMC6784284/" class="usa-link">PMC free article</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/31125418/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?French%20PJ,%20Eoli%20M,%20Sepulveda%20JM,%20de%20Heer%20I,%20Kros%20JM,%20Walenkamp%20A,%20et%20al.%20Defining%20EGFR%20amplification%20status%20for%20clinical%20trial%20inclusion.%20Neuro%20Oncol.%202019;21(10):1263%E2%80%9372." class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="CR26">
<span class="label">26.</span><cite>Li Y, Bao L, Zheng H, Geng M, Chen T, Dai X, et al. E3 ubiquitin ligase TRIM21 targets TIF1gamma to regulate beta-catenin signaling in glioblastoma. Theranostics. 2023;13(14):4919â€“35.
</cite> [<a href="https://doi.org/10.7150/thno.85662" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="/articles/PMC10526654/" class="usa-link">PMC free article</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/37771771/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?Li%20Y,%20Bao%20L,%20Zheng%20H,%20Geng%20M,%20Chen%20T,%20Dai%20X,%20et%20al.%20E3%20ubiquitin%20ligase%20TRIM21%20targets%20TIF1gamma%20to%20regulate%20beta-catenin%20signaling%20in%20glioblastoma.%20Theranostics.%202023;13(14):4919%E2%80%9335." class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="CR27">
<span class="label">27.</span><cite>Higaki E, Kuwata T, Nagatsuma AK, Nishida Y, Kinoshita T, Aizawa M, et al. Gene copy number gain of EGFR is a poor prognostic biomarker in gastric cancer: evaluation of 855 patients with bright-field dual in situ hybridization (DISH) method. Gastric Cancer. 2016;19(1):63â€“73.
</cite> [<a href="https://doi.org/10.1007/s10120-014-0449-9" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/25487305/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?Higaki%20E,%20Kuwata%20T,%20Nagatsuma%20AK,%20Nishida%20Y,%20Kinoshita%20T,%20Aizawa%20M,%20et%20al.%20Gene%20copy%20number%20gain%20of%20EGFR%20is%20a%20poor%20prognostic%20biomarker%20in%20gastric%20cancer:%20evaluation%20of%20855%20patients%20with%20bright-field%20dual%20in%20situ%20hybridization%20(DISH)%20method.%20Gastric%20Cancer.%202016;19(1):63%E2%80%9373." class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="CR28">
<span class="label">28.</span><cite>UniProt: the universal protein knowledgebase in 2025. Nucleic Acids Res. 2025;53(D1):D609â€“17.
</cite> [<a href="https://doi.org/10.1093/nar/gkae1010" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="/articles/PMC11701636/" class="usa-link">PMC free article</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/39552041/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?UniProt:%20the%20universal%20protein%20knowledgebase%20in%202025.%20Nucleic%20Acids%20Res.%202025;53(D1):D609%E2%80%9317." class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="CR29">
<span class="label">29.</span><cite>Liu Y, Yang X, Gan J, Chen S, Xiao Z, Cao Y. CB-dock2: improved protein-ligand blind Docking by integrating cavity detection, docking and homologous template fitting. Nucleic Acids Res. 2022;50(W1):W159â€“64.
</cite> [<a href="https://doi.org/10.1093/nar/gkac394" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="/articles/PMC9252749/" class="usa-link">PMC free article</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/35609983/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?Liu%20Y,%20Yang%20X,%20Gan%20J,%20Chen%20S,%20Xiao%20Z,%20Cao%20Y.%20CB-dock2:%20improved%20protein-ligand%20blind%20Docking%20by%20integrating%20cavity%20detection,%20docking%20and%20homologous%20template%20fitting.%20Nucleic%20Acids%20Res.%202022;50(W1):W159%E2%80%9364." class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="CR30">
<span class="label">30.</span><cite>Singh A, Copeland MM, Kundrotas PJ, Vakser IA. GRAMM web server for protein docking. Methods Mol Biol. 2024;2714:101â€“12.
</cite> [<a href="https://doi.org/10.1007/978-1-0716-3441-7_5" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/37676594/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?Singh%20A,%20Copeland%20MM,%20Kundrotas%20PJ,%20Vakser%20IA.%20GRAMM%20web%20server%20for%20protein%20docking.%20Methods%20Mol%20Biol.%202024;2714:101%E2%80%9312." class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="CR31">
<span class="label">31.</span><cite>Talukdar S, Emdad L, Das SK, Fisher PB. EGFR: an essential receptor tyrosine kinase-regulator of cancer stem cells. Adv Cancer Res. 2020;147:161â€“88.
</cite> [<a href="https://doi.org/10.1016/bs.acr.2020.04.003" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/32593400/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?Talukdar%20S,%20Emdad%20L,%20Das%20SK,%20Fisher%20PB.%20EGFR:%20an%20essential%20receptor%20tyrosine%20kinase-regulator%20of%20cancer%20stem%20cells.%20Adv%20Cancer%20Res.%202020;147:161%E2%80%9388." class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="CR32">
<span class="label">32.</span><cite>Kim SH, Kim JY, Park SY, Jeong WT, Kim JM, Bae SH, et al. Activation of the EGFR-PI3k-CaM pathway by PRL-1-overexpressing placenta-derived mesenchymal stem cells ameliorates liver cirrhosis via ER stress-dependent calcium. Stem Cell Res Ther. 2021;12(1):551.
</cite> [<a href="https://doi.org/10.1186/s13287-021-02616-y" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="/articles/PMC8543968/" class="usa-link">PMC free article</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/34689832/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?Kim%20SH,%20Kim%20JY,%20Park%20SY,%20Jeong%20WT,%20Kim%20JM,%20Bae%20SH,%20et%20al.%20Activation%20of%20the%20EGFR-PI3k-CaM%20pathway%20by%20PRL-1-overexpressing%20placenta-derived%20mesenchymal%20stem%20cells%20ameliorates%20liver%20cirrhosis%20via%20ER%20stress-dependent%20calcium.%20Stem%20Cell%20Res%20Ther.%202021;12(1):551." class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="CR33">
<span class="label">33.</span><cite>Xu S, Liu H, Wang C, Deng Y, Xu B, Yang T, et al. Study of ATF4/CHOP axis-mediated mitochondrial unfolded protein response in neuronal apoptosis induced by methylmercury. Food Chem Toxicol. 2023;182:114190.
</cite> [<a href="https://doi.org/10.1016/j.fct.2023.114190" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/37967789/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?Xu%20S,%20Liu%20H,%20Wang%20C,%20Deng%20Y,%20Xu%20B,%20Yang%20T,%20et%20al.%20Study%20of%20ATF4/CHOP%20axis-mediated%20mitochondrial%20unfolded%20protein%20response%20in%20neuronal%20apoptosis%20induced%20by%20methylmercury.%20Food%20Chem%20Toxicol.%202023;182:114190." class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="CR34">
<span class="label">34.</span><cite>Dauda N, Harvey D, Martindale S, Hume H, Aliu FO. Responsive neglected tropical disease programme delivery: listening and responding to the views and perceptions of beneficiaries. Int Health. 2022;14(Suppl 2):ii38â€“42.
</cite> [<a href="https://doi.org/10.1093/inthealth/ihac037" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="/articles/PMC9492254/" class="usa-link">PMC free article</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/36130244/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?Dauda%20N,%20Harvey%20D,%20Martindale%20S,%20Hume%20H,%20Aliu%20FO.%20Responsive%20neglected%20tropical%20disease%20programme%20delivery:%20listening%20and%20responding%20to%20the%20views%20and%20perceptions%20of%20beneficiaries.%20Int%20Health.%202022;14(Suppl%202):ii38%E2%80%9342." class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="CR35">
<span class="label">35.</span><cite>Monticelli SR, Earley AK, Tate J, Ward BM. The ectodomain of the vaccinia virus glycoprotein a34 is required for cell binding by extracellular virions and contains a large region capable of interaction with glycoprotein b5. J Virol. 2019;93(4).</cite> [<a href="https://doi.org/10.1128/JVI.01343-18" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="/articles/PMC6364035/" class="usa-link">PMC free article</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/30463966/" class="usa-link">PubMed</a>]</li>
<li id="CR36">
<span class="label">36.</span><cite>Liu SM, Tu HY, Wei XW, Yan HH, Dong XR, Cui JW, et al. First-line pyrotinib in advanced HER2-mutant non-small-cell lung cancer: a patient-centric phase 2 trial. Nat Med. 2023;29(8):2079â€“86.
</cite> [<a href="https://doi.org/10.1038/s41591-023-02461-x" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/37488286/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?Liu%20SM,%20Tu%20HY,%20Wei%20XW,%20Yan%20HH,%20Dong%20XR,%20Cui%20JW,%20et%20al.%20First-line%20pyrotinib%20in%20advanced%20HER2-mutant%20non-small-cell%20lung%20cancer:%20a%20patient-centric%20phase%202%20trial.%20Nat%20Med.%202023;29(8):2079%E2%80%9386." class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="CR37">
<span class="label">37.</span><cite>Xu B, Yan M, Ma F, Hu X, Feng J, Ouyang Q, et al. Pyrotinib plus capecitabine versus lapatinib plus capecitabine for the treatment of HER2-positive metastatic breast cancer (PHOEBE): a multicentre, open-label, randomised, controlled, phase 3 trial. Lancet Oncol. 2021;22(3):351â€“60.
</cite> [<a href="https://doi.org/10.1016/S1470-2045(20)30702-6" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/33581774/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?Xu%20B,%20Yan%20M,%20Ma%20F,%20Hu%20X,%20Feng%20J,%20Ouyang%20Q,%20et%20al.%20Pyrotinib%20plus%20capecitabine%20versus%20lapatinib%20plus%20capecitabine%20for%20the%20treatment%20of%20HER2-positive%20metastatic%20breast%20cancer%20(PHOEBE):%20a%20multicentre,%20open-label,%20randomised,%20controlled,%20phase%203%20trial.%20Lancet%20Oncol.%202021;22(3):351%E2%80%9360." class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="CR38">
<span class="label">38.</span><cite>Ding K, Chen X, Li Y, Li W, Ye Y, He T, et al. Gastric cancer harboring an ERBB3 mutation treated with a pyrotinib-irinotecan combo: a case study. Onco Targets Ther. 2021;14:545â€“50.
</cite> [<a href="https://doi.org/10.2147/OTT.S286024" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="/articles/PMC7823137/" class="usa-link">PMC free article</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/33500629/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?Ding%20K,%20Chen%20X,%20Li%20Y,%20Li%20W,%20Ye%20Y,%20He%20T,%20et%20al.%20Gastric%20cancer%20harboring%20an%20ERBB3%20mutation%20treated%20with%20a%20pyrotinib-irinotecan%20combo:%20a%20case%20study.%20Onco%20Targets%20Ther.%202021;14:545%E2%80%9350." class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="CR39">
<span class="label">39.</span><cite>Liu D, Kou F, Gong J, Wang Z, Zhang X, Li J, et al. Pyrotinib alone or in combination with docetaxel in refractory HER2-positive gastric cancer: a dose-escalation phase i study. Cancer Med. 2023;12(9):10704â€“14.
</cite> [<a href="https://doi.org/10.1002/cam4.5830" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="/articles/PMC10225203/" class="usa-link">PMC free article</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/37081722/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?Liu%20D,%20Kou%20F,%20Gong%20J,%20Wang%20Z,%20Zhang%20X,%20Li%20J,%20et%20al.%20Pyrotinib%20alone%20or%20in%20combination%20with%20docetaxel%20in%20refractory%20HER2-positive%20gastric%20cancer:%20a%20dose-escalation%20phase%20i%20study.%20Cancer%20Med.%202023;12(9):10704%E2%80%9314." class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="CR40">
<span class="label">40.</span><cite>Li S, Bao J, Li X, Yang Q, Xu J, Chen S, et al. Multicenter phase i dose escalation and expansion study of pyrotinib in combination with camrelizumab and chemotherapy as first-line treatment for HER2-positive advanced gastric and gastroesophageal junction adenocarcinoma. EClinicalMedicine. 2023;66:102314.
</cite> [<a href="https://doi.org/10.1016/j.eclinm.2023.102314" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="/articles/PMC10679498/" class="usa-link">PMC free article</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/38024480/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?Li%20S,%20Bao%20J,%20Li%20X,%20Yang%20Q,%20Xu%20J,%20Chen%20S,%20et%20al.%20Multicenter%20phase%20i%20dose%20escalation%20and%20expansion%20study%20of%20pyrotinib%20in%20combination%20with%20camrelizumab%20and%20chemotherapy%20as%20first-line%20treatment%20for%20HER2-positive%20advanced%20gastric%20and%20gastroesophageal%20junction%20adenocarcinoma.%20EClinicalMedicine.%202023;66:102314." class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="CR41">
<span class="label">41.</span><cite>Han X, Zhang Y, Li Y, Lin Z, Pei X, Feng Y, et al. Pyrotinib targeted EGFR-STAT3/CD24 loop-mediated cell viability in TSC. Cells. 2022;11:19.</cite> [<a href="https://doi.org/10.3390/cells11193064" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="/articles/PMC9563285/" class="usa-link">PMC free article</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/36231025/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?Han%20X,%20Zhang%20Y,%20Li%20Y,%20Lin%20Z,%20Pei%20X,%20Feng%20Y,%20et%20al.%20Pyrotinib%20targeted%20EGFR-STAT3/CD24%20loop-mediated%20cell%20viability%20in%20TSC.%20Cells.%202022;11:19." class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="CR42">
<span class="label">42.</span><cite>Zhou L, Le K, Chen Q, Wang H. The efficacy and potential mechanisms of pyrotinib in targeting EGFR and HER2 in advanced oral squamous cell carcinoma. BMC Oral Health. 2024;24(1):898.
</cite> [<a href="https://doi.org/10.1186/s12903-024-04459-4" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="/articles/PMC11302363/" class="usa-link">PMC free article</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/39107736/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?Zhou%20L,%20Le%20K,%20Chen%20Q,%20Wang%20H.%20The%20efficacy%20and%20potential%20mechanisms%20of%20pyrotinib%20in%20targeting%20EGFR%20and%20HER2%20in%20advanced%20oral%20squamous%20cell%20carcinoma.%20BMC%20Oral%20Health.%202024;24(1):898." class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="CR43">
<span class="label">43.</span><cite>Hecht JR, Bang YJ, Qin SK, Chung HC, Xu JM, Park JO, et al. Lapatinib in combination with capecitabine plus oxaliplatin in human epidermal growth factor receptor 2-positive advanced or metastatic gastric, esophageal, or gastroesophageal adenocarcinoma: TRIO-013/LOGiCâ€“a randomized phase III trial. J Clin Oncol. 2016;34(5):443â€“51.
</cite> [<a href="https://doi.org/10.1200/JCO.2015.62.6598" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/26628478/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?Hecht%20JR,%20Bang%20YJ,%20Qin%20SK,%20Chung%20HC,%20Xu%20JM,%20Park%20JO,%20et%20al.%20Lapatinib%20in%20combination%20with%20capecitabine%20plus%20oxaliplatin%20in%20human%20epidermal%20growth%20factor%20receptor%202-positive%20advanced%20or%20metastatic%20gastric,%20esophageal,%20or%20gastroesophageal%20adenocarcinoma:%20TRIO-013/LOGiC%E2%80%93a%20randomized%20phase%20III%20trial.%20J%20Clin%20Oncol.%202016;34(5):443%E2%80%9351." class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="CR44">
<span class="label">44.</span><cite>Liu Q, Yang Y, Fan X, Xin X, Pan Q, Zhang Y, et al. Heterogeneity response to afatinib in gastric cancer patient with uncommon epidermal growth factor receptor (EGFR) mutations: a case report. Ann Transl Med. 2021;9(9):814.
</cite> [<a href="https://doi.org/10.21037/atm-20-7312" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="/articles/PMC8246221/" class="usa-link">PMC free article</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/34268427/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?Liu%20Q,%20Yang%20Y,%20Fan%20X,%20Xin%20X,%20Pan%20Q,%20Zhang%20Y,%20et%20al.%20Heterogeneity%20response%20to%20afatinib%20in%20gastric%20cancer%20patient%20with%20uncommon%20epidermal%20growth%20factor%20receptor%20(EGFR)%20mutations:%20a%20case%20report.%20Ann%20Transl%20Med.%202021;9(9):814." class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="CR45">
<span class="label">45.</span><cite>Hu H, Tian M, Ding C, Yu S. The c/ebp homologous protein (CHOP) transcription factor functions in endoplasmic reticulum stress-induced apoptosis and microbial infection. Front Immunol. 2018;9:3083.
</cite> [<a href="https://doi.org/10.3389/fimmu.2018.03083" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="/articles/PMC6328441/" class="usa-link">PMC free article</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/30662442/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?Hu%20H,%20Tian%20M,%20Ding%20C,%20Yu%20S.%20The%20c/ebp%20homologous%20protein%20(CHOP)%20transcription%20factor%20functions%20in%20endoplasmic%20reticulum%20stress-induced%20apoptosis%20and%20microbial%20infection.%20Front%20Immunol.%202018;9:3083." class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="CR46">
<span class="label">46.</span><cite>Ma B, Zhang H, Wang Y, Zhao A, Zhu Z, Bao X, et al. Corosolic acid, a natural triterpenoid, induces ER stress-dependent apoptosis in human castration resistant prostate cancer cells via activation of IRE-1/JNK, PERK/CHOP and TRIB3. J Exp Clin Cancer Res. 2018;37(1):210.
</cite> [<a href="https://doi.org/10.1186/s13046-018-0889-x" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="/articles/PMC6122202/" class="usa-link">PMC free article</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/30176898/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?Ma%20B,%20Zhang%20H,%20Wang%20Y,%20Zhao%20A,%20Zhu%20Z,%20Bao%20X,%20et%20al.%20Corosolic%20acid,%20a%20natural%20triterpenoid,%20induces%20ER%20stress-dependent%20apoptosis%20in%20human%20castration%20resistant%20prostate%20cancer%20cells%20via%20activation%20of%20IRE-1/JNK,%20PERK/CHOP%20and%20TRIB3.%20J%20Exp%20Clin%20Cancer%20Res.%202018;37(1):210." class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="CR47">
<span class="label">47.</span><cite>Deng N, Goh LK, Wang H, Das K, Tao J, Tan IB, et al. A comprehensive survey of genomic alterations in gastric cancer reveals systematic patterns of molecular exclusivity and co-occurrence among distinct therapeutic targets. Gut. 2012;61(5):673â€“84.
</cite> [<a href="https://doi.org/10.1136/gutjnl-2011-301839" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="/articles/PMC3322587/" class="usa-link">PMC free article</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/22315472/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?Deng%20N,%20Goh%20LK,%20Wang%20H,%20Das%20K,%20Tao%20J,%20Tan%20IB,%20et%20al.%20A%20comprehensive%20survey%20of%20genomic%20alterations%20in%20gastric%20cancer%20reveals%20systematic%20patterns%20of%20molecular%20exclusivity%20and%20co-occurrence%20among%20distinct%20therapeutic%20targets.%20Gut.%202012;61(5):673%E2%80%9384." class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="CR48">
<span class="label">48.</span><cite>Zhang J, Ji F, Tan Y, Zhao L, Zhao Y, Liu J, et al. Oncogenic roles of laminin subunit gamma-2 in intrahepatic cholangiocarcinoma via promoting EGFR translation. Adv Sci (Weinh). 2024;11(21):e2309010.
</cite> [<a href="https://doi.org/10.1002/advs.202309010" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="/articles/PMC11151066/" class="usa-link">PMC free article</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/38526177/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?Zhang%20J,%20Ji%20F,%20Tan%20Y,%20Zhao%20L,%20Zhao%20Y,%20Liu%20J,%20et%20al.%20Oncogenic%20roles%20of%20laminin%20subunit%20gamma-2%20in%20intrahepatic%20cholangiocarcinoma%20via%20promoting%20EGFR%20translation.%20Adv%20Sci%20(Weinh).%202024;11(21):e2309010." class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="CR49">
<span class="label">49.</span><cite>Niu Q, Liu J, Huang T, Su B, Zhang Y, Yuan X. Pan-HER tyrosine kinase inhibitor pyrotinib enhances radiosensitivity via ERK1/2 pathway in HER2-positive gastric cancer. Oncol Res Treat. 2023;46(1â€“2):11â€“25.
</cite> [<a href="https://doi.org/10.1159/000528594" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/36481773/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?Niu%20Q,%20Liu%20J,%20Huang%20T,%20Su%20B,%20Zhang%20Y,%20Yuan%20X.%20Pan-HER%20tyrosine%20kinase%20inhibitor%20pyrotinib%20enhances%20radiosensitivity%20via%20ERK1/2%20pathway%20in%20HER2-positive%20gastric%20cancer.%20Oncol%20Res%20Treat.%202023;46(1%E2%80%932):11%E2%80%9325." class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="CR50">
<span class="label">50.</span><cite>Vekaria PH, Kumar A, Subramaniam D, Dunavin N, Vallurupalli A, Schoenen F, et al. Functional cooperativity of p97 and histone deacetylase 6 in mediating DNA repair in mantle cell lymphoma cells. Leukemia. 2019;33(7):1675â€“86.
</cite> [<a href="https://doi.org/10.1038/s41375-018-0355-y" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="/articles/PMC6730676/" class="usa-link">PMC free article</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/30664664/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?Vekaria%20PH,%20Kumar%20A,%20Subramaniam%20D,%20Dunavin%20N,%20Vallurupalli%20A,%20Schoenen%20F,%20et%20al.%20Functional%20cooperativity%20of%20p97%20and%20histone%20deacetylase%206%20in%20mediating%20DNA%20repair%20in%20mantle%20cell%20lymphoma%20cells.%20Leukemia.%202019;33(7):1675%E2%80%9386." class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="CR51">
<span class="label">51.</span><cite>Gopal U, Mowery Y, Young K, Pizzo SV. Targeting cell surface GRP78 enhances pancreatic cancer radiosensitivity through YAP/TAZ protein signaling. J Biol Chem. 2019;294(38):13939â€“52.
</cite> [<a href="https://doi.org/10.1074/jbc.RA119.009091" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="/articles/PMC6755808/" class="usa-link">PMC free article</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/31358620/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?Gopal%20U,%20Mowery%20Y,%20Young%20K,%20Pizzo%20SV.%20Targeting%20cell%20surface%20GRP78%20enhances%20pancreatic%20cancer%20radiosensitivity%20through%20YAP/TAZ%20protein%20signaling.%20J%20Biol%20Chem.%202019;294(38):13939%E2%80%9352." class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="CR52">
<span class="label">52.</span><cite>Yamamori T, Meike S, Nagane M, Yasui H, Inanami O. ER stress suppresses DNA double-strand break repair and sensitizes tumor cells to ionizing radiation by stimulating proteasomal degradation of rad51. FEBS Lett. 2013;587(20):3348â€“53.
</cite> [<a href="https://doi.org/10.1016/j.febslet.2013.08.030" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/24021650/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?Yamamori%20T,%20Meike%20S,%20Nagane%20M,%20Yasui%20H,%20Inanami%20O.%20ER%20stress%20suppresses%20DNA%20double-strand%20break%20repair%20and%20sensitizes%20tumor%20cells%20to%20ionizing%20radiation%20by%20stimulating%20proteasomal%20degradation%20of%20rad51.%20FEBS%20Lett.%202013;587(20):3348%E2%80%9353." class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="CR53">
<span class="label">53.</span><cite>Itoh T, Hatano R, Horimoto Y, Yamada T, Song D, Otsuka H, et al. IL-26 mediates epidermal growth factor receptor-tyrosine kinase inhibitor resistance through endoplasmic reticulum stress signaling pathway in triple-negative breast cancer cells. Cell Death Dis. 2021;12(6):520.
</cite> [<a href="https://doi.org/10.1038/s41419-021-03787-5" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="/articles/PMC8139965/" class="usa-link">PMC free article</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/34021125/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?Itoh%20T,%20Hatano%20R,%20Horimoto%20Y,%20Yamada%20T,%20Song%20D,%20Otsuka%20H,%20et%20al.%20IL-26%20mediates%20epidermal%20growth%20factor%20receptor-tyrosine%20kinase%20inhibitor%20resistance%20through%20endoplasmic%20reticulum%20stress%20signaling%20pathway%20in%20triple-negative%20breast%20cancer%20cells.%20Cell%20Death%20Dis.%202021;12(6):520." class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="CR54">
<span class="label">54.</span><cite>Haas IG. BiP (GRP78), an essential hsp70 resident protein in the endoplasmic reticulum. Experientia. 1994;50(11â€“12):1012â€“20.
</cite> [<a href="https://doi.org/10.1007/BF01923455" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/7988659/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?Haas%20IG.%20BiP%20(GRP78),%20an%20essential%20hsp70%20resident%20protein%20in%20the%20endoplasmic%20reticulum.%20Experientia.%201994;50(11%E2%80%9312):1012%E2%80%9320." class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="CR55">
<span class="label">55.</span><cite>Filipcik P, Curry JR, Mace PD. When worlds collide-mechanisms at the interface between phosphorylation and ubiquitination. J Mol Biol. 2017;429(8):1097â€“113.
</cite> [<a href="https://doi.org/10.1016/j.jmb.2017.02.011" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/28235544/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?Filipcik%20P,%20Curry%20JR,%20Mace%20PD.%20When%20worlds%20collide-mechanisms%20at%20the%20interface%20between%20phosphorylation%20and%20ubiquitination.%20J%20Mol%20Biol.%202017;429(8):1097%E2%80%93113." class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="CR56">
<span class="label">56.</span><cite>Chen Y, Shen H, Wang Z, Huang C, Zhang H, Shao Y, et al. Recruitment of USP10 by GCS1 to deubiquitinate GRP78 promotes the progression of colorectal cancer via alleviating endoplasmic reticulum stress. J Exp Clin Cancer Res. 2024;43(1):261.
</cite> [<a href="https://doi.org/10.1186/s13046-024-03176-8" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="/articles/PMC11396530/" class="usa-link">PMC free article</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/39267084/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?Chen%20Y,%20Shen%20H,%20Wang%20Z,%20Huang%20C,%20Zhang%20H,%20Shao%20Y,%20et%20al.%20Recruitment%20of%20USP10%20by%20GCS1%20to%20deubiquitinate%20GRP78%20promotes%20the%20progression%20of%20colorectal%20cancer%20via%20alleviating%20endoplasmic%20reticulum%20stress.%20J%20Exp%20Clin%20Cancer%20Res.%202024;43(1):261." class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="CR57">
<span class="label">57.</span><cite>Qian Y, Wong CC, Xu J, Chen H, Zhang Y, Kang W, et al. Sodium channel subunit SCNN1b suppresses gastric cancer growth and metastasis via GRP78 degradation. Cancer Res. 2017;77(8):1968â€“82.
</cite> [<a href="https://doi.org/10.1158/0008-5472.CAN-16-1595" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/28202509/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?Qian%20Y,%20Wong%20CC,%20Xu%20J,%20Chen%20H,%20Zhang%20Y,%20Kang%20W,%20et%20al.%20Sodium%20channel%20subunit%20SCNN1b%20suppresses%20gastric%20cancer%20growth%20and%20metastasis%20via%20GRP78%20degradation.%20Cancer%20Res.%202017;77(8):1968%E2%80%9382." class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="CR58">
<span class="label">58.</span><cite>Lee KW, Hong HR, Lim JS, Ko KP, Lee MG, Chi SG. XAF1 drives apoptotic switch of Endoplasmic reticulum stress response through destabilization of GRP78 and CHIP. Cell Death Dis. 2022;13(7):655.
</cite> [<a href="https://doi.org/10.1038/s41419-022-05112-0" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="/articles/PMC9334361/" class="usa-link">PMC free article</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/35902580/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?Lee%20KW,%20Hong%20HR,%20Lim%20JS,%20Ko%20KP,%20Lee%20MG,%20Chi%20SG.%20XAF1%20drives%20apoptotic%20switch%20of%20Endoplasmic%20reticulum%20stress%20response%20through%20destabilization%20of%20GRP78%20and%20CHIP.%20Cell%20Death%20Dis.%202022;13(7):655." class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
</ul></section></section><section id="_ad93_" lang="en" class="associated-data"><h2 class="pmc_sec_title">Associated Data</h2>
<p class="font-secondary"><em>This section collects any data citations, data availability statements, or supplementary materials included in this article.</em></p>
<section id="_adsm93_" lang="en" class="supplementary-materials"><h3 class="pmc_sec_title">Supplementary Materials</h3>
<section class="sm xbox font-sm" id="db_ds_supplementary-material1_reqid_"><div class="media p"><div class="caption">
<a href="/articles/instance/12363034/bin/13046_2025_3485_MOESM1_ESM.docx" data-ga-action="click_feat_suppl" class="usa-link">Supplementary Material 1</a><sup> (12.4KB, docx) </sup>
</div></div></section><section class="sm xbox font-sm" id="db_ds_supplementary-material2_reqid_"><div class="media p"><div class="caption">
<a href="/articles/instance/12363034/bin/13046_2025_3485_MOESM2_ESM.docx" data-ga-action="click_feat_suppl" class="usa-link">Supplementary Material 2</a><sup> (1.5MB, docx) </sup>
</div></div></section></section><section id="_adda93_" lang="en" class="data-availability-statement"><h3 class="pmc_sec_title">Data Availability Statement</h3>
<p>No datasets were generated or analysed during the current study.</p></section></section></section><footer class="p courtesy-note font-secondary font-sm text-center"><hr class="headless">
<p>Articles from Journal of Experimental &amp; Clinical Cancer Research : CR are provided here courtesy of <strong>BMC</strong></p></footer></section></article>

                      

                    </main>
                </div>
            </div>
        </div>

        



<!-- Secondary navigation placeholder -->
<div class="pmc-sidenav desktop:grid-col-4 display-flex">
    <section class="pmc-sidenav__container" aria-label="Article resources and navigation">
        <button type="button" class="usa-button pmc-sidenav__container__close usa-button--unstyled">
            <img src="/static/img/usa-icons/close.svg" role="img" alt="Close" />
        </button>
    <div class="display-none desktop:display-block">
       <section class="margin-top-4 desktop:margin-top-0">
              <h2 class="margin-top-0">ACTIONS</h2>
           <ul class="usa-list usa-list--unstyled usa-list--actions">
               
               <li>
                     <a
                             href="https://doi.org/10.1186/s13046-025-03485-6"
                             class="usa-button usa-button--outline width-24 font-xs display-inline-flex flex-align-center flex-justify-start padding-left-1"
                             target="_blank"
                             rel="noreferrer noopener"
                             data-ga-category="actions"
                             data-ga-action="click"
                             data-ga-label="publisher_link_desktop"
                     >
                         <svg class="usa-icon width-3 height-3" aria-hidden="true" focusable="false" role="img" hidden>
                            <use xlink:href="/static/img/sprite.svg#launch"></use>
                         </svg>
                         <span class="display-inline-flex flex-justify-center flex-1 padding-right-2">View on publisher site</span>
                     </a>
               </li>
               
               
               <li>
                    <a
                            href="pdf/13046_2025_Article_3485.pdf"
                            class="usa-button usa-button--outline width-24 display-inline-flex flex-align-center flex-justify-start padding-left-1"
                            data-ga-category="actions"
                            data-ga-action="click"
                            data-ga-label="pdf_download_desktop"
                    >
                         <svg class="usa-icon width-3 height-3" aria-hidden="true" focusable="false" role="img" hidden>
                            <use xlink:href="/static/img/sprite.svg#file_download"></use>
                        </svg>
                        <span class="display-inline-flex flex-justify-center flex-1">PDF (11.3Â MB)</span>
                    </a>
               </li>
               
                
               <li>
                   <button role="button" class="usa-button width-24 citation-dialog-trigger display-inline-flex flex-align-center flex-justify-start padding-left-1"
                        aria-label="Open dialog with citation text in different styles"
                        data-ga-category="actions"
                        data-ga-action="open"
                        data-ga-label="cite_desktop"
                        data-all-citations-url="/resources/citations/12363034/"
                        data-citation-style="nlm"
                        data-download-format-link="/resources/citations/12363034/export/"
                    >
                        <svg class="usa-icon width-3 height-3" aria-hidden="true" focusable="false" role="img" hidden>
                            <use xlink:href="/static/img/sprite.svg#format_quote"></use>
                        </svg>
                       <span class="display-inline-flex flex-justify-center flex-1 button-label">Cite</span>
                    </button>
               </li>
                
               <li>

                        <button class="usa-button width-24 collections-dialog-trigger collections-button display-inline-flex flex-align-center flex-justify-start padding-left-1 collections-button-empty"
                              aria-label="Save article in MyNCBI collections."
                              data-ga-category="actions"
                              data-ga-action="click"
                              data-ga-label="collections_button_desktop"
                              data-collections-open-dialog-enabled="false"
                              data-collections-open-dialog-url="https://account.ncbi.nlm.nih.gov/?back_url=https%3A%2F%2Fpmc.ncbi.nlm.nih.gov%2Farticles%2FPMC12363034%2F%3Freport%3Dclassic%23open-collections-dialog"
                              data-in-collections="false">
                            <svg class="usa-icon width-3 height-3 usa-icon--bookmark-full" aria-hidden="true" focusable="false" role="img" hidden>
                                <use xlink:href="/static/img/action-bookmark-full.svg#icon"></use>
                            </svg>
                            <svg class="usa-icon width-3 height-3 usa-icon--bookmark-empty" aria-hidden="true" focusable="false" role="img" hidden>
                                <use xlink:href="/static/img/action-bookmark-empty.svg#icon"></use>
                            </svg>
                            <span class="display-inline-flex flex-justify-center flex-1">Collections</span>
                       </button>
               </li>
               <li class="pmc-permalink">
                    <button
                            type="button"
                            class="usa-button width-24 display-inline-flex flex-align-center flex-justify padding-left-1 shadow-none"
                            aria-label="Show article permalink"
                            aria-expanded="false"
                            aria-haspopup="true"
                            data-ga-category="actions"
                            data-ga-action="open"
                            data-ga-label="permalink_desktop"
                    >
                         <svg class="usa-icon width-3 height-3" aria-hidden="true" focusable="false" role="img" hidden>
                            <use xlink:href="/static/img/sprite.svg#share"></use>
                        </svg>
                        <span class="display-inline-flex flex-justify-center flex-1 button-label">Permalink</span>
                    </button>
                   

<div class="pmc-permalink__dropdown" hidden>
    <div class="pmc-permalink__dropdown__container">
          <h2 class="usa-modal__heading margin-top-0 margin-bottom-2 text-uppercase font-sans-xs">PERMALINK</h2>
          <div class="pmc-permalink__dropdown__content">
              <input type="text" class="usa-input" value="https://pmc.ncbi.nlm.nih.gov/articles/PMC12363034/" aria-label="Article permalink">
              <button class="usa-button display-inline-flex pmc-permalink__dropdown__copy__btn margin-right-0" title="Copy article permalink" data-ga-category="save_share" data-ga-action="link" data-ga-label="copy_link">
                  <svg class="usa-icon" aria-hidden="true" focusable="false" role="img">
                    <use xlink:href="/static/img/sprite.svg#content_copy"></use>
                  </svg>
                  <span class="margin-left-1">Copy</span>
              </button>
          </div>
    </div>
</div>
               </li>
           </ul>
       </section>
     </div>

        <section class="pmc-resources margin-top-6 desktop:margin-top-4" data-page-path="/articles/PMC12363034/">
            <h2 class="margin-top-0">RESOURCES</h2>
            
                <div class="usa-accordion usa-accordion--multiselectable" data-allow-multiple>
                    <h3 class="usa-accordion__heading">
                        <button
                        type="button"
                        class="usa-accordion__button"
                        aria-expanded="false"
                        aria-controls="resources-similar-articles"
                        data-ga-category="resources_accordion"
                        data-ga-action="open_similar_articles"
                        data-ga-label="/articles/PMC12363034/"
                        data-action-open="open_similar_articles"
                        data-action-close="close_similar_articles"
                        >
                            Similar articles
                        </button>
                    </h3>
                    <div
                            id="resources-similar-articles"
                            class="usa-accordion__content usa-prose"
                            
                                data-source-url="/resources/similar-article-links/40830980/"
                            
                    >
                        
                    </div>
                    <h3 class="usa-accordion__heading">
                        <button
                        type="button"
                        class="usa-accordion__button"
                        aria-expanded="false"
                        aria-controls="resources-cited-by-other-articles"
                        data-ga-category="resources_accordion"
                        data-ga-action="open_cited_by"
                        data-ga-label="/articles/PMC12363034/"
                        data-action-open="open_cited_by"
                        data-action-close="close_cited_by"
                        >
                             Cited by other articles
                        </button>
                    </h3>
                    <div
                            id="resources-cited-by-other-articles"
                            class="usa-accordion__content usa-prose"
                            
                                data-source-url="/resources/cited-by-links/40830980/"
                            
                    >
                          
                    </div>
                    
                        <h3 class="usa-accordion__heading">
                            <button
                            type="button"
                            class="usa-accordion__button"
                            aria-expanded="false"
                            aria-controls="resources-links-to-ncbi-databases"
                            data-ga-category="resources_accordion"
                            data-ga-action="open_NCBI_links"
                            data-ga-label="/articles/PMC12363034/"
                            data-action-open="open_NCBI_links"
                            data-action-close="close_NCBI_link"
                            >
                                 Links to NCBI Databases
                            </button>
                        </h3>
                        <div
                                id="resources-links-to-ncbi-databases"
                                class="usa-accordion__content usa-prose"
                                data-source-url="/resources/db-links/12363034/"
                        >
                        </div>
                    
                    
                </div>
            
        </section>


        <section
        class="usa-in-page-nav usa-in-page-nav--wide margin-top-6 desktop:margin-top-4"
        data-title-text="On this page"
        data-title-heading-level="h2"
        data-scroll-offset="0"
        data-root-margin="-10% 0px -80% 0px"
        data-main-content-selector="main"
        data-threshold="1"
        hidden
        ></section>
    </section>
</div>


        

<div class="overlay" role="dialog" aria-label="Citation Dialog" hidden>
    <div class="dialog citation-dialog" aria-hidden="true">
        <div class="display-inline-flex flex-align-center flex-justify width-full margin-bottom-2">
            <h2 class="usa-modal__heading margin-0">Cite</h2>
             <button type="button" class="usa-button usa-button--unstyled close-overlay text-black width-auto"  tabindex="1">
                <svg class="usa-icon width-3 height-3" aria-hidden="true" focusable="false" role="img">
                    <use xlink:href="/static/img/sprite.svg#close"></use>
                </svg>
             </button>
        </div>

        

<div class="citation-text-block">
  <div class="citation-text margin-bottom-2"></div>
  <ul class="usa-list usa-list--unstyled display-inline-flex flex-justify width-full flex-align-center">
      <li>
        <button
          class="usa-button usa-button--unstyled text-no-underline display-flex flex-align-center copy-button dialog-focus"
          data-ga-category="save_share"
          data-ga-action="cite"
          data-ga-label="copy"
          tabindex="2">
            <svg class="usa-icon width-3 height-3" aria-hidden="true" focusable="false" role="img">
                <use xlink:href="/static/img/sprite.svg#content_copy"></use>
            </svg>
            <span>Copy</span>
        </button>
      </li>
      <li>
          <a
              href="#"
              role="button"
              class="usa-button usa-button--unstyled text-no-underline display-flex flex-align-center export-button"
              data-ga-category="save_share"
              data-ga-action="cite"
              data-ga-label="download"
              title="Download a file for external citation management software"
              tabindex="3">
                <svg class="usa-icon width-3 height-3" aria-hidden="true" focusable="false" role="img">
                    <use xlink:href="/static/img/sprite.svg#file_download"></use>
                </svg>
                <span class="display-none mobile-lg:display-inline">Download .nbib</span>
                <span class="display-inline mobile-lg:display-none">.nbib</span>
            </a>
      </li>
      <li>
          

<div class="display-inline-flex flex-align-center">
  <label class="usa-label margin-top-0">Format:</label>
  <select aria-label="Format" class="usa-select citation-style-selector padding-1 margin-top-0 border-0 padding-right-4" tabindex="4" >
    
      <option data-style-url-name="ama"
              value="AMA"
              >
        AMA
      </option>
    
      <option data-style-url-name="apa"
              value="APA"
              >
        APA
      </option>
    
      <option data-style-url-name="mla"
              value="MLA"
              >
        MLA
      </option>
    
      <option data-style-url-name="nlm"
              value="NLM"
              selected="selected">
        NLM
      </option>
    
  </select>
</div>
      </li>
  </ul>
</div>
    </div>
</div>

        <div class="overlay" role="dialog" hidden>
  <div id="collections-action-dialog" class="dialog collections-dialog" aria-hidden="true">
   <div class="display-inline-flex flex-align-center flex-justify width-full margin-bottom-2">
        <h2 class="usa-modal__heading margin-0">Add to Collections</h2>
    </div>
    <div class="collections-action-panel action-panel">
      


<form id="collections-action-dialog-form"
      class="usa-form maxw-full collections-action-panel-form action-panel-content action-form action-panel-smaller-selectors"
      data-existing-collections-url="/list-existing-collections/"
      data-add-to-existing-collection-url="/add-to-existing-collection/"
      data-create-and-add-to-new-collection-url="/create-and-add-to-new-collection/"
      data-myncbi-max-collection-name-length="100"
      data-collections-root-url="https://www.ncbi.nlm.nih.gov/myncbi/collections/">

    <input type="hidden" name="csrfmiddlewaretoken" value="k4K89PPnrqJdIMauqjOM3o0dDPVE4HDTH1ICcKBj6vkElnPcdnshJ1bnMDaTCEUy">

    <fieldset class="usa-fieldset margin-bottom-2">
        <div class="usa-radio">
            <input type="radio"
            id="collections-action-dialog-new"
            class="usa-radio__input usa-radio__input--tile collections-new  margin-top-0"
            name="collections"
            value="new"
            data-ga-category="collections_button"
            data-ga-action="click"
            data-ga-label="collections_radio_new" />
            <label class="usa-radio__label" for="collections-action-dialog-new">Create a new collection</label>
        </div>
        <div class="usa-radio">
            <input type="radio"
            id="collections-action-dialog-existing"
            class="usa-radio__input usa-radio__input--tile collections-existing"
            name="collections"
            value="existing"
            checked="true"
            data-ga-category="collections_button"
            data-ga-action="click"
            data-ga-label="collections_radio_existing" />
            <label class="usa-radio__label" for="collections-action-dialog-existing">Add to an existing collection</label>
        </div>
    </fieldset>

    <fieldset class="usa-fieldset margin-bottom-2">
        <div class="action-panel-control-wrap new-collections-controls">
           <label for="collections-action-dialog-add-to-new" class="usa-label margin-top-0">
                Name your collection
               <abbr title="required" class="usa-hint usa-hint--required text-no-underline">*</abbr>
          </label>
          <input
            type="text"
            name="add-to-new-collection"
            id="collections-action-dialog-add-to-new"
            class="usa-input collections-action-add-to-new"
            pattern="[^&quot;&amp;=&lt;&gt;/]*" title="The following characters are not allowed in the Name field: &quot;&amp;=&lt;&gt;/"
            maxlength=""
            data-ga-category="collections_button"
            data-ga-action="create_collection"
            data-ga-label="non_favorties_collection"
            required
          />
        </div>
        <div class="action-panel-control-wrap existing-collections-controls">
             <label for="collections-action-dialog-add-to-existing" class="usa-label margin-top-0">
                Choose a collection
              </label>
              <select id="collections-action-dialog-add-to-existing"
                      class="usa-select collections-action-add-to-existing"
                      data-ga-category="collections_button"
                      data-ga-action="select_collection"
                      data-ga-label="($('.collections-action-add-to-existing').val() === 'Favorites') ? 'Favorites' : 'non_favorites_collection'">
              </select>
              <div class="collections-retry-load-on-error usa-input-error-message selection-validation-message">
                Unable to load your collection due to an error<br>
                <a href="#">Please try again</a>
              </div>
        </div>
    </fieldset>

    <div class="display-inline-flex">
        <button class="usa-button margin-top-0 action-panel-submit"
            type="submit"
            data-loading-label="Adding..."
            data-pinger-ignore
            data-ga-category="collections_button"
            data-ga-action="click"
            data-ga-label="add">
          Add
        </button>
        <button class="usa-button usa-button--outline margin-top-0 action-panel-cancel"
                aria-label="Close 'Add to Collections' panel"
                ref="linksrc=close_collections_panel"
                data-ga-category="collections_button"
                data-ga-action="click"
                data-ga-label="cancel">
          Cancel
        </button>
    </div>
</form>
    </div>
  </div>
</div>

        

      </div>
    </div>
  </div>



        
    
    

<footer class="ncbi-footer ncbi-dark-background " >
    
        <div class="ncbi-footer__icon-section">
            <div class="ncbi-footer__social-header">
                Follow NCBI
            </div>

            <div class="grid-container ncbi-footer__ncbi-social-icons-container">
                
                    <a href="https://twitter.com/ncbi"
                       class="ncbi-footer__social-icon ncbi-footer__social-icon--gray"
                       target="_blank"
                       rel="noreferrer noopener">
                        <svg width="40"
                             height="40"
                             viewBox="0 0 40 40"
                             fill="none"
                             xmlns="http://www.w3.org/2000/svg"
                             focusable="false"
                             aria-hidden="true">
                            <path d="m6.067 8 10.81 13.9L6 33.2h4.2l8.4-9.1 7.068 9.1H34L22.8 18.5 31.9 8h-3.5l-7.7 8.4L14.401 8H6.067Zm3.6 1.734h3.266l16.8 21.732H26.57L9.668 9.734Z">
                            </path>
                        </svg>
                        <span class="usa-sr-only">NCBI on X (formerly known as Twitter)</span>
                    </a>
                

                
                    <a href="https://www.facebook.com/ncbi.nlm"
                       class="ncbi-footer__social-icon ncbi-footer__social-icon--gray"
                       target="_blank"
                       rel="noreferrer noopener">
                        <svg width="16"
                             height="29"
                             focusable="false"
                             aria-hidden="true"
                             viewBox="0 0 16 29"
                             fill="none"
                             xmlns="http://www.w3.org/2000/svg">
                            <path d="M3.8809 21.4002C3.8809 19.0932 3.8809 16.7876 3.8809 14.478C3.8809 14.2117 3.80103 14.1452 3.54278 14.1492C2.53372 14.1638 1.52334 14.1492 0.514288 14.1598C0.302626 14.1598 0.248047 14.0972 0.248047 13.8936C0.256034 12.4585 0.256034 11.0239 0.248047 9.58978C0.248047 9.37013 0.302626 9.30224 0.528931 9.3049C1.53798 9.31688 2.54837 9.3049 3.55742 9.31555C3.80103 9.31555 3.8809 9.26097 3.87957 9.00272C3.87158 8.00565 3.85428 7.00592 3.90753 6.00884C3.97142 4.83339 4.31487 3.73115 5.04437 2.78467C5.93095 1.63318 7.15699 1.09005 8.56141 0.967577C10.5582 0.79319 12.555 0.982221 14.5518 0.927641C14.7102 0.927641 14.7462 0.99287 14.7449 1.13664C14.7449 2.581 14.7449 4.02668 14.7449 5.47104C14.7449 5.67604 14.6517 5.68669 14.4946 5.68669C13.4523 5.68669 12.4113 5.68669 11.3703 5.68669C10.3506 5.68669 9.92057 6.10868 9.90593 7.13904C9.89661 7.7647 9.91525 8.39303 9.89794 9.01869C9.88995 9.26364 9.96583 9.31822 10.2015 9.31688C11.7204 9.30623 13.2393 9.31688 14.7595 9.3049C15.0257 9.3049 15.0723 9.3728 15.0444 9.62439C14.89 10.9849 14.7515 12.3467 14.6144 13.7085C14.5691 14.1571 14.5785 14.1585 14.1458 14.1585C12.8386 14.1585 11.5313 14.1665 10.2254 14.1518C9.95119 14.1518 9.89794 14.2317 9.89794 14.4899C9.90593 19.0799 9.89794 23.6752 9.91125 28.2612C9.91125 28.5674 9.8407 28.646 9.53186 28.6433C7.77866 28.6273 6.02414 28.6366 4.27094 28.634C3.82499 28.634 3.87158 28.6992 3.87158 28.22C3.87602 25.9472 3.87913 23.6739 3.8809 21.4002Z">
                            </path>
                        </svg>
                        <span class="usa-sr-only">NCBI on Facebook</span>
                    </a>
                

                
                    <a href="https://www.linkedin.com/company/ncbinlm"
                       class="ncbi-footer__social-icon ncbi-footer__social-icon--gray"
                       target="_blank"
                       rel="noreferrer noopener">
                        <svg width="25"
                             height="23"
                             viewBox="0 0 26 24"
                             fill="none"
                             xmlns="http://www.w3.org/2000/svg"
                             focusable="false"
                             aria-hidden="true">
                            <path d="M14.6983 9.98423C15.6302 9.24808 16.5926 8.74754 17.6762 8.51991C19.673 8.09126 21.554 8.30824 23.1262 9.7526C24.2351 10.7723 24.7529 12.1115 25.0165 13.5612C25.1486 14.3363 25.2105 15.1218 25.2015 15.9081C25.2015 18.3043 25.2015 20.6898 25.2082 23.0806C25.2082 23.3468 25.1549 23.444 24.8621 23.4414C23.1297 23.4272 21.3992 23.4272 19.6704 23.4414C19.4041 23.4414 19.3429 23.3588 19.3442 23.1019C19.3535 20.5194 19.3442 17.9368 19.3442 15.3543C19.3442 14.0005 18.3258 12.9448 17.0266 12.9488C15.7273 12.9528 14.6983 14.0071 14.6983 15.361C14.6983 17.9328 14.6917 20.5047 14.6983 23.0753C14.6983 23.3708 14.6198 23.444 14.3296 23.4427C12.6185 23.4294 10.9079 23.4294 9.19779 23.4427C8.93155 23.4427 8.86099 23.3735 8.86232 23.1086C8.8783 19.7619 8.88628 16.4144 8.88628 13.066C8.88628 11.5688 8.87874 10.0708 8.86365 8.57182C8.86365 8.3575 8.90758 8.27896 9.14054 8.28029C10.9048 8.29094 12.6687 8.29094 14.4321 8.28029C14.6464 8.28029 14.6983 8.34818 14.6983 8.54653C14.6903 9.00047 14.6983 9.45441 14.6983 9.98423Z">
                            </path>
                            <path d="M6.55316 15.8443C6.55316 18.2564 6.55316 20.6699 6.55316 23.082C6.55316 23.3629 6.48127 23.4388 6.19906 23.4374C4.47737 23.4241 2.75568 23.4241 1.03399 23.4374C0.767751 23.4374 0.69986 23.3629 0.701191 23.1006C0.709178 18.2648 0.709178 13.4281 0.701191 8.59053C0.701191 8.34026 0.765089 8.27237 1.01669 8.2737C2.74991 8.28435 4.48048 8.28435 6.20838 8.2737C6.47462 8.2737 6.5465 8.33627 6.54517 8.6065C6.54783 11.0186 6.55316 13.4308 6.55316 15.8443Z">
                            </path>
                            <path d="M3.65878 0.243898C5.36804 0.243898 6.58743 1.45529 6.58743 3.1406C6.58743 4.75801 5.32145 5.95742 3.60819 5.96807C3.22177 5.97614 2.83768 5.90639 2.47877 5.76299C2.11985 5.61959 1.79344 5.40546 1.51897 5.13334C1.24449 4.86123 1.02755 4.53668 0.881058 4.17902C0.734563 3.82136 0.661505 3.43788 0.666231 3.05141C0.67555 1.42601 1.9362 0.242566 3.65878 0.243898Z">
                            </path>
                        </svg>
                        <span class="usa-sr-only">NCBI on LinkedIn</span>
                    </a>
                

                
                    <a href="https://github.com/ncbi"
                       class="ncbi-footer__social-icon ncbi-footer__social-icon--gray"
                       target="_blank"
                       rel="noreferrer noopener">
                        <svg width="28"
                             height="27"
                             viewBox="0 0 28 28"
                             fill="none"
                             xmlns="http://www.w3.org/2000/svg"
                             focusable="false"
                             aria-hidden="true">
                            <path d="M16.7228 20.6334C17.5057 20.5527 18.2786 20.3944 19.0301 20.1608C21.3108 19.4193 22.5822 17.8259 22.963 15.4909C23.1228 14.5112 23.1814 13.5287 22.9883 12.5437C22.8106 11.6423 22.4013 10.8028 21.8007 10.1076C21.7526 10.0605 21.7197 10 21.7064 9.934C21.6931 9.86799 21.7 9.79952 21.7262 9.73748C22.0856 8.6206 21.9711 7.51969 21.601 6.42677C21.582 6.3497 21.5345 6.2827 21.468 6.23923C21.4016 6.19577 21.3211 6.17906 21.2429 6.19248C20.7329 6.21649 20.2313 6.33051 19.7611 6.52928C19.1103 6.7908 18.4899 7.12198 17.9104 7.51703C17.84 7.56996 17.7581 7.60551 17.6713 7.62078C17.5846 7.63605 17.4954 7.6306 17.4112 7.60489C15.2596 7.05882 13.0054 7.06203 10.8554 7.61421C10.7806 7.63586 10.7018 7.63967 10.6253 7.62534C10.5487 7.611 10.4766 7.57892 10.4148 7.53167C9.64788 7.03247 8.85171 6.58918 7.96368 6.33359C7.65781 6.24338 7.34123 6.19458 7.02239 6.18849C6.94879 6.17986 6.87462 6.19893 6.81432 6.242C6.75402 6.28507 6.71191 6.34904 6.69621 6.42145C6.32342 7.51437 6.2209 8.61527 6.56307 9.73348C6.59635 9.84264 6.64694 9.93316 6.54177 10.0516C5.47666 11.2604 5.09988 12.6834 5.19574 14.2676C5.2663 15.4244 5.46201 16.5466 6.01454 17.5769C6.84399 19.1171 8.21664 19.9119 9.85158 20.3352C10.3938 20.4706 10.9444 20.5698 11.4998 20.632C11.5384 20.7492 11.4506 20.7798 11.408 20.8291C11.1734 21.1179 10.9894 21.4441 10.8634 21.7942C10.7622 22.0458 10.8315 22.4039 10.6065 22.5516C10.263 22.7766 9.83827 22.8485 9.42421 22.8871C8.17936 23.0056 7.26471 22.4877 6.6283 21.4348C6.25552 20.8184 5.76956 20.3325 5.08523 20.0663C4.76981 19.9325 4.42139 19.8967 4.08537 19.9638C3.7898 20.029 3.73788 20.1901 3.93891 20.4111C4.03639 20.5234 4.14989 20.6207 4.27575 20.6999C4.9796 21.1318 5.51717 21.7884 5.80152 22.5636C6.37002 23.9973 7.48039 24.5697 8.93825 24.6323C9.43741 24.6575 9.93768 24.615 10.4254 24.5058C10.5892 24.4672 10.6531 24.4872 10.6517 24.6762C10.6451 25.4936 10.6637 26.3123 10.6517 27.131C10.6517 27.6635 10.1684 27.9297 9.58663 27.7393C8.17396 27.2671 6.84977 26.5631 5.66838 25.656C2.59555 23.2891 0.720966 20.1861 0.217704 16.3376C-0.357453 11.9127 0.911353 8.00824 3.98551 4.73881C6.11909 2.42656 8.99932 0.939975 12.1203 0.540191C16.5351 -0.0601815 20.4347 1.14323 23.7232 4.16373C26.2449 6.47869 27.724 9.37672 28.1048 12.7726C28.5828 17.0325 27.3686 20.7945 24.4768 23.9827C22.9762 25.6323 21.0956 26.8908 18.9982 27.6488C18.8783 27.6927 18.7585 27.738 18.636 27.7726C18.0356 27.9404 17.6189 27.6395 17.6189 27.0098C17.6189 25.7452 17.6308 24.4806 17.6295 23.2159C17.6329 22.9506 17.6128 22.6856 17.5696 22.4238C17.4325 21.6664 17.3419 21.484 16.7228 20.6334Z">
                            </path>
                        </svg>
                        <span class="usa-sr-only">NCBI on GitHub</span>
                    </a>
                

                
                    <a href="https://ncbiinsights.ncbi.nlm.nih.gov/"
                       class="ncbi-footer__social-icon ncbi-footer__social-icon--gray"
                       target="_blank"
                       rel="noreferrer noopener">
                        <svg width="26"
                             height="26"
                             viewBox="0 0 27 27"
                             fill="none"
                             xmlns="http://www.w3.org/2000/svg"
                             focusable="false"
                             aria-hidden="true">
                            <path d="M23.7778 26.4574C23.1354 26.3913 22.0856 26.8024 21.636 26.3087C21.212 25.8444 21.4359 24.8111 21.324 24.0347C19.9933 14.8323 14.8727 8.80132 6.09057 5.85008C4.37689 5.28406 2.58381 4.99533 0.779072 4.99481C0.202773 4.99481 -0.0229751 4.83146 0.00455514 4.21479C0.0660406 3.08627 0.0660406 1.95525 0.00455514 0.826734C-0.0413285 0.0815827 0.259669 -0.0193618 0.896534 0.00266238C6.96236 0.222904 12.3693 2.24179 16.9889 6.16209C22.9794 11.2478 26.1271 17.7688 26.4372 25.648C26.4629 26.294 26.3179 26.5271 25.6609 26.4684C25.0827 26.417 24.4991 26.4574 23.7778 26.4574Z">
                            </path>
                            <path d="M14.8265 26.441C14.0924 26.441 13.2371 26.6795 12.6626 26.3786C12.0092 26.0372 12.3781 25.0644 12.246 24.378C11.1154 18.5324 6.6849 14.5497 0.74755 14.1001C0.217135 14.0615 -0.0104482 13.9422 0.0134113 13.3659C0.0519536 12.1454 0.0482829 10.9213 0.0134113 9.69524C-0.00127145 9.14464 0.196946 9.03268 0.703502 9.04736C9.21217 9.27128 16.5994 16.2511 17.2804 24.7231C17.418 26.4446 17.418 26.4446 15.6579 26.4446H14.832L14.8265 26.441Z">
                            </path>
                            <path d="M3.58928 26.4555C2.64447 26.4618 1.73584 26.0925 1.06329 25.4289C0.39073 24.7653 0.00933763 23.8617 0.0030097 22.9169C-0.00331824 21.9721 0.365937 21.0635 1.02954 20.3909C1.69315 19.7184 2.59675 19.337 3.54156 19.3306C4.48637 19.3243 5.39499 19.6936 6.06755 20.3572C6.7401 21.0208 7.1215 21.9244 7.12782 22.8692C7.13415 23.814 6.7649 24.7226 6.10129 25.3952C5.43768 26.0677 4.53409 26.4491 3.58928 26.4555Z">
                            </path>
                        </svg>
                        <span class="usa-sr-only">NCBI RSS feed</span>
                    </a>
                
            </div>
        </div>
    

    <div data-testid="gridContainer"
         class="grid-container ncbi-footer__container">
        <div class="grid-row ncbi-footer__main-content-container"
             data-testid="grid">
            
                <div class="ncbi-footer__column">
                    
                        <p class="ncbi-footer__circled-icons-heading">
                            Connect with NLM
                        </p>
                    

                    <div class="ncbi-footer__circled-icons-list">
                        
                            <a href=https://twitter.com/nlm_nih class="ncbi-footer__social-icon ncbi-footer__social-icon--circled" target="_blank" rel="noreferrer noopener">
                                <svg width="32"
                                     height="32"
                                     viewBox="0 0 40 40"
                                     fill="none"
                                     xmlns="http://www.w3.org/2000/svg"
                                     focusable="false"
                                     aria-hidden="true">
                                    <path d="m6.067 8 10.81 13.9L6 33.2h4.2l8.4-9.1 7.068 9.1H34L22.8 18.5 31.9 8h-3.5l-7.7 8.4L14.401 8H6.067Zm3.6 1.734h3.266l16.8 21.732H26.57L9.668 9.734Z">
                                    </path>
                                </svg>
                                <span class="usa-sr-only">NLM on X (formerly known as Twitter)</span>
                            </a>
                        

                        
                            <a href=https://www.facebook.com/nationallibraryofmedicine class="ncbi-footer__social-icon ncbi-footer__social-icon--circled" target="_blank" rel="noreferrer noopener">
                                <svg width="13"
                                     height="24"
                                     viewBox="0 0 13 24"
                                     fill="none"
                                     xmlns="http://www.w3.org/2000/svg"
                                     focusable="false"
                                     aria-hidden="true">
                                    <path d="M4.11371 23.1369C4.11371 23.082 4.11371 23.0294 4.11371 22.9745V12.9411H0.817305C0.6709 12.9411 0.670898 12.9411 0.670898 12.8016C0.670898 11.564 0.670898 10.3287 0.670898 9.09341C0.670898 8.97903 0.705213 8.95158 0.815017 8.95158C1.8673 8.95158 2.91959 8.95158 3.97417 8.95158H4.12057V8.83263C4.12057 7.8055 4.12057 6.7738 4.12057 5.74897C4.1264 4.92595 4.31387 4.11437 4.66959 3.37217C5.12916 2.38246 5.94651 1.60353 6.95717 1.1921C7.64827 0.905008 8.3913 0.764035 9.13953 0.778051C10.0019 0.791777 10.8644 0.830666 11.7268 0.860404C11.8869 0.860404 12.047 0.894717 12.2072 0.90158C12.2964 0.90158 12.3261 0.940469 12.3261 1.02968C12.3261 1.5421 12.3261 2.05452 12.3261 2.56465C12.3261 3.16857 12.3261 3.7725 12.3261 4.37642C12.3261 4.48165 12.2964 4.51367 12.1912 4.51138C11.5369 4.51138 10.8804 4.51138 10.2261 4.51138C9.92772 4.51814 9.63058 4.5526 9.33855 4.61433C9.08125 4.6617 8.84537 4.78881 8.66431 4.97766C8.48326 5.16652 8.3662 5.40755 8.32972 5.66661C8.28476 5.89271 8.26027 6.1224 8.25652 6.35289C8.25652 7.19014 8.25652 8.02969 8.25652 8.86923C8.25652 8.89439 8.25652 8.91955 8.25652 8.95615H12.0219C12.1797 8.95615 12.182 8.95616 12.1614 9.10714C12.0768 9.76596 11.9876 10.4248 11.9029 11.0813C11.8312 11.6319 11.7626 12.1824 11.697 12.733C11.6719 12.9434 11.6787 12.9434 11.4683 12.9434H8.26338V22.899C8.26338 22.979 8.26338 23.0591 8.26338 23.1392L4.11371 23.1369Z">
                                    </path>
                                </svg>
                                <span class="usa-sr-only">NLM on Facebook</span>
                            </a>
                        

                        
                            <a href=https://www.youtube.com/user/NLMNIH class="ncbi-footer__social-icon ncbi-footer__social-icon--circled" target="_blank" rel="noreferrer noopener">
                                <svg width="21"
                                     height="15"
                                     viewBox="0 0 21 15"
                                     fill="none"
                                     xmlns="http://www.w3.org/2000/svg"
                                     focusable="false"
                                     aria-hidden="true">
                                    <path d="M19.2561 1.47914C18.9016 1.15888 18.5699 0.957569 17.2271 0.834039C15.5503 0.678484 13.2787 0.655608 11.563 0.65332H9.43556C7.71987 0.65332 5.4483 0.678484 3.77151 0.834039C2.43098 0.957569 2.097 1.15888 1.74242 1.47914C0.813665 2.32097 0.619221 4.62685 0.598633 6.89384C0.598633 7.31781 0.598633 7.74101 0.598633 8.16345C0.626084 10.4121 0.827391 12.686 1.74242 13.521C2.097 13.8412 2.4287 14.0425 3.77151 14.1661C5.4483 14.3216 7.71987 14.3445 9.43556 14.3468H11.563C13.2787 14.3468 15.5503 14.3216 17.2271 14.1661C18.5676 14.0425 18.9016 13.8412 19.2561 13.521C20.1712 12.6929 20.3725 10.451 20.3999 8.22064C20.3999 7.74025 20.3999 7.25986 20.3999 6.77946C20.3725 4.54907 20.1689 2.30724 19.2561 1.47914ZM8.55942 10.5311V4.65201L13.5601 7.50005L8.55942 10.5311Z"
                                          fill="white" />
                                </svg>
                                <span class="usa-sr-only">NLM on YouTube</span>
                            </a>
                        
                    </div>
                </div>
            

            
                <address class="ncbi-footer__address ncbi-footer__column">
                    
        <p>
            <a class="usa-link usa-link--external"
            href="https://www.google.com/maps/place/8600+Rockville+Pike,+Bethesda,+MD+20894/%4038.9959508,
            -77.101021,17z/data%3D!3m1!4b1!4m5!3m4!1s0x89b7c95e25765ddb%3A0x19156f88b27635b8!8m2!3d38.9959508!
            4d-77.0988323"
            rel="noopener noreferrer" target="_blank">National Library of Medicine
            <br/> 8600 Rockville Pike<br/> Bethesda, MD 20894</a>
        </p>
    
                </address>
            

            
                <ul class="usa-list usa-list--unstyled ncbi-footer__vertical-list ncbi-footer__column">
                    
                        <li class="ncbi-footer__vertical-list-item">
                            









    <a href="https://www.nlm.nih.gov/web_policies.html" class="usa-link  usa-link--alt ncbi-footer__link"  >
        

        
            Web Policies
        

        
    </a>


                        </li>
                    
                        <li class="ncbi-footer__vertical-list-item">
                            









    <a href="https://www.nih.gov/institutes-nih/nih-office-director/office-communications-public-liaison/freedom-information-act-office" class="usa-link  usa-link--alt ncbi-footer__link"  >
        

        
            FOIA
        

        
    </a>


                        </li>
                    
                        <li class="ncbi-footer__vertical-list-item">
                            









    <a href="https://www.hhs.gov/vulnerability-disclosure-policy/index.html" class="usa-link usa-link--external usa-link--alt ncbi-footer__link" rel="noreferrer noopener" target='_blank' >
        

        
            HHS Vulnerability Disclosure
        

        
    </a>


                        </li>
                    
                </ul>
            

            
                <ul class="usa-list usa-list--unstyled ncbi-footer__vertical-list ncbi-footer__column">
                    
                        <li class="ncbi-footer__vertical-list-item">
                            









    <a href="https://support.nlm.nih.gov/" class="usa-link  usa-link--alt ncbi-footer__link"  >
        

        
            Help
        

        
    </a>


                        </li>
                    
                        <li class="ncbi-footer__vertical-list-item">
                            









    <a href="https://www.nlm.nih.gov/accessibility.html" class="usa-link  usa-link--alt ncbi-footer__link"  >
        

        
            Accessibility
        

        
    </a>


                        </li>
                    
                        <li class="ncbi-footer__vertical-list-item">
                            









    <a href="https://www.nlm.nih.gov/careers/careers.html" class="usa-link  usa-link--alt ncbi-footer__link"  >
        

        
            Careers
        

        
    </a>


                        </li>
                    
                </ul>
            
        </div>

        
            <div class="grid-row grid-col-12" data-testid="grid">
                <ul class="ncbi-footer__bottom-links-list">
                    
                        <li class="ncbi-footer__bottom-list-item">
                            









    <a href="https://www.nlm.nih.gov/" class="usa-link  usa-link--alt ncbi-footer__link"  >
        

        
            NLM
        

        
    </a>


                        </li>
                    
                        <li class="ncbi-footer__bottom-list-item">
                            









    <a href="https://www.nih.gov/" class="usa-link  usa-link--alt ncbi-footer__link"  >
        

        
            NIH
        

        
    </a>


                        </li>
                    
                        <li class="ncbi-footer__bottom-list-item">
                            









    <a href="https://www.hhs.gov/" class="usa-link usa-link--external usa-link--alt ncbi-footer__link" rel="noreferrer noopener" target='_blank' >
        

        
            HHS
        

        
    </a>


                        </li>
                    
                        <li class="ncbi-footer__bottom-list-item">
                            









    <a href="https://www.usa.gov/" class="usa-link usa-link--external usa-link--alt ncbi-footer__link" rel="noreferrer noopener" target='_blank' >
        

        
            USA.gov
        

        
    </a>


                        </li>
                    
                </ul>
            </div>
        
    </div>
</footer>

    


        
        
    
  <script  type="text/javascript" src="https://cdn.ncbi.nlm.nih.gov/core/pinger/pinger.js"> </script>


    
        

<button class="back-to-top" data-ga-category="pagination" data-ga-action="back_to_top">
    <label>Back to Top</label>
    <svg class="usa-icon order-0" aria-hidden="true" focusable="false" role="img">
        <use xlink:href="/static/img/sprite.svg#arrow_upward"></use>
    </svg>
</button>
    


        
    
    
    
        
    <script type="application/javascript">
    window.ncbi = window.ncbi || {};
    window.ncbi.pmc = window.ncbi.pmc || {};
    window.ncbi.pmc.options = {
        logLevel: 'INFO',
        
        staticEndpoint: '/static/',
        
        citeCookieName: 'pmc-cf',
    };
</script>
    <script type="module" crossorigin="" src="/static/assets/base-133c6271.js"></script>
    
    <script type="text/javascript" src="https://cdn.ncbi.nlm.nih.gov/core/jquery/jquery-3.6.0.min.js">&#xA0;</script>
    <script type="text/javascript">
        jQuery.getScript("https://cdn.ncbi.nlm.nih.gov/core/alerts/alerts.js", function () {
            galert(['div.nav_and_browser', 'div.header', '#universal_header', '.usa-banner', 'body > *:nth-child(1)'])
        });
    </script>


    <script type="text/javascript">var exports = {};</script>
     <script src="/static/CACHE/js/output.13b077bc3ffd.js"></script>

    <script type="module" crossorigin="" src="/static/assets/article-44d04358.js"></script>
    
    

    </body>
</html>
